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Abstract
Enzymes are biological catalysts capable of an enormous array of reactions. They
demonstrate the ability to be reshaped and repurposed as synthetic tools by the process
of enzyme engineering. Industrially, enzymes have been exploited for their ability to
synthesise high value chiral molecules with excellent stereoselectivity. They are capable
of functioning at low temperatures, near neutral pH and are completely biodegradable.
Methods to harness the synthetic potential of enzymes have been extensively developed
and applied over recent years. Directed evolution is one such approach that mimics natures
evolution strategy but over a significantly shorter time frame. It involves iterative cycles
of mutagenesis and screening until a required function is achieved. Advances in structural
biology have enabled a huge number of enzyme structures to become available. These can
help to implicate important catalytic residues in an enzyme, in turn, focussing engineering
efforts to likely mutagenic hotspots. This can lead to greater chances of obtaining a desirable
enzyme function if paired with an effective mutagenesis and screening strategy.
In this thesis we use combinatorial active site saturation testing, a focused directed evolution
method, to engineer a low-specificity L-threonine aldolase from Escherichia coli for improved
stereoselectivity. We target the reversible retro-aldol cleavage reaction of phenylserine,
an industrially interesting compound with four possible stereoisomers. Stereoselective
variants are identified following the development of an effective high-throughput screen.
Further, we use this screen to identify and produce rational combinations of variants. This
achieves an enzyme that is 500-fold stereoselective for a single phenylserine stereoisomer.
We also aim to provide insight into the poor stereoselectivity of the wild-type enzyme using
molecular mechanics and quantum mechanics/molecular mechanics simulations. These are
performed on an obtained 1.6 Å crystal structure of Escherichia coli threonine aldolase. We
further propose plausible mechanisms for the stereogenic step of the aldol-condensation
reaction.
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Chapter 1
Introduction
1.1 Biocatalysis
Enzymes are macromolecular structures essential to the function of all living organisms.
Fundamental to life, enzymes are biological catalysts (biocatalysts) with the ability to
facilitate an extraordinary number of diverse reactions. Since the turn of the millennium,
applications of biocatalyts have started to become more apparent. They offer a safe, cheap
and green route for the synthesis of valuable molecules; features largely absent in their
chemocatalyst counterparts. Furthermore, biocatalysts are capable of functioning with high
chemo-, regio-, diastereo-, and enantioselectivity, near neutral pH and at low temperatures
[Bornscheuer and Kazlauskas, 2006, Chen et al., 2017, Reetz, 2004]. By nature enzymes
are evolvable meaning they can be reshaped to perform a specific function. Harnessing this
evolvability by laboratory based approaches is broadly referred to as protein engineering
and is considered the driving force for useful applications of biocatalysts.
As a process, biocatalysis describes these useful applications of enzymes and is said to be
in its third wave [Bornscheuer et al., 2012, Turner and Truppo, 2013]. This grading is
very much based on the rate at which synthetically useful biocatalysts can be produced.
The first wave became apparent over 100 years ago as scientists used natural biological
extracts to mediate a desired reaction. An example is the synthesis of R-mandelonitrile from
benzaldehyde and cyanide with isolated plant extracts [Rosenthaler, 1908]. The second
wave emerged in the late 1900’s as the substrate scope of enzymes was realised. This
was facilitated by improvements in structural biology guiding early protein engineering
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efforts [Estell et al., 1985]. In this wave, biocatalysts were apparent in the resolution
of chiral intermediates [Matsumae et al., 1993], the synthesis of agrochemicals [Griengl
et al., 2000] and in the production of cholesterol-lowering statins [Müller, 2005]. Now well
into the third wave, and possibly even approaching the fourth [Truppo, 2017], biocatalysis
is imperative to the fine chemical, food and pharmaceutical industries. With respect to
the pharmaceutical industry, biocatalysis has only recently cemented its place as a viable
process. Typically, the lead times required for their development is considered too long
and not worth the investment of time and money. However, this new era is equipped with
advances in directed evolution methods and computation that are capable of accelerating
the process (Section 1.2). Improvements in these directed evolution techniques are
considered to be one of two factors associated with increasing biocatalyst implementation.
The other is the ease of access to enzymes.
Almost one billion gene sequences from the genomes of 38,000 different organisms are
now publicly available in the GenBank database1. As shown in Figure 1.1, the number
of sequences continues to grow at an almost exponential rate, thanks to advances in
sequencing technology. However, all this information provides is an incomprehensibly
large number of sequences composed of different combinations of four nucleotide bases.
We therefore require an approach to make use of such a database. Bioinformatics is a
field focused on interpreting biological data in silico, using mathematical and statistical
techniques [Diniz and Canduri, 2017]. Tools within this field can be utilised to mine
databases, returning useful information. Novel and potent biocatalysts can be identified
through structural alignments of coding sequences of enzymes with known function [Höhne
et al., 2010]. Key information relating to conserved amino acid positions in ancestral
families of enzymes can be obtained. In turn this has lead to biocatalysts with broader
substrate range, promiscuous activities, enhanced stabilities and altered stereoselectivities
[Diniz and Canduri, 2017, Fesko et al., 2018, Kamerlin and Warshel, 2010, Jochens and
Bornscheuer, 2010].
The repetoire of biocatalytic reactions extends to (but is not limited to): reductions,
oxidations, transaminations and condensations. All of these have synthetically useful
applications (Figure 1.2) [Urano et al., 2011, Chen et al., 2010, Jennewein et al.,
1Statistics from https://www.ncbi.nlm.nih.gov/genbank/statistics/
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Figure 1.1: Number of gene sequences available in GenBank since its release in 1982.
2006]. Urano et al. [Urano et al., 2011] successfully engineered an amino alcohol
dehydrogenase for optimal production of D-pseudoephadrine (used in decongestant
and anti-asthmatic compounds). Their enzyme catalysed the stereoselective reduction
of (S)-1-phenyl-1-keto-2-methylaminopropane into D-pseudoephedrine with three fold
greater efficiency than the wild-type (Figure 1.2A).
In another example, Chen et al. [Chen et al., 2010] developed an efficient enzymatic route
to an anti-diabetic drug candidate ((S)-2-amino-3-(6-o-tolylpyridin-3-yl)propanoic acid)
(Figure 1.2B). Using a one-pot, two-enzyme system they achieved a 66% isolated yield
of (S)-2-amino-3-(6-o-tolylpyridin-3-yl)propanoic acid and 99.9% e.e. under industrially
relevant conditions. The two-step reaction first involved an R-selective oxidation of the
racemic amino acid substrate, forming the alpha keto acid with a subsequent transamination
to the target compound.
The synthetic use of an aldolase enzyme was demonstrated for 2-deoxy-D-ribose
5-phosphate aldolase (DERA) [Jennewein et al., 2006]. Through directed evolution a
10-fold improved stereoselective DERA variant was obtained, with respect to the wild-type
enzyme, for the aldol-condensation of 2-deoxy-D-ribose 5-phosphate from acetaldehyde and
D-glyceraldehyde 3-phosphate (Figure 1.2C). The target compound is used as a key chiral
intermediate in the synthesis of vastatin drugs [Jennewein et al., 2006].
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Figure 1.2: Industrially implemented biocatalyts. A: The stereoselective reduction by
an aminoalcohol dehydrogenase [Urano et al., 2011]. B: Stereoselective oxidation by an
R-aminoacid oxidase and a stereoselective transamination by a S-aminotransferase [Urano
et al., 2011]. C: The stereoselective aldol-condensation of an engineered 2-deoxy-D-ribose
5-phosphate aldolase (DERA) [Jennewein et al., 2006].
One excellent example of a biocatalyst from the third wave [Bornscheuer et al., 2012] is
the engineered transaminase for the synthesis of sitagliptin [Savile et al., 2010]. Used as
a dipeptidyl peptidase-4 inhibitor in the treatment of type II diabetes [Williams-Herman
et al., 2008], sitagliptin required a complex chemical manufacturing scheme. This involved
high pressure and a rhodium-based chiral catalyst [Hansen et al., 2009] (Figure 1.3A).
The requirement of such a catalyst added significant cost to the process and furthermore
reduced yield due to necessary additional purification steps. Savile et al. [Savile
et al., 2010] used a combination of in silico design and directed evolution to achieve a
highly selective transaminase (Figure 1.3B). The problematic chemocatalytic steps were
subsequently bypassed with a safer, greener, cheaper and higher yielding biocatalytic route.
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The engineered enzyme provided sitagliptin with a 10-13% increase in overall yield, a 53%
increase in productivity (kg L−1 per day), a 19% reduction in total waste, elimination of
heavy metals and a reduction in total manufacturing cost [Savile et al., 2010]. Remarkably,
the final implemented transaminase contained 27 amino acid substitutions with respect to
the wild-type enzyme. Four of these were identified from structure guided in silico docking,
eight from saturation mutagenesis, five from random mutagenesis and ten from homology
libraries. Even more remarkably this variant was achieved over the space of a single year.
With this example it is easy to see the need for industrial biocatalysts. Given the available
tools in the current wave, we might expect an increasing number of chemocatalyts to be
replaced by their biological counterparts.
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Figure 1.3: Chemocatalytic and biocatalytic routes to sitagliptin phosphate. A: The
chemocatalytic route involves enamine formation followed by asymmetric hydrogenation
at high pressure (250 psi) with a rhodium catalyst. This yields sitagliptin at 97% e.e.
with trace amounts of rhodium. B: The biocatalytic route implements the engineered
transiminase for direct amination of the presitagliptin keytone, providing enantiopure
sitagliptin (99.95% e.e.). Figure adapted from [Savile et al., 2010].
1.2 Directed Evolution
Since the origin of life, organisms have been challenged by selection pressures forcing
them to adapt and change. We refer to these adaptations as evolution. Today, we
see diverse classifications of living organisms due to many iterations of evolution. The
relationship between genotype and phenotype is imperative where changes in the DNA
prove desirable when expressed in an organism. For centuries humans have used methods
such as cross-breeding to select and enhance the quality of livestock and crops. Modern day
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advances in genetics and molecular biology allow for targeted, single-gene evolution. As a
process, directed evolution can be separated into two parts. The first involves generating
genetic diversity in a gene of interest using a mutagenesis strategy. Secondly, variants must
be screened with an effective screen linking genotype to phenotype. Once variants with
desirable traits are identified the process is repeated as many times as necessary (Figure
1.4).
Figure 1.4: A generalised schematic of directed evolution. A gene of interest for an enzyme
of particular function is first selected. A: A library of genetic variants is created using
random or focused methods. B: Genes are expressed to produce enzyme variants. C:
Desirable or improved variants are identified by a screen linking genotype and phenotype.
D: Iterations of the process are performed for further improvements in function as many
times as necessary.
Many methods for generating genetic diversity exist in protein engineering. These are
considered to be either, random, homology guided or focussed based approaches and shall
be discussed in the following sections.
1.2.1 Protein Engineering
Random mutagenesis is considered the most effective method to apply in the absence of
structural information. One of the most well used methods is error-prone PCR (epPCR)
[Leung, 1989, Chen and Arnold, 1993]. It was discovered that under certain conditions,
a low-fidelity DNA polymerase would introduce random point mutations across a gene.
The identified conditions involved variations in magnesium concentration, supplementation
with manganese and use of mutagenic dNTP analogues. It was found that error rates of
between 103-104 could be achieved by this method [Wilson and Keefe, 2000]. As mutations
are introduced during the PCR elongation step, it is possible to tune the mutational
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frequency by the number of cycles [Wilson and Keefe, 2000] (Figure 1.5). The method first
demonstrated success in 1993 when Chen and Arnold evolved the protease, subtilisin E, to
function in a highly non-natural environment [Chen and Arnold, 1993]. They performed
three successive rounds of random mutagenesis to identify a variant that functioned
256-times more efficiently than the wild-type enzyme in 60% dimethylformamide.
Figure 1.5: A schematic representation of error-prone PCR. Random point mutations
accumulate through successive cycles of elongation. The mutational frequency can be tuned
by the conditions of the reaction and the number of cycles.
Around the same time as the emergence of epPCR an alternative, recombinatory method for
generating gene diversity was identified. Stemmer et al. [Stemmer, 1994a] described the
DNA shuffling method where families of homologous genes are fragmented and recombined
by PCR to create large mutagenic libraries. While not strictly random, diverse libraries are
generated through homology guidance. Stemmer et al. [Stemmer, 1994b] demonstrated
the effectiveness of this method with a TEM-1 β-lactamase. Three iterations of DNA
shuffling were performed with subsequent screening. This identified a variant with a
32,000-fold increase in the minimum required inhibitory concentration for the antibiotic
cefotaximine [Stemmer, 1994b]. The variant was 2000-fold more efficient than an epPCR
approach targeting the same system [Palzkill and Botstein, 1992]. This approach has since
been widely used in directed evolution. A further example is observed for an engineered
aldolase with altered stereoselectivity [Williams et al., 2003]. Similarly, through three
rounds of DNA shuffling and screening a N-acetylneuraminic acid lyase variant with an
8
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80-fold improvement in kcat/Km for a non-natural, fructose 1,6-bisphosphate substrate was
identified. This manifested as a 100-fold change in the stereoselectivity of the reaction.
While epPCR and recombinatory methods significantly differ in generating library diversity,
they can be combined for great effect. In one example an engineered subtilisin E variant was
obtained with a 50-fold improvement in thermostability (measured as increased half-life at
65oC) [Zhao et al., 1998]. The two part engineering effort first obtained five thermostable
variants by epPCR. Secondly, these were recombined using a staggered extension process
(stEP) (Figure 1.6). This involved a modified PCR protocol where the elongation step is
extremely abbreviated with heat denaturation. As the temperature is lowered the short
elongated fragments anneal to complementary full length templates for further elongation.
Slowly these fragments increase in size until full length genes are obtained.
Figure 1.6: The staggered extension process (StEP) recombination for an improved
theromostable subtilisin E using a modified PCR protocol. Single primers and single strands
of DNA for the epPCR variants are shown. A: Denatured template genes are primed with
one defined primer. B: Short fragments are produced in an abbreviated elongation. C: A
further cycle of stEP allows fragments to randomly prime to a template and extend further.
D: StEP cycles are repeated until full-length genes are produced. E: A library of full length
gene variants is obtained for subsequent screening. Figure adapted from [Zhao et al., 1998].
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1.2.2 Focused mutagenesis
An enzyme 100 residues in length has 1.26x10130 possible combinants. It would be
impossible to screen even a single percentage of these. However, this "numbers problem"
is a well addressed topic in enzyme engineering. Previous successes in directed evolution
would suggest engineering efforts be focused around the active site of an enzyme [Reetz
et al., 2001]. Given there are close to 150,000 structures available in the PDB2 we might
expect such information to be available for a particular enzyme or a homologue. In turn, this
can be used to implicate key residues in enzyme catalysis, narrowing engineering efforts.
However, saturation of just eight residues still yields 2.6x1010 possible combinations; still an
apparent "numbers problem". To apply some perspective, that would require screening of
around eight mutants a second, non-stop, for 100 years to fully sample the entire sequence
space.
1.2.2.1 Combinatorial active site saturation testing (CASTing)
Combinatorial active site saturation testing (CASTing) is a method developed by Reetz et
al. [Reetz et al., 2005, 2006] targeting this "numbers problem". It uses knowledge-driven
systematisation of focused libraries around the binding pocket. The method couples an
effective mutagenesis strategy with an efficient screen to enable sampling of a huge,
focused, sequence space. Libraries are generated through the use of degenerate codons.
These are codons constructed with a mixed population of nucleotides at a given position.
As well as the four standard DNA bases (A, T, C and G), several other letters are used with
combinations of each standard base assigned (Table 1.1).
By the CASTing approach, multiple residues are grouped and targeted for saturation
mutagenesis with degenerate codons. This enables synergistic combinations between
multiple residues to be identified. When a variant with desirable function is obtained,
iterative rounds of CASTing are performed with this as the new parent template. This
process is termed iterative saturation mutagenesis (ISM) [Reetz et al., 2006]. A hypothetical
CASTing and ISM strategy is shown in Figure 1.7.
2Statistics from https://www.rcsb.org/stats/growth/overall
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Degenerate codon
usage key
Base Bases
T T
A A
C C
G G
Y C T
R A G
S G C
W A T
K T G
M A C
B C G T
D A G T
H A C T
V A C G
N A C G T
Table 1.1: Single letter code (base) used when referring to degenerate amino acid codons
and their nucleotide bases.
Figure 1.7: A hypothetical CASTing and ISM strategy. The route through the CASTing
method is shown as a red dashed line with the group of the best variant for each round
highlighted with a red circle. Four groups of amino acid residues are chosen (1-4) for
targeted saturation with an appropriate degenerate codon. Each group must contain one
or more amino acids. Round A of CASTing is performed on each group with an effective
screen to identify desirable variants. The best variant (from group 2 in this case) is then
used as the parent template for ISM with groups 1, 3 and 4. A further improved variant is
identified with added group 4 substitutions. This iterative process is continued for rounds
C and D, where each time an improved variant is identified.
By sampling the targeted residues in groups, rather than simultaneously, a significant
reduction in screening effort is achieved. This is useful as we might expect to obtain an
improved variant with the desired level of function over a much reduced time period. To
highlight effectiveness of the CASTing strategy it is necessary to discuss the screening effort.
In the example highlighted in Figure 1.7 we might imagine each group to contain two
residues targeted for saturation with the NNK degenerate codon. This will incorporate all
11
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amino acid variants with the lowest level of redundancy (32 codons for 20 amino acids).
Screening effort can be calculated based on the number of targeted sites and the desired
coverage of each library3 using equation 1.1 [Patrick et al., 2003]. Where L is the required
screening effort, F is the library completeness (99.9% = 0.99 (must be <1)) and V is the
total number of possible codon combinations (32 x 32 for NNK), 4713 transformants would
be required to screen 99% of each group assuming all codons have an equal probability of
occurring.
L = −V ln(1− F) (1.1)
The total screening effort requires sampling of 61,300 transformants. While still significant,
this number is minuscule when considering it effectively samples a sequence space of
2.6x1010 combinants. If we were to reduce the library completeness to 95% and saturate
all positions in the groups with the NDT degenerate codon (12 codons for 12 amino acids,
see Section 4.1.1) this would reduce the total screening effort to 5590. This is a 75-fold
reduction in screening effort at the expense of eight amino acids and 4% library coverage.
From these examples it is clear to see how CASTing can be effectively applied to tackle the
"numbers problem" [Reetz et al., 2008].
When contrasted to other directed evolution methods, CASTing has shown considerable
improvements [Reetz et al., 2004, 2006]. In initial investigations, an expoxide hydrolase
was targeted by directed evolution for improved stereoselectivity [Reetz et al., 2004]
(Figure 1.8). The wild-type enzyme showed a 4.6-fold S-selectivity preference in the
resolution of racemic glycidyl phenyl ether. Using epPCR and subsequent screening of
20,000 transformants, a variant was identified with an 11-fold S-selectivity preference
[Reetz et al., 2004]. Using the CASTing approach, six groups of residues around the active
site were targeted. With the same screening effort of 20,000 transformants, a 115-fold
S-selective variant was obtained [Reetz et al., 2006].
3A CASTing tool (CASTer) is available for download from the Max-Planck Gesellschaft website
(https://www.kofo.mpg.de/en/research/biocatalysis) and can be used to calculate screening effort.
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Figure 1.8: The hydrolytic cleavage of rac-glycidyle phenyl ether by an expoxide hydrolase.
Reetz et al. [Reetz et al., 2006] used epPCR and CASTing to methods to separately engineer
the same epoxide hydrolase. The CASTing variant demonstrated a 115-fold S-preference
for the resolution of rac-glycidyle phenyl ether. By epPCR an 11-fold S-selective enzyme
was identified; 10-fold lower than that engineered by CASTing .
1.2.3 Directed evolution assisted by computational design
With growing computational power, we are now in an era where de novo enzymes can
be created entirely by in silico design [Kries et al., 2013]. The ability to design enzymes
that catalyse non-natural reactions opens the door for an endless number of biological
possibilities.
The first de novo protein to be predicted to a high degree of accuracy was for a novel protein
fold called Top7 [Kuhlman et al., 2003]. Following production of the in silico model, the
protein was expressed in vivo, purified and its structure solved. Astonishingly, this lay within
1.2 Å RMSD of the model [Kuhlman et al., 2003]. Top7 set the benchmark for future de
novo design with functional enzymes soon appearing. A retro-aldolase [Jiang et al., 2008],
kemp eliminase [Röthlisberger et al., 2008] and Diels-Alderase [Siegel et al., 2010] were
all identified in vitro following generation of their in silico models. The computational
algorithms used to create these enzymes are however not yet robust enough to credit
levels of enzyme activity comparable with those in nature. Coupling in silico design with
laboratory evolution has however demonstrated to be an effective method in achieving
comparable levels [Khersonsky et al., 2010, Althoff et al., 2012]. In one example the de
novo kemp eliminase [Röthlisberger et al., 2008] was further subject to directed evolution
studies targeting improved catalytic efficiency (kcat/Km) [Blomberg et al., 2013]. The
starting enzyme catalysed the cleavage of 5-nitrobenzisoxazole with a kcat/Km of 1,300 M−1
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s−1. The enzyme was evolved through 17 rounds of directed evolution involving epPCR,
DNA shuffling, and iterative cycles of CASTing (ISM). This produced a final 17 mutant
variant with a kcat/Km of 230,000 M−1 s−1. While this is not considered close to "enzyme
perfection" [Knowles, 1991] it is comparable to natural enzyme catalytic efficiency. It should
be noted that "enzyme perfection" is achieved when the rate determining step of the enzyme
catalysed reaction is quicker than the diffusion limit (108-109 M−1 s−1) as is observed with
triosephosphate isomerase (TIM).
In another example a de novo aldolase [Jiang et al., 2008] was engineered to demonstrate
natural enzyme like efficiency [Althoff et al., 2012, Giger et al., 2013, Obexer et al., 2017].
The enzyme was created in silico through careful placement of an active site catalytic
lysine in a designed hydrophobic pocket. A well characterised TIM barrel scaffold was
used and the final active enzyme was called retro-aldolase 95 (RA95). This catalysed the
cleavage of rac-4-hydroxy-4-(6-methoxy-2-naphthyl)-2-butanone (methadol) into acetone
and 2-napthaldehyde (Figure 1.9) but with low efficiency (kcat/Km = 0.19 M−1 s−1). The
enzyme was evolved, first through 13 rounds of directed evolution consisting of epPCR and
DNA shuffling with further focused saturation mutagenesis. Around 800 transformants
from each round of evolution were screened using a microtitre plate assay. The screen
used a fluorescence based detection method enabling activity of the most active variants to
be identified. The final enzyme (RA95.5-8) displayed efficiency over 4000-fold that of the
starting RA95 (kcat/Km = 480 M−1 s−1). This enzyme was now also notably enantioselective
with a 14-fold preference for R-methadol (RA95 = 2-fold selective for S-methadol) [Giger
et al., 2013].
Figure 1.9: The retro-aldol cleavage of rac-4-hydroxy-4-(6-methoxy-2-naphthyl)-2-butanone
(methadol) into acetone and 2-napthaldehyde by a de novo retro-aldolase (RA95).
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Recently the emergence of ultra-high-throughput screening has enabled the constrained
screening limit of classical microtitre assays to be dramatically increased [Yang and
Withers, 2009, Guo et al., 2012]. Droplet-based microfluidic systems compartmentalise
transformants and their reactions into individual aqueous droplets [Guo et al., 2012]. These
droplets can be loaded with fluorogenic substrates and screened by fluorescence-activated
droplet sorters (FADS) [Agresti et al., 2010, Yang and Withers, 2009]. It is reported
that around 2000 droplets can be screened per second [Guo et al., 2012]. Obexer et
al. [Obexer et al., 2017] have used this technology to further enhance the efficiency of
RA95.5-8 for R-methadol. An efficiency of 34,000 M−1 s−1 (kcat/Km) was achieved for the
best variant from screening 108 transformants. This enzyme, RA95.5-8F, also showed to
be 480-fold selective for cleavage of R-methadol. The enzyme was also used to investigate
the synthetically interesting C-C bond forming aldol reaction. This condensation reaction
(Figure 1.9) had shown to be thermodynamically unfavourable for the synthesis of methadol
(K = 1.2 M−1), however driving the reaction with excess acetone gave a conversion of 67%
with an e.e. of 98.4% for R-methadol.
While the use of computation to create important biocatalysts has been demonstrated. It
is clear that further advancements are required if we are to achieve synthetically useful
enzymes without the need of additional laboratory evolution. Given these remarkable
successes it seems appropriate to rework Figure 1.4 to factor in the capabilities of
computational design in modern day directed evolution (Figure 1.10).
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Figure 1.10: An appropriate schematic for modern day protein engineering where in silico
enzyme design can be used to produce functional enzymes. When used in combination
with a directed evolution strategy the best results are obtained [Blomberg et al., 2013,
Savile et al., 2010, Giger et al., 2013]. A: The synthetic gene for the computationally
predicted enzyme is synthesised and inserted into an appropriate host. B: Expression of the
recombinant enzyme. C: The computationally designed enzyme can be characterised for a
specified function. D: If the variant proves desirable, the diverse libraries of the gene can
be generated (E) for subsequent expression (F) and screening. Iterations of the evolution
process (steps D, E, F and G) can then be performed as many times as necessary.
1.3 Aldolases
In the previous sections we have given examples of aldolases as biocatalysts [Jennewein
et al., 2006, Obexer et al., 2017]. They are of particular interest due to their ability to create
new C-C bonds with excellent control over the formation of new stereogenic centers. The
ability to create new C-C bonds allows for growing complexity to be introduced into organic
molecules, a feature key to production of high value compounds [Gwon et al., 2012, Windle
et al., 2014]. Aldolases are a family of specific lyases that catalyse the condensation reaction
between an aldehyde acceptor and a ketone donor [Machajewski and Wong, 2000](Figure
1.11).
Unsurprisingly, one of the most prevalent ways nature achieves C-C bond formation is
through the use of aldolases, given many natural metabolites exist as aldehyde and ketone
moieties [Windle et al., 2014]. This family of enzymes can be divided into two classes
16
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Figure 1.11: The reversible aldol condensation reaction between an aldehyde acceptor and
a ketone donor.
based on their preference for activation of the donor molecule (Figure 1.12). The first of
these, Class I aldolases, activate their donor molecule by formation of a Schiff base with a
conserved active site lysine [Gefflaut et al., 1995]. Class II aldolases typically employ the
use of a zinc ion cofactor for catalysis [Fessner et al., 1996]. A generalised mechanism for
these enzymes is given in Figure 1.12.
Figure 1.12: Generalised mechanisms for class I and class II aldolases. Type I aldolases:
The donor molecule is activated by the formation of a Schiff base with a conserved active
site lysine. Type II aldolases: The zinc-dependent reaction where deprotonation of the
donor molecule results in the addition of the acceptor molecule to the enediolate forming
the new C-C bond.
The use of non-native substrates in aldolases began to emerge after a publication by Wong
and Whitesides [Wong and Whitesides, 1983] in the 1980s demonstrated the promiscuity
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of fructose 1,6-bisphosphate aldolase in using a range of aldehyde acceptor molecules in
catalysis. It has now long been shown that many enzymes of the aldolase family are
capable of accepting a range of electrophilic aldehyde acceptor molecules to generate
novel compounds [Windle et al., 2014]. Variability in the nucleophilic donor molecule
however, has shown to be far less prevalent. For this reason Class I aldolases are further
classified by their preference for the ketone donor. These include, but are not limited to,
dihydroxyacetone or dihydroxyacetone phosphate, pyruvate or phospheneolpyruvate and
glycine [Clapes et al., 2010]. Those active with glycine are more commonly referred as
threonine aldolases (TA). These enzymes are of particular interest due to their ability to
create two new adjacent stereocenters. These enzymes shall be discussed in the following
section.
1.4 Threonine aldolases
The creation of two new stereogenic centers yields four new possible stereoisomers.
This can be confusing given multiple nomenclatures are used when referring to different
substrates with identical stereochemistries. To aid understanding it seems appropriate to
summarise those used for particularly relevant TA compounds (threonine and phenylserine
(PS))(Figure 1.13).
TAs catalyse the reversible cleavage of threonine into acetaldehyde and glycine. They are
divided into two types based on their excellent enantiomeric preference for these substrates
and are referred as L- or D-TAs (Figure 1.14). Within these types are further divisions
depending on the stereoselective preference at the β-position (diastereoselectivity).
L-allo-TA preferentially cleaves L-allo-threonine, L-TA preferentially cleaves L-threonine and
low-specificity L-TA cleaves both L-threonine diasteromers. For D-TAs, only low-specificity
enzymes are known. While this classification gives rise to multiple subdivisions of TA, the
exact evolutionary function of these enzymes is not known. The active site pockets in all
solved crystal structures, appears far to large to just accommodate threonine [Kielkopf and
Burley, 2002, di Salvo et al., 2014, Uhl et al., 2015]. Further TA gene knockouts don’t prove
lethal in organisms [Liu et al., 1998]. Liu et al have reported that Escherichia coli (E. coli)
TA (eTA) directed cleavage of L-threonine is not a prominent source of glycine within the
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Figure 1.13: Structures of threonine, phenylserine (PS) and the stereochemical
nomenclature used across the literature for each of their stereoisomers. Vertical green
boxes are used to show pairs of enantiomers where the stereochemistry at both the α and
β carbon is different. Horizontal pink boxes represent pairs of diastereomers/epimers of a
single enantiomer where the stereochemistry at only the β position is different.
Figure 1.14: The reversible retro-aldol reaction of L- and D-threonine catalysed by L- and
D- types of TA.
cell. If the main pathway via serine hydroxymethyltransferase is blocked it may however
suffice as an alternative route [Liu et al., 1998]. It was shown that 4-phosphoerythronate
dehydrogenase deficient E. coli strains required L-TA for synthesis of pyridoxal 5’-phosphate
(PLP). The enzyme is capable of catalysing the condensation of glycoaldehyde and glycine
to form L-4-hydroxythreonine. Once phosphorylated to L-4-phosphohydroxythreonine, this
compound is used as an intermediate in the PLP synthesis pathway [Kim et al., 2010].
Suitably, PLP is also an essential cofactor in TA catalysed reactions [Liu et al., 1997].
L- and D-TAs are evolutionarily and structurally distinct. L-TAs belong to the aspartate amino
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transferase fold family and D-TAs to the alanine racemase family [Paiardini et al., 2003].
They classify as group 1 members with respect to the classification of enantiocomplementary
enzymes. This includes enzymes with different folds and mirror-image active sites [Mugford
et al., 2008, Uhl et al., 2015]. Unlike L-TAs, D-TAs require divalent metal ions for function
[Liu et al., 2000]. The first crystal structure of a D-TA from Alcaligenes xylosoxidans (A.
xylosoxidans) showed a well coordinated manganese ion within the active site (Figure 1.15A
and B).
Several high-resolution structures have been solved for L-TAs, these include the
low-specificity L-enzymes from E. coli (Section 5.2.2) [di Salvo et al., 2014] and Thermotoga
maritima [Kielkopf and Burley, 2002] as well as an L-allo-enzyme from Aeromonas jandaei
(A. jandaei) [Qin et al., 2014]. The structures of these enzymes all exhibit identical
protein folds which overlay perfectly despite only having 36% sequence identity 4 (Figure
1.15C). Furthermore the active sites of the enzymes are virtually indistinguishable (Figure
1.15D). Docking experiments were performed on the D-TA in order to determine a likely
substrate binding pose. The enzyme was docked with 2R3R and 2R3S PS with suitable
poses suggesting a histidine to be involved in proton abstraction through a coordinated
water molecule. Further it appeared that the manganese ion likely functions as a key Lewis
acid in the mechanism (Figure 1.16). To date no mutagenesis studies have been performed
on D-TAs. These will be necessary to implicate the role of individual residues in catalysis.
4Protein sequences were aligned for low-specificity L-TAs from E. coli (gene ItaE) and T. maritima (gene
Tmari1752) and L-allo-TA from A. jandaei (gene ItaA) using the Clustal Omega program (available at
http://www.clustal.org/omega)
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Figure 1.15: A: The active site of the first crystal structure of a D-TA from A. xylosoxidans
(PDB file 4V15) [Uhl et al., 2015]. A coordinated manganese ion (purple sphere) is in
close proximity to the PLP cofactor (pink) forming a Schiff base with a lysine residue. A
stacking interaction between an active site tyrosine is observed with the pyridine ring of
PLP. B: The active site of an L-TA from T. maritima (PDB file 1M6S) [Kielkopf and Burley,
2002]. The PLP cofactor (purple) forms a Schiff base to an active site lysine with a stacking
interaction forming between a histidine and the pyridine ring of PLP. C: Three tetrameric
L-TA structures, low-specificity L-TAs from E. coli (purple) and T. maritima (orange) and
L-allo-TA from A. jandaei (blue) aligned by their mainchain Cα-atoms. Despite having low
protein sequence identity (36%) high structural similarity is observed for the enzymes. D:
Expanded view of the active site for enzymes shown in C. Residues and their orientations
show to be virtually identical. Both E. coli and T.maritima TAs show covalently bound PLP
to lysine residues. The A. jandaei enzyme shows covalently bound ligand (glycine) to the
PLP cofactor.
In contrast L-TAs have been subject to a considerable number of mutagenesis studies [Gwon
and Baik, 2010, Giger et al., 2012, di Salvo et al., 2014, Fesko et al., 2018]. It was initially
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Figure 1.16: A proposed mechanism for D-TA retro-aldol cleavage. Upon addition of
substrate a transaldimation reaction occurs and PLP binds to the substrate through a Schiff
base. The positively charged manganese ion coordinates the bound substrate through
interaction with the negatively charged aldol oxygen. A histidine residue functions as
the general base abstracting the hydroxyl proton through a water molecule. The C-C
bond is cleaved yielding a resonance stabilised aldimine (PLP-glycine) and free aldehyde.
Reprotonation then occurs through the histidine-water relay. A further transaldimation
allows release of glycine and reforms the PLP-enzyme linkage.
proposed that an active site histidine directly mediated proton abstraction in the retro-aldol
cleavage mechanism [Giger et al., 2012]. More recently, di Salvo et al. [di Salvo et al., 2014]
have shown this to be unlikely. Mutagenesis of the proposed histidine to a non-basic residue
still yielded activity and further, threonine bound crystal structures revealed a coordinated
water molecule in place for proton abstraction. A mechanism for retro-aldol cleavage by
L-TA is shown in Figure 1.17.
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Figure 1.17: A generalised mechanism for L-TA retro-aldol cleavage. Through addition of
substrate a transaldimation reaction occurs and PLP binds to the substrate through a Schiff
base linkage. C-C bond cleavage occurs as the hydroxyl proton of the substrate is abstracted
by a nucleophilic base. This yields the resonance stabilised aldimine (PLP-glycine) and free
aldehyde. Reprotonation ensues and glycine is released through transaldimation with the
appropriate active site lysine.
Synthetically, TAs are of interest due to their high enantioselectivity and promiscuity in
accepting an extensive range of aldehydes [Steinreiber et al., 2007, Chen et al., 2017,
Beaudoin et al., 2018]. Through condensation with glycine, TAs can synthesise single
enantiomer β-hydroxy-α-amino acid products. These compounds are extremely important
to pharmaceutical and agrochemical industries [Patel, 2013]. Antibiotics including
chloramphenicol, thiamphenicol and vancomycin all exibit these key structural units in
their active structures. Further, β-hydroxy-α-amino acids can be used directly as the active
pharmaceutical ingredient (API), for example L-DOPS an active Parkinson’s disease drug.
Subsequently, routes to these compounds are required. TAs offer such a route however they
are restricted in their applications due to poor selectivity at the β-position resulting in a
mix of diasteromers and further, poor yields. Notably, TAs have also been used for their
excellent enantioselectivity in the resolution of racemic β-hydroxy-α-amino acids [Herbert
et al., 1994].
23
Introduction
1.5 Main Aims
The main aims of this thesis are to engineer eTA to exhibit improved stereoselectivity
towards a single diasteromer of PS. These efforts will be divided across three results chapters
with their aims detailed below.
1.5.1 To clone the gene, express and purify the enzyme and develop a
high-throughput screening assay
In the first results chapter, this thesis will focus on cloning the eTA gene and subsequent
expression and purification of the enzyme. Particular attention will also be given to
development of a high-throughput screen. This screen will be used to identify variants
with improved PS stereoselectivity through spectrophotometric detection of benzaldehyde.
1.5.2 To engineer eTA by directed evolution
In the second results chapter efforts will be directed to the screening of focussed libraries.
We aim to screen pairs of residues around the active site of eTA by the method of CASTing
and ISM [Reetz et al., 2005, 2006]. This will aim to identify synergistic interactions that
would otherwise be unidentifiable by single site saturation mutagenesis. We will use the
results of CASTing and ISM to make rational combinations of variants and characterise their
stereoselectivity using Michaelis-Menten kinetics.
1.5.3 To obtain structural insight into the poor stereoselective
mechanism of eTA
In the third and final results chapter, this thesis will use X-ray crystallography to obtain
a high resolution structure of eTA. With this structure we aim to gain insight into the
poor stereoselectivity observed in the enzyme for PS. For this we will use molecular
mechanics (MM) to investigate binding of pre-3R and pre-3S orientations of benzaldehyde.
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Further, more robust quantum mechanics/molecular mechanics (QM/MM) simulations will
investigate the mechanism of the stereogenic step in reaction.
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Materials and Methods
2.1 Materials
2.1.1 Technical equipment
Equipment Manufacturer
Avanti J-26 XP centrifuge Beckman Coulter, Brea, California, USA
Micro Centaur MSE, London, UK
Microplate well dispenser Genetix, UK
Gallenkamp Economy Incubator SIZE 1 Sanyo, Watford, UK
Microplate Shaker JENCONS, UK
Orbisafe Orbital Incubator Sanyo, Watford, UK
MS1 Minishaker IKA, Staufen, Germany
Vortex Genie 2 Scientific Industries, New York, USA
Vari-Gel midi system CamLab, Cambridge, UK
Mini-PROTEAN Electrophoresis system Bio-Rad Laboratories, Hertfordshire, UK
PowerPac Basic power supply Bio-Rad Laboratories, Hertfordshire, UK
AKTAprime plus GE healthcare, Little Chalfont, UK
Supadex S200 26/60 gel filtration column Little Chalfont, UK
Uvicon 930 spectrophotometer Kontron Instruments, UK
Nanodrop 2000c spectrophotometer Thermo Fisher Scientific, Massachusetts, US
FLUOstar Galaxy plate reader BMG Labtech, Ayelsbury, Bucks, UK
Jenway 3020 pH meter Bibby Scientific, Stone, UK
PTC-100 Programmable Thermal Controller GMI-Inc, Minneapolis, US
Grant JB1 Waterbath Grant Instruments, Shepreth, UK
Table 2.1: Equipment, and manufacturer, used in this thesis.
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Chemical Manufacturer
Agarose Melford Laboratories, Suffolk, UK
Ammonium Acetate Fisher Scientific, Loughborough, UK
Agar Melford Laboratories, Suffolk, UK
Ammonium persulphate Acros Organics, (Fisher Scientific)
Acrylamide, 30% Severn Biotech, Kiddiminster, UK
Ampicillin Formedium, Norfolk, UK
Benzaldehyde Acros Organics, (Fisher Scientific)
Bromophenol Blue Sigma-Aldrich, Dorset, UK
Dimethyl sulphoxide (DMSO) Sigma-Aldrich, Dorset, UK
DNase Sigma-Aldrich, Dorset, UK
Ethanol Fisher Scientific, Loughborough, UK
Ethylenediamine tetra acetic acid (EDTA) Sigma-Aldrich, Dorset, UK
Glycerol Fisher Scientific, Loughborough, UK
Glycine Fisher Scientific, Loughborough, UK
Instablue BDH Biochemical, Poole, UK
Isopropylβ-D-1-thiogalactopyranoside (IPTG) Generon, Berkshire, UK
Imidazole Acros Organics (Fisher Scientific)
Lysozyme Sigma-Aldrich, Dorset, UK
β-mercaptoethanol Stratagene, Cambridge, UK
L-threo-phenylserine (2S3R) Santa Cruz Biotech, US
L-erythro-phenylserine (2S3S) NetChem, New Brunswick, CA
Polyethylene glycol 400 Sigma-Aldrich, Dorset, UK
Propan-2-ol Fisher Scientific, Loughborough, UK
Pyrodoxal 5’-phosphate Sigma-Aldrich, Dorset, UK
Sodium chloride Fisher Scientific, Loughborough, UK
Sodium dodecyl suplhate (SDS) Sigma-Aldrich, Dorset, UK
Sodium hydroxide (NaOH) Fisher Scientific, Loughborough, UK
Sodium phosphate (dibasic) Sigma-Aldrich, Dorset, UK
Sodium phosphate (monobasic) Sigma-Aldrich, Dorset, UK
Tetramethlethylediamine (TEMED) Sigma-Aldrich, Dorset, UK
Tris base Sigma-Aldrich, Dorset, UK
Tryptone Sigma-Aldrich, Dorset, UK
Yeast extract Sigma-Aldrich, Dorset, UK
Table 2.2: Chemicals, and their manufacturer, used in this thesis.
2.1.2 Media
Unless otherwise stated all media used in this thesis was 2 TY. 1 L of this media contained
16 g tryptone, 10 g yeast extract, 5g NaCl and autoclaved at 121oC for 20 minutes. If solid
phase 1.5% (w/v) agar was supplemented prior to autoclaving.
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2.2 General methods
2.2.1 Centrifugation
Samples less than 2 mL were centrifuged at the appropriate rpm using a Micro Centaur
bench top centrifuge at room temperature unless stated otherwise. Those samples greater
than 2 mL were centrifuged using an Avanti J-26 XP at 4 oC unless stated otherwise.
2.2.2 pH measurements
pH measurements were performed at room temperature using a Jenway 3020 pH meter,
calibrated according to the manufacturer’s guidelines.
2.2.3 Antibiotic stocks
Ampicillin and tetracyclin were used at a working concentration of 50 µg mL−1 in both solid
and liquid phase media where specified. Stocks were made at 50 mg mL−1 and stored at
-20oC.
2.2.4 Culture growth
Single colonies were picked, using a sterile tip, from 2 TY plates supplemented with 50 µg
mL−1 of the necessary antibiotic and used to inoculate 5 mL of 2 TY media containing 50
µg mL−1 of the necessary antibiotic. Cultures were grown over night for 16 hours at 37oC,
with shaking at 200 rpm in an orbital incubator. For expressions of 1 L: 50 µL of starter
culture was used to inoculate a 50 mL day culture and incubated for 8 hours at 37oC, with
shaking at 200 rpm in a 250 mL conical flask. 10 mL of day culture was used to inoculate 1
L of 2 TY supplemented with 50 µg mL−1 ampicillin in a 2.5 L conical flask. Cultures were
incubated at 37oC, with shaking at 200 rpm until an optical density (O.D) of 0.6 at 600 nm
was reached. Protein expression was induced by addition of IPTG to a final concentration
of 0.1 mM. For 50 mL expressions: 50 µL of the starter culture was used to innoculate 50
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mL of 2 TY containing 50 µg mL−1 ampicillin in a 250 mL conical flask. Cultures were
incubated at 37oC, with shaking at 200 rpm until an optical density (O.D) of 0.6 at 600 nm
was reached. Protein expression was induced by addition of IPTG to a final concentration
of 0.1 mM.
2.2.5 Glycerol stocks
Glycerol stocks were made from starter cultures (Section 2.2.4). A 50% (v/v) stock of
bacterial culture was created by adding 250 µL of culture to 250 µL of sterile glycerol in a
sterile Nunc CryoTube and stored at -80oC.
2.3 DNA methods
2.3.1 Bacterial strains
Bacterial strains used in DNA manipulations were:
E. coli XL1-Blue (Agilent Technologies, Cheshire, UK)
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ proAB lacIqZ∆M15 Tn10 (Tetr)]
E. coli XL10-Gold (Agilent Technologies, Cheshire, UK)
Tetr∆(mcrA)183∆(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte
[F’ proAB lacIq Z∆M15 Tn10(Tetr)Amy Camr]
E. coli BL21 (Agilent Technologies, Cheshire, UK)
(B F− ompT hsdS(r−B m
−
B ) dcm
+ Tetr endA Hte
2.3.2 Cloning the gene for E. coli threonine aldolase into the pKK223-3
expression vector
The codon optimised gene for low-specificity L-threonine aldolase from E. coli (ItaE),
was previously ordered from Genescript (New Jersey, USA) pre-cloned into a pUC57
vector (pUC57-ItaE). The pKK223-3 plasmid was provided by Professor Alan Berry
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and used to create the pKK-ItaE construct for expression of low-specificity L-threonine
aldolase from E. coli (eTA) (see Figure 3.3B). The fast cloning method described by
Li et al. [Li et al., 2011] was used with sets of primers designed to amplify both
ItaE and pKK223-3 in a way that allowed for recombination. Two reactions were
set up to amplify both the gene and plasmid separately in 0.5 mL thin walled PCR
tubes. Reactions contained 5 x Q5 buffer (10 µL), 2 µM dNTPs (5 µL), nuclease
free water (29 µL), Q5 DNA polymerase (0.5 µL) with either pUC57-ItaE (0.5 µL) or
pKK223-3 (0.5 µL). Reactions also included, for amplification of ItaE: 10 µM forward
primer (5’-ACAGGAAACAGAATTCATGGAACATCACCATCACCACCAC-3’) (2.5 µL) and 10
µM reverse primer (5’-AGAAGCTTGGCTGCAGTTATTAACGCGCCAGAAACGCACG-3’)
(2.5 µL) or for amplification of pKK223-3: 10 µM forward primer
(5’-CTGCAGCCAAGCTTCTGTTTTG-3’) (2.5 µL) and 10 µM reverse primer
(5’-GAATTCTGTTTCCTGTGTAAATTGTTATCC-3’) (2.5 µL).
The conditions for the PCR reaction were as follows. For ItaE: 98oC (30 s) followed by 20
cycles of 98oC (10 s), 71 oC (20 s), 72 oC (30 s). A final extension step at 72oC (120 s)
completed the reaction which was then kept on ice at 4 oC. For pKK223-3: 98oC (30 s)
followed by 20 cycles of 98oC (10 s), 65oC (20 s), 72 oC (150 s). A final extension step at
72oC (120 s) completed the reaction which was then kept on ice at 4 oC.
45 µL of each reaction was combined in a sterile 0.5 mL thin walled PCR tube with 1 µL
of DpnI enzyme and incubated for 1 hour at 37oC. 2.5 µL of the reaction mixture was then
transformed into E. coli XL10-Gold cells (Section 2.3.5).
2.3.3 Plasmid purification
5 mL cultures of 2 TY supplemented with 50 µg mL−1 ampicillin were inoculated with single
colonies of 5 µL of a glycerol stock and grown for 16 hours with shaking at 200rpm in an
orbital shaker. Plasmid DNA was then purified from these starter cultures using a Wizard
Plus SV Minipreps DNA Purification System (Promega, Southampton, UK) according to the
manufacturer’s guidelines. DNA quantification was performed using a Nanodrop2000.
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2.3.4 Agarose gel electrophoresis
Agarose gel electrophoresis was performed with 1% (w/v) agarose disolved in TAE buffer.
A 1 kb DNA ladder was used for determining fragment sizes.
10 x TAE buffer
10 mM EDTA
200 mM glacial acetic acid
400 mM tris base
2.3.5 Transformation
Transformations were carried out using the heat shock method according to the method
provided with the cells used. Plasmid DNA was transformed into either E. coli XL1-Blue E.
coli XL10-Gold and E. coli BL21-Gold cells as specified in each section.
2.4 Protein methods
2.4.1 Protein purification
E. coli cells containing the His6-tagged eTA or variant were cultured as in Section 2.2.4
and purified using Chelating Sepharose fast flow resin, chelated with nickel ions in a batch
purification method.
For 1 L expressions: Cell pellet was harvested from 1 L of bacterial culture by centrifugation
at 12 000 g for 20 min. The cell pellet was re-suspended in 50 mL of wash buffer per 10
g of cells using a manual homogeniser. The re-suspended cells were lysed at 20 kpsi using
a Cell Disruptor from Constant Cell Disruption Systems (Northamptonshire, UK). Insoluble
cell debris was separated from the soluble protein by centrifugation at 40000 g for 45 min
at 4oC. A fraction of the crude soluble lysate supernatant was analysed by SDS PAGE. This
supernatant, containing protein fraction, was then loaded onto 5 mL of Chelating Sepharose
Fast Flow resin in a 50 mL Falcon tube, and incubated for 30 min with agitation at 4oC.
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Centrifugation at 4000 g for 5 min at 4oC produced a supernatant containing any non-bound
proteins, a fraction of this supernatant was analysed by SDS PAGE as a wash sample. The
resin was then thoroughly re-suspended using 40 mL of washing buffer and centrifuged at
4000 g for 5 min at 4oC after which the supernatant was discarded, this step was repeated
three times. Elution of the His6-tagged protein was achieved by addition of 20 mL elution
buffer and incubation for 1 hour at 4oC with agitation. After centrifugation at 4000 g for 5
min at 4oC the supernatant containing the His6- tagged protein was collected.
For 50 mL expressions (all CASTing variants): Cell pellets were harvested at 6000 g for 20
min and stored at -20oC for 1 hour or until required. The cell pellet was then re-suspended
in 2 mL of wash buffer. The re-suspended cells were lysed by sonication. Re-suspended
cells were kept on ice and subject to 3 rounds of sonication at 40% amplitude for 30
seconds with 30 seconds resting on ice in between each round. Insoluble cell debris was
separated from the soluble protein by centrifugation at 12000 g for 1 hour at 4oC using
a Micro Centaur benchtop centrifuge. A fraction of the crude soluble lysate supernatant
was analysed by SDS PAGE. This supernatant, containing protein fraction, was then loaded
onto an equilibrated gravity flow column containing 2 mL of Chelating Sepharose Fast Flow
resin and incubated for 30 min with agitation. Fractions of the unbound flow through were
collected and analysed by SDS PAGE. 40 mL (4 column volumes) of wash buffer were added
to the column and after flow though after each 10 mL analysed by SDS PAGE. The resin was
then thoroughly re-suspended using 2 mL of elution buffer and left for 30 minutes. The His6-
tagged protein was then collected.
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Wash buffer
50 mM Tris/HCl pH 7.4
20 mM Imadazole
500 mM NaCl
Elution buffer 50 mM Tris/HCl pH 7.4
500 mM Imadazole
500 mM NaCl
2 x loading buffer for SDS PAGE:
2 mL 10% (w/v) SDS
200 µL 0.2% (w/v) bromophenol blue in ethanol
125 mg DTT
1 mL glycerol
170 µL 1 M Tris/HCl pH 6.9
163 µL H2O
2.4.2 Protein dialysis
Dialysis of proteins was performed using BioDesign dialysis tubing (14,000 Da molecular
weight cut off). Proteins were dialysed into the appropriate buffer at 500 times the volume
of the protein. Dialysis was performed with stirring at 4oC for 6 hours then a fresh buffer
was used for a final 6 hours of dialysis. Or using a 2 mL Slide-A-Lyzer MINI Dialysis Device,
20,000 Da molecular weight cut off (Thermo Fisher Scientific (Life Technologies)).
2.4.3 Protein concentration determination
Protein concentration was determined using a Nanodrop 2000. Values for the molar
co-extinction coefficient were input and the molecular weight of the protein. 2µL of purified
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protein was added to the pedestal and three repeats of the measurement were performed.
The final concentration was determined as the average of the three repeats.
2.4.4 Increasing protein concentration
Protein samples were concentrated using a Vivaspin Protein Concentrator (10 kDa
molecular weight cut off) according to the manufacturer’s guidelines.
2.4.5 Sodium dodecyl sulphate polyacrylamide gel electrophoresis
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) was performed
using pre-cast Mini-PROTEAN Gels, 8-16% (Bio-Rad Laboratories) or in home made gels
in resolving gel (15% (v/v) acrylamide) and stacking gel (3.75 % (v/v) acrylamide). Gels
were made as described below:
Resolving gel:
7500 µL 30% (w/v) acrylamide
3750 µL 1.5 M Tris/HCl pH 8.8
3500 µL dH2O
150 µL 10% (w/v) SDS
50 µL 25% (w/v) APS
5 µL TEMED
Stacking gel
625 µL 30% (w/v) acrylamide
625 µL 1.0 M Tris/HCl pH 6.9
3650 µL dH2O
50 µL 10% (w/v) SDS
50 µL 25% (w/v) APS
5 µL TEMED
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Running buffer
14.4 g glycine
3 g Tris base
1 g SDS
140 g β-mercaptoethanol
dH2O made up to 1 L
2.4.6 Size exclusion chromatography
Size exclusion chromatography was performed to obtain the purest fraction possible for
crystallographic analysis (Section 5.2). An AKTA Prime purification system (GE Healthcare
Life Sciences) was used with a 16/60 Superdex S200 column equilibrated with with
degassed 50 mM sodium phosphate buffer, pH 8.0. Purified protein was injected onto
the column at 10 mg mL−1. 2 mL fractions were collected at a flow rate of 2 mL min−1.
The main peak of eTA eluted after approximately 50 mL (Figure 2.1). Collected fractions
were analysed by SDS PAGE with the most concentrated of those pooled. eTA was then
concentrated to 10 mg mL−1 by as per Section 2.4.4.
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Figure 2.1: Gel filtration trace of concentrated eTA at 280nm. Also shown: SDS PAGE
gel of collected fractions. Lane 1). Molecular weight marker. Lanes 2-15). Collected eTA
fractions. Lanes 5-12). Fractions 25-32 from gel filtration trace.
2.5 Assay and screening methods
2.5.1 Wavelength absorbance measurements.
Wavelength reaction spectra were obtained on a Nanodrop 2000 using the described
conditions. Reactions were set up on a 0.5 mL scale. For each measurements 2 µL of
the reaction was placed onto the pedestal with instant measurement. The sample was then
wiped off using a dust free wipe. 2 µL of the same reaction was then re-added and a
measurement taken. The process was repeated as necessary.
2.5.2 Library generation and site-directed mutagenesis
CASTing libraries for groups 1 (H83N DT F87N DT , 2 (H126N DT F127N DT ) and 3 (A81N DT
L86N DT ) were generated by PCR using designed mutagenic primers (Appendix Table
A.2) and a QuikChange lightning mutagenesis kit (Agilent Technologies, Cheshire, UK).
Reactions contained: 10 x reaction buffer, nuclease free H2O, 2 mM dNTPs, 100 ng of the
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respective forward and reverse primers, 50 ng of parent template DNA and pfu turbo DNA
polymerase. The PCR reactions were as follows: 95oC (30 s) followed by 17 cycles of 95oC
(30 s), 55oC (60 s), 68oC (336 s). Reactions were then subject to Dpn I digest for 1 hour
at 37oC. 3 µL of this was then transformed into 100 µL of E. coli XL10-Gold as per Section
2.3.5. By this process roughly 1000 colonies were achieved for each library.
Site-directed mutagenesis for rational combinations of variants was performed as described
above using the respective primers from Appendix Table A.2.
For group 4 (Y30N DT R229N DT ) libraries were generated by PCR using designed mutagenic
primers (Appendix Table A.2and QuikChange Lightning Multi Site-Directed Mutagenesis
Kit (Agilent Technologies, Cheshire, UK). Reactions contained 10 x reaction buffer, nuclease
free H2O, 2 mM dNTPs, 100 ng of each of the respective forward primers, 50 ng of parent
template DNA, Quik solution (2% (v/v)) and QuikChange Lightning Multi enzyme blend.
The PCR reaction was performed as follows: 95oC (30 s) followed by 30 cycles of 95oC (30
s), 55oC (60 s), 68oC (336 s). Reactions were then subject to Dpn I digest for 1 hour at
37oC. 3 µL of this was then transformed into 100 µL of E. coli XL10-Gold as per Section
2.3.5. By this process roughly 1000 colonies were achieved following transformation.
2.5.3 Colony picking and library culture
2 mL 96 deep well plates (Fisher Scientific Ltd) were dispensed with 1.5 mL of sterile 2
TY media containing 50 µg mL−1 ampicillin using a Genetix plate filler. Colonies from
the respective CASTing libraries were picked and used to inoculate six individual wells
of the deep well plates. Positive controls (colonies containing the pKK-ItaE construct
(Section 2.3.2) were picked and used to inoculate wells H7-9. Negative controls (colonies
containing empty pKK-mod (Section 2.3.2) were picked and used to inoculate wells H10-12.
A breathable plate seal was used on each plate. Plates were incubated, with shaking (200
rpm) at 30oC for 5 hours. IPTG was then added to a final concentration of 0.1 mM using a
1200 µL electronic multichannel pipette. Cultures were then left to express, with shaking
(200 rpm), at 30oC for 16 hours.
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2.5.4 Screening fraction preparation
For preparation of the enzyme fraction in Section 3.5.1, 1 g of frozen E. coli XL10-Gold
pellet containing overexpressed eTA was resuspended in 20 mL of 50 mM sodium phosphate
buffer pH 8.0. This was lysed by sonication (Section 2.4.1) and kept on ice for use in the
PS cleavage assay.
Cultures from Section 2.5.3 were used to make a glycerol reference plate. 100 µL of culture
was added to 100 µL sterile 50% glycerol in 250 µL 96 well plates. These were sealed and
stored at -20oC. Cultures were pelleted by centrifugation at 1000 g for 20 minutes and
supernatant discarded. Pellets were then frozen at -80oC for 1 hour or until required. 2
mL of degassed lysis buffer was added to each well using a Genetix plate filler and pellets
thoroughly re-suspended by pipetting up and down. Plates were left to incubate for 1 hour
at 37oC and then centrifuged at 6000 g for 1 hour. The soluble supernatant was then used
directly as the fraction for screening.
Lysis buffer
50 mM sodium phosphate, pH 8.0
100 mM NaCl
1 mM EDTA
2 mM MgCl2
0.2 mg mL−1 lysozyme
0.05 mg mL−1 DNase
2.5.5 A high-throughput screen to identify threonine aldolase
stereoselectivity
UV-transparent microwell plates (Greiner Bio-One Ltd) were used for activity
measurements. 140 µL of screening buffer containing 50 mM sodium phosphate, pH
8.0 and 50 µM PLP was dispensed into each well using an electronic multiwell pipette
(Starstedt, UK). 10 µL of the respective enzyme fraction (Section 2.5.4) was added to the
assay buffer using a reverse pipette technique. These were then left to shake (100 rpm)
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at 30oC for 10 minutes. 0.6 mM stocks of 2S3R and 2S3S phenylserine were made up in
50 mM sodium phosphate buffer, pH 8.0. Screening was performed on a FLUOstar Galaxy
plate reader. The pump for automated substrate injection was first cleaned thoroughly by
washing with 70% ethanol followed by dH2O. Several pump volumes of 50 mM sodium
phosphate, pH 8.0, were then passed though before the pump was loaded with the
necessary PS substrate. Plates were screened using a modified script that involved an
initial injection of 50 µL of substrate into all wells with an immediate Abs260 reading. Wells
were injected and read horizontally (A1-12, B1-12 etc.). This first inject and measure step
took 2 min 43 s. The subsequent measurement step involved Abs260 readings in the same
order as previous at took 2 min 40 s to complete. Four measurement steps were performed
in total, values from these were used to determine the activity in each well. An identical
procedure was then followed but for screening with the other PS epimer.
2.5.6 Crude lysate further selectivity assay
UV transparent microwell plates (Greiner Bio-One Ltd) were used for further activity
measurements. 120 µL of screening buffer containing 50 mM sodium phosphate, pH
8.0 and 58 µM PLP was dispensed into each well using an electronic multiwell pipette
(Starstedt, UK). 30 µL of the identified screened fractions was added to the assay buffer
using a reverse pipette technique. These were then left to shake (100 rpm) at 30oC for
10 minutes. 0.6 mM stocks of 2S3R and 2S3S PS were made. The selectivity screen
was performed in triplicate on a FLUOstar Galaxy plate reader. The pump for automated
substrate injection was first cleaned thoroughly by washing with 70% ethanol followed
by dH2O. Several pump volumes of 50 mM sodium phosphate, pH 8.0, were then passed
though before the pump was loaded with the necessary PS substrate. Individual wells were
screened for 1 minute following injections of 50 µL of substrate. Abs260 readings were taken
every 3 seconds and initial rates calculated. An identical procedure was then followed but
for screening with the other PS epimer with all measurements in triplicate.
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2.5.7 Purified enzyme selectivity assay
The purified enzyme selectivity assay was performed using the same methods as described
in Section 2.5.6 with a few alterations. Rather than adding crude lysate fractions to assay
buffer, 50 µg of purified enzyme was added to each well. All buffer components and
volumes were adjusted accordingly.
2.5.8 Enzyme kinetics
Steady-state Michaelis-Menten kinetics were performed for the retro-aldol cleavage of 2S3R
and 2S3S PS. Fresh stocks of each substrate were made on the same day as the kinetic
experiment in 50 mM sodium phosphate, pH 8.0. PLP was also made up as a fresh stock in
the same buffer. Enzymes were used as day old preparations following purification (Section
2.4). One hour prior to kinetic analysis, substrates and buffers were incubated in a water
bath at 30o. Enzymes were kept on ice and DMSO was kept at room temperature. Kinetics
were measured for a range of substrate concentrations using an appropriate amount of
enzyme. Each reaction was performed following a specific order using a clean tip for
addition of each reaction ingredient. First 100 µL (10% (v/v)) of DMSO was added to
a quartz cuvette (path length 1 cm), 50 mM sodium phosphate was added next followed
by the required volumes of substrate. PLP was further added and thorough mixing by
pipetting up and down. To start the reaction an appropriate amount of enzyme was added
to the cuvette. A lid was placed on top and the cuvette was carefully inverted two times.
This was then quickly placed into the Uvicon spectrophotometer for activity measurements.
A linear increase in absorbance was followed at 279 nm. A rate for this linear reaction was
determined (∆Abs279 min
−1) and used to calculate the specific activity of the enzyme. The
molar extinction coefficient of 1.4 x 10−3 M−1 cm−1 for benzaldehyde at 279 nm was used
as described by Liu et al. [Liu et al., 1998]. Kinetic parameters kcat and Km were obtained
by fitting the data to the Michaelis-Menten equation (equation 2.1) on GraphPad Prism 7.
vo =
Vmax[S]
Km + [S]
(2.1)
40
Materials and Methods
2.6 Crystallographic methods
The crystallisation conditions for a similar E. coli threonine aldolase had previously been
described [di Salvo et al., 2014]. Conditions used were optimised around; 0.2 M MgCl2
hexahydrate, 0.1M HEPES (pH 7.5), 30% PEG 400. Crystals were grown by the sitting drop
vapour diffusion method and sizeable crystals were observed after 8 days at 20oC.
2.6.1 Data collection and data processing
Data collection was carried out at Diamond Light Source macromolecular crystallography
beamline I02. Data were collected from single crystals for all structures at 100 K. The
auto processed data from Fast DP, XIA2 3dii, XIA2 3d and DIALS were used to present
diffraction data and determine unit cell parameters. The structure for eTA was achieved
using molecular replacement in PHASER [McCoy et al., 2007], with a previously solved
structure of a homologous protein (PDB file 4LNL).
2.6.2 Refinement
Refinement was performed using REFMAC 5 [Murshudov et al., 1997]. Structures
underwent rigid body refinement followed by numerous rounds of restrained refinement.
After each round of refinement, model building and adjustments were made using COOT
[Emsley and Cowtan, 2004] including the insertion of solvent molecules and metal atoms.
The PLP ligand was designed using PRODRG [Schuttelkopf and van Aalten, 2004].
2.7 Computational modelling methods
2.7.1 Definition of non-standard residues
Topology files for the non-standard residues (benzaldehyde and PLP-glycine (PXG)) were
generated using the Antechamber package within AmberTools16 and the general AMBER
force field. These topology files were used for the subsequent MD simulations.
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2.7.2 Molecular mechanics molecular dynamics simulations
Molecular mechanics (MM) molecular dynamics (MD) simulations were performed using
the AMBER molecular mechanics ff14SB force field [Maier et al., 2015] and AmberTools16
to perform MD simulations. In all cases 150 psec of MD was simulated using the sander
program within AmberTools16. The first 50 psec of simulation were restrained with a force
constant of 50 kcal/mol Å−1 between the CA atom of benzaldehyde and the CG2 atom of
PXG. This also included an initial heating phase to 300K. The restraint was removed for the
final 100 psec of simulation.
2.7.3 Quantum mechanics/molecular mechanics (QM/MM) MD
simulations
QM/MM MD were performed for umbrella sampling simulations [Torrie and Valleau, 1977].
QM and MM regions were defined as shown in Figure 2.2. The semiempirical QM method,
pm6 [Stewart, 2007], was applied to ligands, benzaldehyde and PXG. In PXG the phosphate
group and adjoining CH2 group was excluded from the QM region resulting in a QM charge
of -1. QM regions were defined in the input scripts and link atoms placed between QM
and MM atoms, where covalently bonded, to fulfil the valences of these atoms. A 20 Å
surrounding sphere (about benzaldehyde and PXG) was treated using the AMBER MM
ff14SB [Maier et al., 2015] forcefield during simulation. All atoms outside the sphere
remained static during simulation. Umbrella sampling involved a -0.1 Å stepwise reduction
between the distance of the CA atom of benzaldehyde and the CG2 atom of PXG. For
this a force constant of 100 kcal/mol Å−1 was applied. A dihedral restraint about the
stereochemical coordinate was applied for 3R product forming reactions as instances of
these "flipping" into a pre-3S orientation were observed. For this an upper and lower force
constant of 50 kcal/mol Å−1 was applied to keep the benzaldehyde ligand between 0-180o
of the stereochemical coordinate (Figure 5.7).
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Figure 2.2: QM and MM regions for QM/MM MD umbrella sampling simulations. The
total non-static modelling region is contained within the sphere. Everything outside
this region remains static. The QM region (purple sticks) contains the atoms belonging
to benzaldehyde and PXG ligands (but not the phosphate group and adjoining CH2).
Everything else is in the MM region.
2.7.4 Visualisation of simulations
MM and QM/MD trajectory files were generated using the AmberTools package cpptaj [Roe
and Cheatham III, 2013]. These were visualised in PyMOL Molecular Graphics System
[DeLano, 2009], Version 1.8.7.0.
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E. coli Threonine Aldolase
3.1 Introduction
Low-specificity L-threonine aldolase (TA) from Escherichia coli (eTA) was first described by
Liu et al. [Liu et al., 1998]. They found eTA cleaves both diastereomers of L-threonine with
around a 42-fold preference for L-allo-threonine . While classified as a threonine aldolase,
eTA demonstrated to be rather more active with L-phenylserine (PS). The stereoselectivity
is however reduced with a 1.3-fold preference for the cleavage of 2S3R PS over 2S3S PS
(Figure 3.1) [Liu et al., 1998]. This poor diastereoselectivity is recurring in L-TAs with
substrates other than threonine [Steinreiber et al., 2007, Beaudoin et al., 2018]. PS and
PS-derived compounds are considered to be synthetically interesting as intermediates or
active ingredients, for example L-DOPS, used in the treatment of Parkinson’s [Ogawa et al.,
1985] and the antibiotic thiamphenicol [Ratzan et al., 1974] (Figure 3.2).
Figure 3.1: The reversible retro-aldol cleavage of 2S3R and 2S3S PS into benzaldehyde
and glycine. A reaction catalysed by eTA with poor stereoselectivity [Liu et al., 1998].
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Figure 3.2: Molecular structure of the Parkinson’s drug L-DOPS and the antibiotic
thiamphenicol. Both drug compounds display structural similarities to PS.
Synthesis of PS compounds using TAs has focused on exploiting different temperatures,
solvents [Chen et al., 2017], phases [Tibhe et al., 2013], and enzyme imobilisation
strategies [Tibhe et al., 2013] to obtain improved stereoselectivity. However, few have
used enzyme engineering to achieve desirable improvements [Gwon and Baik, 2010]. It
would appear this is in part due to lack of an appropriate high-throughput screen. One
of the main difficulties is having a suitable method that can discriminate between PS
diastereomers under kinetically controlled synthesis. While this can be achieved through
high-performance liquid chromatography (HPLC) or nuclear magnetic resonance (NMR),
these methods rather limit the throughput of screening. This can be overcome if the
direction of the screened reaction is reversed. By following the retro-aldol cleavage
of optically pure 2S3R and 2S3S PS, two comparable reactions relating to enzyme
stereoselectivity are obtained (Figure 3.1). Reisinger et al. [Reisinger et al., 2006]
developed a method based on this retro-aldol cleavage of PS. They used a direct colony
based assay where in-cell TA cleavage of PS was coupled to a benzaldehyde dehydrogenase.
Subsequent oxidation of benzaldehyde into benzoic acid via the dehydrogenase formed
NADH which could be measured by fluorescence. Individual colonies harbouring TA
variants could be transferred to a membrane and screened for activity with 2S3R and
2S3S PS. The success of this method in identifying stereoselective variants was however
not reported. [Reisinger et al., 2006].
The aims of this results chapter are to clone the gene for the low-specificity L-eTA into a
suitable expression system. We shall express, purify and kinetically characterise the enzyme
with optically pure 2S3R and 2S3S PS. Further we aim to develop a unique, high-throughput
screen, applicable for the screening of eTA variants for improved stereoselectivity.
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3.2 Cloning the gene for eTA
A synthetic codon optimised gene for the low-specificity L-eTA (ItaE) had previously been
ordered by the Berry Lab (Appendix Figure A.1). The gene came pre-cloned into a pUC57
vector. This was transformed into XL10-Gold cells (Section 2.3.5). Ligation independent
cloning (fast cloning) [Li et al., 2011] was used for insertion of ItaE into a pKK223-3
expression vector. Primers were designed to amplify pKK223-3 and ItaE by PCR in a way that
allowed the formation of the recombinant expression plasmid (pKK-ItaE) with ItaE present
at the multiple cloning site (MCS) (Appendix Table A.1). Clear bands for the plasmid and
the gene at the correct size were observed following PCR and agarose gel electrophoresis
(Figure 3.3).
Following ligation independent cloning, the pKK-ItaE construct was transformed into
XL10-Gold cells (Section 2.3.5). Ten single colonies were selected and cultured overnight
in 2 TY media (Section 2.2.4). From these, glycerol reference stocks were stored (Section
2.2.5) and DNA was prepared (Section 2.3.3). Successful cloning of the pKK-ItaE construct
was highlighted in restriction digest experiments (Figure 3.3). DNA from lanes 1 and 2
of Figure 3.3C was sent for sequencing analysis using universal primers PTRC-99A-for and
PTRC-99A-rev. These would bind either side of the ItaE gene in the MCS as shown in Figure
3.3B. The correct sequence was observed for both DNA samples affirming successful cloning
(Figure 3.4).
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Figure 3.3: A: PCR amplified ItaE and pKK223-3 at the expected sizes. Lane M: 10 kb
DNA ladder. Lane 1: PCR amplified ItaE (1 kb). Lane 2: PCR amplified pKK223-3 (4.6
kb ). B: The resulting expression plasmid (pKK-ItaE) from ligation independent cloning
[Li et al., 2011]. The plasmid contains ampicillin (Amp) and tetracycline (Tet) resistance
genes, an origin of replication (Ori) and a tac promoter (pTac). The ItaE gene was cloned
into the MCS with flanking PstI and EcoRI restriction sequences. Sites for PTRC-99A-for and
PTRC-99A-rev universal primers are highlighted either side of the MCS. C: Agarose gel for
the restriction digests of pKK-ItaE constructs. Top: Lane M: 10 kb DNA ladder. Lanes 1-10:
Double digested DNA from individual ligation independent cloning transformants. DNA
was digested with EcoRI and HindIII restriction enzymes to separate the gene and plasmid
to give two bands of 1 kb and 4.6 kb respectively as highlighted in Figure 3.3. Bottom: Lane
M: 10 kb DNA ladder. Lanes 1-10: NdeI double digested DNA. pKK-ItaE constructs would
be expected to show two bands of 2.8 kb and 2.9 kb. These bands would not be expected
to be visible individually, rather a single band between the 2.5 kb and 3 kb ladder markers.
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Figure 3.4: Sequencing data for correct construct obtained from ligation independent
cloning. Results were aligned to the codon optimised ItaE gene sequence. For the reverse
alignment the sequence data was reverse complimented so pairwise data could be observed.
3.3 Expression and purification of eTA
The tac promoter in pKK-ItaE (Figure 3.3B), is a hybrid of the trp and lac promoters [De Boer
et al., 1983]. Expression of genes under this promoter can occur by induction with IPTG.
Several aldolase enzymes used in the lab were shown to express at high levels in 2 TY
media following IPTG induction. A similar protocol was therefore followed (Section 2.2.4).
pKK-ItaE was transformed into E. coli BL21 cells and left to grow on 2 TY agar containing
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50 µg mL−1 ampicillin. Single colonies were picked and used to inoculate 5 mL overnight
cultures of 2 TY supplemented with 50 µg mL−1 ampicillin. Glycerol stocks of E. coli
BL21-pKK-ItaE cultures were stored and a further 50 µL of the culture was used to inoculate
a 50 mL day culture. This was incubated for a further 8 hours at 37oC, with shaking.
10 mL of day culture was used to inoculate 1 L of 2 TY supplemented with 50 µg mL−1
ampicillin. Cultures were incubated at 37oC, with shaking until an optical density (O.D) of
0.6 at 600 nm was reached. Protein expression was induced by addition of IPTG to a final
concentration of 0.1 mM.
eTA, encoded by the ItaE gene, was purified using a batch method by nickel affinity
chromatography (Section 2.4.1). The His6-tag on eTA enabled efficient isolation of the
enzyme. Samples were taken throughout the purification for analysis by SDS-PAGE (Figure
3.5). An overexpressed band was observed around 37 kDa in the cell lysate fraction.
The same band was also observed at a similar level in the soluble and unbound fractions
suggesting the nickel resin to have been overloaded. The eluted fraction showed a single
band for purified eTA corresponding to the expected mass of the enzyme (37 kDa). eTA
was dialysed into 50 mM sodium phosphate buffer (pH 8.0) and an aliquot was prepared
and sent for accurate mass determination by mass spectrophotometry (Figure 3.6). The
peak in the deconvoluted spectrum was within 1 Da of the expected mass of eTA and
is within the error limit of the instrument. This provided final conformation that eTA
had been successfully cloned, expressed and purified and was ready for further enzymatic
characterisation.
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Figure 3.5: SDS-PAGE gel for the purification of eTA. Samples were loaded as labelled
above and ran at a 20-fold dilution. Large amounts of overexpressed eTA remain in the
unbound fraction suggesting the resin to be overloaded with the recombinant protein. The
eluted fraction shows a very strong single band at the expected size for eTA (37 kDa) with
no suggestion of contaminating proteins.
Figure 3.6: Deconvoluted mass spectrum for eTA. The main peak shows a mass of 37446
Da which is within 1 Da of the expected mass of eTA (37447 Da). Sample was analysed
under denaturing conditions in acetonitrie.
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3.4 Characterisation of eTA stereoselectivity with 2S3R and 2S3S PS
eTA has been shown to be poorly stereoselective in the retro-aldol cleavage of 2S3R and
2S3S PS [Liu et al., 1998]. This provides an ideal system (enzyme and substrates) to target
for improving the stereoselectivity. 2S3R and 2S3S PS substrates were ordered as single
enantiomer compounds (Section 2.2).
3.4.1 An activity assay for the reversible cleavage of PS
Benzaldehyde and PS display different UV absorbance spectra due to the different
conjugation of electrons within their aromatic rings. To observe this the spectra of
benzaldehyde and 2S3R PS were measured. 1 mM of each compound was added to 50
mM sodium phosphate buffer, pH 8.0. Separate measurements of each compound were
performed and the spectra recorded (Figure 3.7). A distinct λmax at 250 nm was observed
for benzaldehyde that was not apparent for 2S3R PS. This difference in absorbance between
substrate and product spectra allows the aldol and retro-aldol reactions in Figure 3.1 to be
followed continuously. To demonstrate this two separate reactions were performed. In the
first 50µM eTA was added to 1 mM 2S3R PS and the spectra recorded over 5 minutes (Figure
3.8A). The results show clear production of benzaldehyde from the characteristic peak at
250 nm. Interestingly, the results also suggest that any wavelength between 230-300 nm is
suitable for following the retro-aldol cleavage of PS.
In the second reaction 200 µg of eTA was added to 1 mM benzaldehyde, 30 mM glycine and
the spectra recorded. It is necessary to use an excess of glycine to shift the unfavorable aldol
equilibrium [Franz and Stewart, 2014] and observe PS formation (Figure 3.8B). A reduction
in the benzaldehyde peak suggests it has been consumed in the aldol condensation reaction
however this provides no information on the stereoselectivity of the reaction.
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Figure 3.7: Wavelength absorbance spectra for benzaldehyde and 2S3R PS measured
using a JASCO spectrophotometer with a path length of 1 cm. A solution containing 0.1
mM benzaldehyde (purple) in 50 mM sodium phosphate pH 8.0 was measured against a
reference cuvette (pathlength 1 cm) containing the same buffer. The spectrum for 2S3R PS
(green) was also measured at 0.1 mM concentration in 50 mM sodium phosphate buffer,
pH 8.0.
Figure 3.8: A: Cleavage reaction progression. 50 µg of eTA was added to 1 mM 2S3R PS
in 50 mM sodium phosphate buffer pH 8.0 and 50 µM PLP in a 1 mL reaction volume.
Spectra were recorded over 5 minutes using a Nanodrop 2000 with 1 mm pathlength. B:
Condensation reaction progression. 200 µg of eTA was added to 1 mM benzaldehyde, 30
mM glycine in 50 mM sodium phosphate buffer pH 8.0 and 50 µ M PLP in a 1 mL reaction
volume. Spectra are shown at 3 minute intervals and a final spectrum measured after 24
hours.
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3.4.2 eTA kinetic characterisation
Michaelis-Menten kinetics were performed on purified eTA at a range of 2S3R and
2S3S PS concentrations (Section 2.5.8). The specific activity of eTA at each substrate
concentration was calculated using the molar extinction coefficient of 1.4 x 10−3 M−1
cm−1 for benzaldehyde at 279 nm [Liu et al., 1998]. These values were plotted against
substrate concentration and Michaelis-Menten curves produced (Figure 3.9) giving kinetic
parameters Km and kcat (Table 3.1). The results show virtually identical results for the
cleavage of both L- epimers with specificity constants (kcat/Km) of 5750 min−1mM−1 for
the 2S 3R and 5650 min−1mM−1 for 2S 3S PS. The selectivity preference (SP) compares
these two values for a measure of stereoselectivity as given by equation 3.1.
SP =
(kcat/Km)3S
(kcat/Km)3R
(3.1)
Figure 3.9: Michaelis-Menten kinetics curve for cleavage of both 2S3R and 2S3S PS
epimers. Measurements were performed in 50 mM sodium phosphate buffer pH 8.0, 50µM
PLP, 10% (v/v) DMSO at 30 oC. Each measurement was performed in a final volume of 1
mL in a quartz cuvette with a 1 cm path length . Reactions were started by addition of an
appropriate amount of enzyme and initial rates measured.
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2S3R Phenylserine 2S3S Phenylserine
kcat Km kcat/Km kcat Km kcat/Km SP
Protein (min−1) (mM) (min−1mM−1) (min−1) (mM) (min−1mM−1) 3* (S/R)
wild-type eTA 92± 3 0.016± 0.002 5750± 740 96± 3 0.017± 0.002 5650± 690 1.0
Table 3.1: Kinetic parameters for the eTA catalysed cleavage of 2S3R and 2S3S PS. The
selectivity preference (SP) at the 3 position is calculated from kcat/KM ratios for both 2S3R
and 2S3S PS
3.5 Development of a high-throughput assay for stereoselective
screening.
If improvements in stereoselectivity are to be engineered then a suitable screen is
required. It is also necessary to consider the thermodynamics with tasks of this nature
(Figure 3.10). Under kinetically controlled conditions the epimerisation barrier (∆∆G3R /
∆∆G3S) will determine the stereoselectivity where the transition state energies (E•PS‡) are
representative of the the kcat/Km value of the reaction. As this energy barrier difference
will remain the same independent of the aldol or retro-aldol reaction, we would expect
stereoselective variants to be equally selective in both synthesis and cleavage reactions.
The retro-aldol reaction will therefore be used as both optically pure 2S3R and 2S3R PS
compounds are owned. Furthermore we are able to make use of the favoured position of
equilibrium.
The screen must be suitable for the throughput required. Given that the structure of eTA
is available, this provides a very good starting point for a rational approach where key
residues can be identified. CASTing, employed by Reetz et al. [Reetz et al., 2006](Section
1.2.2.1), uses an effective strategy to sample a hotspot within a mutagenesis landscape. It
was decided that CASTing would be used for engineering efforts as multiple stereoselective
enzymes have been created with this approach [Sandström et al., 2012, Rowles et al.,
2016, Prasad et al., 2011]. The calculations for adequate screening of CASTing libraries
are discussed in Section 1.2.2.1. However, from previous studies, screening of around 3000
variants was suggested [Reetz et al., 2006, Prasad et al., 2011]. With this, a plate based
screen seemed the most appropriate way to proceed. In Section 3.4.1 we had shown an
effective spectrophotometric method to monitor the cleavage of PS using purified eTA. If the
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Figure 3.10: A hypothetical free energy diagram showing the reaction for a simplified
eTA (left) catalysed PS condensation/cleavage where E is enzyme, G is glycine, BA is
Benzaldehyde and PS is phenylserine. The respective 2S3R and 2S3S diastereomers are
denoted by 3R and 3S respectively. The left profile shows the wild-type eTA catalysed
reaction. In all instances the Gibbs free energy of the starting products, free benzaldehyde
and glycine, will remain constant. The Gibbs free energy for both 2S3R and 2S3S PS epimers
will also remain fixed and the difference between these two energies will determine the
thermodynamic ratio once equilibrium is reached. Under kinetic conditions the ratio of the
epimers will be dictated by the difference in the energy barriers∆∆G3R/∆∆G3S . The right
profile shows a hypothetical free energy profile for an improved 2S3S PS stereoselective
eTA variant.
same conversion could be shown using crude lysate this will provided a sufficient method
for monitoring eTA activity.
3.5.1 Crude lysate activity assay
As shown in figure 3.8 the λmax for benzaldehyde is around 250 nm. Detecting changes
in absorbance around this region can be difficult due to large amounts of background
absorbance. Several experiments were set up to investigate the cleavage of 2S3R PS using
an eTA crude lysate fraction (Section 2.5.4). Figure 3.11A showed clean spectra could be
obtained that followed the cleavage reaction progression when using a reference cuvette.
Removing the reference cuvette showed the change in spectra could be observed sitting on
top of the large background absorbance peak from the crude soluble extract (Figure 3.11B).
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To ensure the reaction being observed was eTA mediated, a negative control was performed
using a cell extract containing empty pKK-mod (Figure 3.11C ). From these results it was
clear the reaction could be observed using a eTA crude lysate at the given conditions.
It should be noted that for the experiments in this section the eTA cell lysate was prepared
from pellets produced by large scale expression (Section 2.2.4). This method reliably
produced large amounts of recombinant eTA whereas the screening method would require
suitable levels of expression in a 2 mL culture. To see if activity could still be observed at
this scale a plate based assay was developed.
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Figure 3.11: Wavelength absorbance spectra for crude cell fractions from a Uvicon
spectrophotometer. A: Activity for 5 µL of crude lysate fraction was measured using a
reference to hide background absorbance. The enzyme containing fraction was prepared
as per the methods in Section 2.5.4 and added to to a reaction buffer containing 50 mM
sodium phosphate pH 8.0, 50 µM PLP and 0.1 mM 2S3R PS in a total reaction volume of 1
mL. Spectra were recorded every minute over a 10 minute period. B: The reference cuvette
was removed and the reaction was repeated. This showed the background absorbance
underneath the peak being measured. C: Negative control showing a similarly prepared
fraction as in A, containing E. coli XL10-Gold pKK-mod crude lysate. The fraction was
assayed by the same methods as in A. D: Absorbance spectrum for 5 µL of the crude lysate
fraction in 1 mL sodium phosphate buffer pH 8.0. This amount appears to be suitable for
observing eTA activity without saturating the detector in the spectrophotometer.
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3.5.2 Small-scale expression test
Three different controls containing empty E. coli XL10-Gold, XL10-Gold ItaE and XL10-Gold
pKK-mod (containing only the pKK223-3 plasmid) were grown from single colonies in 2
mL deep well plates (Section 2.5.3). Following IPTG induction and overnight expression,
samples were lysed, pelleted (Section 2.5.4) and each crude lystate soluble fraction
analysed by SDS PAGE (Figure 3.12). Those fractions containing the recombinant pKK-ItaE
showed a clear overexpressed band at the correct size for eTA (37 kDa).
Figure 3.12: SDS PAGE gel showing soluble fractions for each small scale expression
test. Wells contained the two negative control fractions: E. coli XL10-Gold soluble and
XL10-Gold pKK-mod soluble and the positive control fraction XL10-Gold ItaE containing the
expressed eTA. For the positive control fractions a strong overexpressed band is observed
at the expected size for eTA (37 kDa).
3.5.2.1 Small-scale activity assay
To ensure sufficient levels of activity in the eTA containing fraction an activity assay was
performed. 50 µL of the crude lysate fractions were added to 0.15 mM of 2S3R or 2S3S PS.
The rates of reactions were measured and plotted for each epimer (Figure 3.13). Almost
identical levels of activity were observed for the fractions containing overexpressed eTA,
whereas the two negative control fractions showed no activity for either of the epmiers.
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Both XL10-Gold ItaE and XL10-Gold pKK-mod fractions were used to visualise activity in a
plate assay.
Figure 3.13: Initial rates for the cleavage of 2S3R and 2S3S PS with positive and negative
control fractions. Rates were measured using the activity assay from Section 3.4.1 and rates
calculated from the change in absorbance at 250 nm. 50 µL of each soluble fraction were
added to 50 mM sodium phospahte buffer pH 8.0 containing 50 µM PLP. Each reaction
contained 0.15 mM of the respective PS diastereomer. Activities were measured on a
Nanodrop 2000.
3.5.3 Plate screen development
To be effectively applied in a high-throughput screen, the crude lysate activities observed
in previous sections must be observable in a 96-well plate. Conditions to satisfy this
requirement were identified as described. eTA containing crude lysate soluble fractions
were prepared as per the methods in Section 2.5.4. To determine a suitable amount
of lysate to use in the plate screen, different volumes were assayed and their 2S3R PS
retro-aldol activity observed over 10 minutes (Figure 3.14A). It was suggested that 10 µL
of the crude lysate soluble fraction was the optimum amount. This would keep absorbance
within the detection range of the plate reader with significant observable activity. A repeat
assay of positive and negative control fractions was performed at the identified conditions
(Figure 3.14B). It was noticed that the error at the beginning of the reactions was larger
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than expected. This was due to an unexpected decrease in absorbance in one of the
measurements over the first 50 s (Figure 3.14B). Automated injection of substrate by the
plate reader in some instances causes the formation of bubbles. This altered the path length
of the well and the absorbance. Degassing buffers, thorough cleaning of injector apparatus
and varying concentrations of DNase and lysozyme in the lysis buffer failed to completely
eliminate the problem. As a result it was decided that the initial absorbance reading at
time=0 would not be used when measuring the rate. A further solution to eliminating the
chance of false positives was to perform a secondary activity assay on hits with triplicate
measurements.
Figure 3.14: A: Different volumes of the eTA crude lysate soluble fractions were tested to
find a suitable range for the plate screen. 10 µL gives sufficient activity while remaining
within the linear absorbance detection range of the plate reader. 30 µL and 50 µL assays
show very clear conversion however the reactions appear to reach equilibrium before 10
minutes. Each reaction contained the given volume of soluble fraction, 50 mM sodium
phosphate buffer pH 8.0 and 50 µM PLP. Reactions were started by automated injection of
2S3R PS to a final concentration of 0.15 mM. Measurements were taken every 6 seconds
for 10 minutes using a FLUOstar Galaxy plate reader. B: Continuous activity following
the cleavage of 2S3R PS by increase in absorbance at 260 nm in the presence of 10 µL of
soluble XL10-Gold ItaE fraction. Negative control reactions containing XL10-Gold cells with
empty pKK-mod showed no increase in absorbance suggesting no PS cleavage. Reactions
contained 50 mM sodium phosphate buffer pH 8.0, 50 µM PLP and 10 µL of either the
positive or negative control fraction. Reactions were performed in triplicate and started by
automated injection of 2S3R PS to a final concentration of 0.15 mM. Measurements taken
every 6 seconds for 10 minutes using a FLUOstar Galaxy plate reader. One positive control
shows an initial decrease in absorbance over the first 50 seconds due to formation of bubbles
following substrate injection.
The minimum required concentration of PS to observe activity is around 0.15 mM. The
screen will therefore only identify stereoselective variants with a Km greater than this value.
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The initial rates measured for PS epimers in the assay will be roughly proportional to kcat/Km
which will give an idea of stereoselectivity as discussed in Section 3.5.
3.5.4 Validity of the screen
The full process of the developed screen, from library to stereoselective mutant, is shown in
Figure 3.15. With the screen working for positive and negative controls a blind screening
assay was performed. A 2 mL deep well plate was inoculated with positive and negative
control single colonies and note made of which went in each. The screening methods in
Section 2.5.5 were followed and activities of the wells measured (Figure 3.16). Impressively
the screen worked in identifying all of the positive control wells where a threshold change
in absorbance of of 0.2 was set (∆Abs260). One single well identified a positive control
that was not expected. It is thought this is likely due to a cross contamination during
inoculation. The results suggest the screen is effective in identifying eTA activity. In the
following Chapter this screen will be implemented for identifying improved stereoselective
variants for PS by CASTing.
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Figure 3.15: A schematic diagram of the developed screen with suitable throughput for
screening CASTing libraries. 1: CASTing libraries are produced by PCR using degenerate
NDT codons and transformed into XL10-Gold supercompetent cells. 2: Colonies are picked
and grown in 2 mL deep well plates before expression is induced by addition of IPTG. 3a:
Cells are pelleted by centrifugation and re-suspended in a lysis buffer. Cells debris is next
pelleted to obtain a crude lysate soluble fraction 3b: Reference libraries are made from cell
fractions and stored in 25% (v/v) glycerol at -80oC. 4: PS screening plates are set up. Plates
only differ in the PS epimer used (2S3R or 2S3S PS). The exact same amount of enzyme
containing fraction is added to the plates before the reaction is started by addition of the
substrate by a plate sample injector. 5: Activities are analysed by change in Absorbance
at 260 nm. Hits with different observable activities for a single epimer are further assayed
to eliminate the chance of false positive results. 6: Selective hits are purified using nickel
affinity chromatography. 7: Purified enzymes are kinetically characterised for quantitative
assessment of increase in stereoselectivity.
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Figure 3.16: Blind screen to identify positive and negative control wells. A 2 mL deep well
plate containing growth media was inoculated with single positive and negative control
colonies. Positive colonies were added to the plate as shown by yellow boxes in the map
plate. The activity assay was performed measuring the 2S3R PS cleavage. All positive
colonies were identified. A threshold activity of 0.2 ∆ Abs260 for the screen was set.
One additional well (G4) was identified as a positive which was possibly due to cross
contaminated during inoculation. The activity screening plate contained 50 mM sodium
phosphate pH 8.0, 50 µM PLP, and 10 µL of the soluble enzyme fractions. The reactions
were started by addition of 2S3R PS to a final concentration of 0.2 mM
3.6 Summary
The gene for the low-specificity L-threonine aldolase from E. coli has successfully been
cloned using a ligation independent approach. This was successfully expressed, purified
and kinetically characterised for the cleavage of both 2S3R and 2S3S PS. The eTA has shown
to have no stereoselectivity preference for either of the L-PS epimers (1.02 2S3R), providing
a perfect system for engineering stereoselectivity.
An assay for the retro-aldol cleavage of PS has been developed showing any absorbance
between 230-300 nm can be used to follow activity. This has further been applied in the
development of a high-throughput screen capable of measuring the activity of eTA in crude
lysate. With this screen in place we now have a method of detecting stereoselective eTA
variants if paired with an effective mutagenesis strategy.
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Directed Evolution of E. coli Threonine Aldolase
4.1 CASTing, a method for directed evolution
Many previous enzyme evolution studies have utilised methods such as error-prone PCR
(epPCR) [Leung, 1989, Cadwell and Joyce, 1992] and DNA shuffling [Stemmer, 1994b]
to create libraries of variants with desirable traits. While epPCR can be effectively tuned
to control the rate of random mutational frequency [Chen and Arnold, 1993], it can
create a needle in a haystack scenario involving huge amounts of screening effort before
desirable traits are identified. Furthermore, the evolution strategy must be coupled to a
screen capable of achieving the throughput required for success in a realistic time frame.
Screening effort is the number of variants required to sample an available sequence space.
Focused directed evolution, as discussed in Section 1.2.2, targets residues likely implicated
in enzyme catalysis. The aims of this chapter are to use CASTing [Reetz et al., 2005, 2006]
for focused directed evolution of E. coli threonine aldolase (eTA). We use a known structure
of eTA to identify eight residues in close proximity of the ligand binding site which we
target for saturation with NDT codons. The developed screen from Chapter 3 is employed to
sample libraries of variants for improved stereoselectivity with 2S3R and 2S 3S phenylserine
(PS) substrates.
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4.1.1 The NDT degenerate codon
Degenerate codons can be used to introduce a specific set of amino acids into a protein.
While we are able to get all 20 of the canonical amino acids in with a single codon such
as NNK or NNS (Table 1.1). This does not give a 20:20 ratio, where 20 codons encode 20
amino acids. What we see are instances where the same amino acid is encoded up to three
separate times and others only once. The actual ratio of codons to amino acids with NNK
and NNS is 32:20 [Kille et al., 2012].
NDT is the single best degenerate codon for getting a balanced mix of side chain
functionality. It has been shown to produce smaller, higher quality libraries than NNK in
engineering improved stereoselectivity and activity in enzymes [Reetz et al., 2008]. NDT
encodes 12 codons with 12 different amino acids. The available bases, codons, and the
corresponding amino acid residues for an NDT codon are shown in Figure 4.1. In this thesis,
all the positions listed in Section 4.2.1 were targeted using the NDT condon. Primers used
for mutagenesis are shown in Appendix Figure A.2.
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Figure 4.1: Codon wheel highlighted for bases included in the NDT degenerate codon. The
four bases encoded by N (A (green), T (red), G (purple) and C (blue)) are in the center
of the wheel. Those encoded by D (A T and G) are coloured as before and shown in the
second ring. The outer ring highlights thymine (T) in red as this is the only possible base
in the codon at this position. Outside the ring, residues capable of insertion are listed by
their three letter code in black. The eight not coded for and stop codons are shown in grey.
Amino acid structures are also shown and colour coded according to their function.
4.2 Threonine aldolase mutagenesis
Several different L-threonine aldolases (L-TA) have been subject to engineering efforts,
giving clues to enzyme selectivity and specificity [di Salvo et al., 2014, Qin et al., 2014,
Giger et al., 2012, Gwon et al., 2012]. The structure of an E. coli threonine aldolase has
been published by di Salvo et al. [di Salvo et al., 2014, Kielkopf and Burley, 2002]. Having
this structure provides a useful starting point for the selection of sites to target with focused
mutagenesis.
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4.2.1 Selection of residues for CASTing of eTA
Eight residues were picked that were in, or close to, the active site of eTA. These were
subjected to the CASTing method [Reetz et al., 2006] (Section 1.2.2.1) and paired into
four CASTing groups of two amino acids. Residues were chosen based on their location
within the protein, and grouped on likely pairwise interactions (Figure 4.2). eTA exists as
a homotetramer containing four equivalent active sites [di Salvo et al., 2014](Section 5.2).
Each active site contains residues from three of the individual monomers (Figure 4.2).
Figure 4.2: eTA shown as the homotetramer composed of chains A (Yellow), chain B
(green) chain C (pink) and chain D (brown) from PBD entry 4LNL. The homotetramer was
generated from the deposited dimer structure along the 2-fold symmetry axis. Residues
from three of the monomer subunits form four equivalent active sites. One of these is
expanded to show the selected CASTing residues and their pairwise grouping: Group 1:
His83 and Phe87, Group 2: His126 and Phe127, Group 3: Leu86 and Ala81, Group 4:
Tyr30 and Arg229. The PLP cofactor in a Schiff base with 2S3S threonine (white) and 2S3R
threonine (purple) is also shown.
Group 1 consists of His83 and Phe87. Both of these residues have been subject to mutational
studies however only for the cleavage of threonine [di Salvo et al., 2014]. His83 is
hypothesised as the catalytic base in the retro-aldol cleavage but retains significant activity
when mutated to a non-basic residue suggesting this not to be the case [di Salvo et al.,
2014]. Phe87 is interestingly the only residue to differ in the active site of eTA and A.
jandaei TA. Mutating this residue to an alanine in eTA has little effect on the selectivity or
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specificity of the enzyme for threonine cleavage [di Salvo et al., 2014]. Group 2 contains
His126 and Phe127. His126 is another basic residue in close proximity to the substrate
aldol oxygen (Figure 4.2). It could potentiate selectivity, acting as the catalytic base in the
retro-aldol mechanism. A H126F variant was found to have increased specificity for 2S3S
threonine cleavage but with no increase in selectivity [di Salvo et al., 2014]. In the A.
jandaei TA the equivalent histidine (His128) showed improved activity for both L-threonine
epimers in a H128Y variant [Qin et al., 2014]. Interestingly, they also found a H128D
mutant with a small 1.8-fold increase in selectivity for L-allo-threonine with respect to the
wild-type enzyme. This variant however, displayed less than 10% of the original activity.
Group 3 contains Ala81 and Leu86. This group differs to the others in that the residues are
located within the secondary shell of the active site. No published engineering studies have
been performed on these residues. Group 4 contains Tyr30 and Arg229. It was recently
shown the homologous residue to Arg229 in A. jandaei could be changed to an alanine
to give improved alanine racemase, and reduced TA, activity [Fesko et al., 2018]. Baik et
al. [Gwon et al., 2012] report a Y30C variant as one of four in Streptomyces coelicolor TA
leading to a five-fold improvement in stereoselectivty for synthesis of L-threo-DOPS (2S3R
dihydroxyphenylserine). However, no structure or full gene sequence has been published
so it is not possible to confirm whether this is a homologous residue in eTA.
While several of these positions have been subject to mutagenesis studies, none have
investigated the affect with PS substrates. Also, the potential synergistic interactions
between multiple active site residues remains largely unexplored. One study by Giger et
al. [Giger et al., 2012] simultaneously targeted four conserved positions within another
low-specificity L-TA from Caulobacter crescentus. These were targeted by CASTing with
NNS degenerate codons. A high-throughput screen was developed whereby a glycine
auxotrophic cell strain was created. The knockouts of genes leading to synthesis of glycine
in the cell were shown to be lethal to cell growth [Giger et al., 2012]. Subsequent screening
of the generated libraries of the TA only yielded colonies still capable of performing the
retro-aldol cleavage on either 2S3R or 2S3S threonine. The result concluded that a well
conserved histidine (homologous to His83 in eTA) was essential for retro-aldol activity as
no mutations were tolerated at this position [Giger et al., 2012].
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4.2.2 Generation of eTA CASTing libraries
While statistically we can calculate the required screening effort as shown in Section 4.1,
this makes a further assumption that each nucleotide base is equally probable of occurring
in each CASTing library. For this to be true, there must be no bias in the gene mutagenesis
with degenerate primers. Upon inquiry, machine mixed degenerate primers were described
as susceptible to "skewing" due to all four (for base N) nucleoside phosphoramidites not
hitting the column at the exact same time. Hand mixed degenerate primers, that are not
susceptible to this machine bias, were ordered and the occurrence of each base at N, D and
T positions following mutagenesis was observed (Figure 4.3).
Figure 4.3: NDT sequencing data for CASTing groups 1-4 calculated from the of each base
observed for each NDT degenerate codon. 15 colonies for each library were randomly
selected and sent for sequencing. Group 4 only contains sequence data for 14 mutants due
to one unidentifiable sequence read. The expected ratio for each base is shown in row 1.
Nucleotide bases A, T, C and G are shown in green, red, blue and black respectively. At
degenerate base N: A, T, C and G are expected to be present in equal amounts (1/4, 1/4,
1/4, 1/4). At degenerate base D: A, T, and G should also be present in equal amounts
(1/3, 1/3, 1/3). Base T is used as the final nucleotide in the codon and should be the only
nucleotide present. Each amino acid position is highlighted using the single letter alphabet
nomenclature and its position in the eTA protein sequence.
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The results from sequencing show in all cases, the expected bases corresponding to N, D
and T were observed. While next generation sequencing could be used to sequence a larger
portion of each library, this was deemed unnecessary given all bases were observed and no
unexpected mutations were seen. It was decided, for each group, 540 total colonies would
be screened. This would give added confidence that a significant potion of the sequence
space for each group was covered.
4.3 CASTing of eTA
Mutagenesis was performed for all libraries as described in Section 2.5.2. Libraries were
transformed into competent E. coli cells following DpnI digestion and resulting colonies
were picked and grown (Section 2.5.3). Reference plates for each library were made and
stored at -80oC in case further analysis was required (Section 2.5.4). Crude lysate fractions
were prepared (Section 2.5.4) and screened using the developed high-throughput screening
method (Section 2.5.5). To give an idea of the developed selection process, an example of
the screening and identification procedure is shown (Figure 4.4)1. Variants with a threshold
activity level of 0.2 ∆Abs260, over a six minute screening period are highlighted in green in
the activity plates (Figure 4.4A). To constitute further analysis as a hit, both an activity of 0.2
∆Abs260, and at least a two-fold activity preference for either of the L-PS epimers is required.
In well analysis, wells with at least one activity greater than 0.2 ∆Abs260 are identified
(Figure 4.4B). These identified values are then used to calculate the level of selectivity for
each enzyme fraction for the respective L-PS epimer (selectivity analysis) (Figure 4.4C). It
is ultimately this selectivity analysis that is used to identify hits for further characterisation.
From this point in the thesis all screening activity plates (Figure 4.4A) and the well identifier
analysis (Figure 4.4B) will be shown as appendix figures. The calculated selectivity analyses
are shown as main text figures. For these, a dark purple colour would be suggestive of a
strongly selective variant (up to 10-fold) for 2S3R PS or dark brown for 2S3S PS (Figure
4.4C).
1The reader might also refer back to Figure 3.15 for clarity of the screening process
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Figure 4.4: From enzyme fraction to identifiable hit: the process of screening one full
plate of library variants. Results for the first plate of screened variants for CASTing group 1
(H83N DT F87N DT ) are shown. A: Two UV-transparent plates are set up in parallel containing
50 mM sodium phosphate pH 8.0 and 10 µL of each prepared lysate fraction. Positive
controls containing wild-type eTA are shown in wells H7-9 and negative controls containing
empty pKK-mod in wells H10-12. Reactions are started by automated injection of either
2S3R or 2S3S PS to each of the respective UV plates to a final concentration of 0.15 mM
using a Fluorostar Galaxy plate reader. The change in absorbance at 260 nm is measured
over 9 minutes Readings from the final 6 minutes are used to calculate the change in rate
to allow the injected wells to first settle. Those wells with a 0.2 ∆Abs260 or greater are
highlighted in green. The 2S3R PS screening plate is shown on the left and 2S3S PS on the
right. B: Well identifier analysis: Activity ratios for wells with at least one activity reaching
0.2 ∆Abs260 or greater are highlighted (2S3R / 2S3S). Those in purple will have greater
levels of activity for the 2S3R PS retro-aldol cleavage and those in brown for 2S3S PS. C:
Selectivity analysis. The level of selectivity observed for each well variant is given by the
intensity of purple or brown. Those in a dark purple would be suggestive of at least a
10-fold selective variant for 2S3R PS. In the example shown no significant active, selective
variants are observed.
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4.3.1 Group 1, H83N DT F87N DT
540 individual colonies from the group 1 library were picked and grown in deep well plates.
Crude lysate fractions were prepared and screened. Activity plates and well identifier
analysis for group 1 are shown in Appendix Figures A.2-A.4. Calculated selectivity analysis
was used to find possible selective variants (Figure 4.5). Several wells met the required
criteria for further investigation, all of which suggested variants with increased 2S3S PS
selectivity. It was expected that false positive results would be identified and eliminated
in the subsequent follow-up screen. The activity assay described in Section 3.4.1 was
performed as a further screen on promising, selective lystate fractions (Figure 4.6A). From
this, three variants, 4 F1, 4 G10 and 5 F9, still showed promising 2S3S PS selectivity.
Samples 4 F1, 4 G10 and 5 F9 were purified (Figure 4.6B) and their selectivity again
measured with a purified selectivity screen (Figure 4.6C). The selectivity of samples 4 G10
and 5 F9 was subsequently quantified by Michaelis-Menten kinetics (Figure 4.6D) to obtain
kinetic parameters kcat and Km (Table 4.1).
Sequencing showed 4 G10 and 5 F9 to be H83S F87Y and H83C F87Y mutants respectively.
Both, showed small increases in the selectivity for 4 G10, the most so with a 2.6-fold
selectivity preference (SP) for the 2S3S PS epimer. Both showed decreases in kcat and
Km with a 30-fold reduction in the 2S3S PS specificity constants (kcat/Km) with respect to
wild-type eTA.
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Figure 4.5: Selectivity analysis for CASTing group 1 (H83N DT F87N DT ). Selectivity of
variants reaching the threshold level of activity are highlighted for each plate. A measure
of plate selectivity is given by the intensity of the purple or brown colour for 2S3R and 2S3S
PS respectively. Wells H7-9 contain the wild-type eTA crude lysate positive control and wells
H10-12 contain empty plasmid pKK-mod crude lysate negative control. Values in the top
left of each plate denote the nomenclature used to identify each screening plate where 1.1
identifies the plate as CASTing group 1 , plate 1 and 1.6 as CASTing group 1, plate 6.
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Figure 4.6: A: Nanodrop activity assay of hits showing measurable activity. 70 µL of
the lysate fraction was added to 50 mM sodium phosphate buffer pH 8.0 and 50 µM
PLP. Reactions were started by addition of either 2S3R or 2S3S PS and the rate for each
epimer (2S3R in purple and 2S3S in brown) retro-aldol cleavage measured over time.
B: SDS PAGE gel for the three purified variants, 4 F1, 4 G10 and 5 F9. Each protein
was purified using nickel affinity chromatography. Lanes were loaded as shown and run
against a protein ladder. All proteins showed strong bands corresponding to masses of
overexpressed eTA variants (37 kDa). C: Purified selectivity assay. Reactions contained 50
mM sodium phosphate buffer pH 8.0, 50 µM PLP and 0.1 mM of each of the PS epimers
(2S3R in purple and 2S3S in brown). Reactions were started by addition of 1 µM of
the purified enzymes and the change in absorbance at 250nm measured using a Uvicon
spectrophotometer. D: Michaelis-Menten kinetics curves for 4 G10 and 5 F9. Retro-aldol
activity for the cleavage of each of the PS epimers (2S3R in purple and 2S3S in brown) at a
range of concentrations was measured. Each activity measurement was performed at 30oC
in 50 mM sodium phosphate buffer pH 8.0 containing 50 µM PLP, 10% (v/v) DMSO and an
appropriate amount of enzyme. The change in absorbance at 279 nm was measured and
the specific activity calculated using the molar extinction coefficient of 1400 M−1cm−1 as
described by Liu et al. [Liu et al., 1998].
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2S3R Phenylserine 2S3S Phenylserine
kcat Km kcat/Km kcat Km kcat/Km SP
Protein (min−1) (mM) (min−1mM−1) (min−1) (mM) (min−1mM−1) 3* (S/R)
wild-type eTA 92± 3 0.016± 0.002 5750± 740 96± 3 0.017± 0.002 5650± 690 1.0
H83S F87Y (4 G10) 61± 5 0.8± 0.18 76± 18 75± 4 0.38± 0.07 197± 38 2.6 (S)
H83C F87Y (5 F9) 51± 3 0.65± 0.09 78±12 58± 2 0.5± 0.05 116±12 1.5 (S)
Table 4.1: Kinetic parameters for the purified variants from CASTing group 1 (H83N DT
F87N DT ). Kinetics measured for the enzyme catalysed cleavage of 2S3R and 2S3S PS. The
selectivity preference (SP) at the 3 position is calculated from kcat/Km ratios. For both
variants kcat is reduced and Km increased with respect to wild-type eTA. Sample 4 G10
shows a double H83S F87Y mutant with a 2.6-fold SP for 2S3S PS.
4.3.2 Group 2, H126N DT F127N DT
The group 2 CASTing library targeted residues H126 and F127. The initial plate screen
was performed as with group 1 in Section 4.3.1. Activity plates and well identifier analysis
are shown in Appendix Figures A.5-A.7. Selectivity analysis highlighted eight variants that
met the criteria for follow up screening (Figure 4.7). Although the Nanodrop assay used
for the follow up screen in Section 4.3.1 is suitable for measuring the selectivity of the
samples it requires significantly more manual intervention as continuous measurements
cannot reliably be made with this model2. Increased throughput with the same results can
be achieved using a modified version of the plate reader screen and is thus used for all
subsequent follow up screening experiments (Section 2.5.6).
The eight lysate samples with promising selectivity were further screened and the respective
retro-aldol activity for each of the PS epimers plotted (Figure 4.8). The results showed
that the identified "hits" had been false positives as no significant levels of selectivity were
observed in the follow up screen. Therefore no further characterisation of these variants
was performed.
2The Nanodrop2000 model used does not contain the cuvette holder of the 2000c model and measurements
are therefore made on the sample pedestal. This requires fresh application of between 1-2.5 µL of the reaction
before each measurement is made to avoid sample evaporation.
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Figure 4.7: Selectivity analysis for CASTing group 2 (H126N DT F127N DT ). Selectivity of
variants reaching the threshold level of activity are highlighted for each plate. A measure of
plate selectivity is given by the intensity of the purple or brown colour for 2S3R and 2S3S PS
respectively.Wells H7-9 contain the wild-type eTA positive control and wells H10-12 contain
empty plasmid (pKK-mod) negative control. Values in the top left of each plate denote the
nomenclature used to identify each screening plate where 2.1 identifies the plate as CASTing
group 2 plate 1 and 2.6 as CASTing group 2 plate 6.
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Figure 4.8: Follow up screen for eight group 2 (H126N DT F127N DT ) variants. Reactions
were performed in a Fluorostar Galaxy plate reader. 30 µL of each lysate fraction was
added to 50 mM sodium phosphate pH 8.0 containing 50 µM PLP. Reactions were started
by addition of the respective PS epimers (2S3R in purple and 2S3S in brown) to a screening
concentration of 0.15 mM. The total reaction volume for each well was 200 µL. Retro-aldol
activity was recorded observing the change in absorbance at 260 nm. None of the measured
lysate samples displayed any noteworthy improvements in selectivity.
4.3.3 Group 3, A81N DT L86N DT
Group 3 contains residues A81 and L86. These are not active site residues but instead
appear behind His 83 and Phe 87 (Figure 4.2). The library was screened for variants with
improved selectivity. Activity plates and well identifier analysis are shown in Appendix
Figures A.8-A.10. It is clear that the majority of the mutations had little affect on the activity
of the enzyme variants, with the vast majority reaching the threshold levels of retro-aldol
activity for both the PS epimers. Fifteen variants were identified with levels of activity
and selectivity for further screening (Figure 4.9). These were further screened as shown
in Figure 4.10. The results suggested no noteworthy improvements in selectivity within
the conditions of the screen. Subsequently none of these were taken forward for kinetic
characterisation. The results further suggest that the two positions A81 and L86 are unlikely
to be key residues in determining stereoselectivity and have little effect on the activity of
the enzyme.
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Figure 4.9: Selectivity analysis for CASTing group 3 (A81N DT L86N DT ). Selectivity of
variants reaching the threshold level of activity are highlighted for each plate. A measure of
plate selectivity is given by the intensity of the purple or brown colour for 2S3R and 2S3S
PS respectively. Wells H7-9 contain the wild-type eTA positive control and wells H10-12
contain empty plasmid (pKK-mod) negative control. Values in the top left of each plate
denote the nomenclature used to identify each screening plate.
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Figure 4.10: Follow up screen for fifteen group 3 (A81N DT L86N DT ) variants. Reactions
were performed in a Fluorostar Galaxy plate reader. 30 µL of each lysate fraction was
added to 50 mM sodium phosphate pH 8.0 containing 50 µM PLP. Reactions were started
by addition of the respective PS epimers (2S3R in purple and 2S3S in brown) to a screening
concentration of 0.15 mM. The total reaction volume for each well was 200 µL. Retro-aldol
activity was recorded observing the change in absorbance at 260 nm. None of the measured
lysate samples displayed any noteworthy improvements in selectivity.
4.3.4 Group 4, Y30N DT R229N DT
The final library for screening in the first CASTing cycle was group 4. This group contained
residues Y30 and R229. Unlike the other previously screened groups, these residues are
not within close sequence proximity despite appearing almost adjacent in the active site
(Figure 4.2). The library for this group was created using a multi site-directed mutagenesis
kit (Section 2.5.2). Screening of the group 4 library was performed and retro-aldol activity
for the enzyme catalysed reactions recorded (Appendix Figures A.11-A.13). 37 hits met
the criteria for further analysis (Figure 4.11), significantly more than seen in screening of
the previous libraries. These samples were further screened as shown in Figures 4.12A-C.
Several of the hits taken forward from plate 4.1 in Figure 4.11 were shown to be false
positives; however multiple variants still demonstrated a clear preference for cleavage of
2S3S PS. This was also seen for the majority of the other variants in the screen. Of the
37 hits initially identified, 24 of those still displayed at least a two-fold preference for the
retro-aldol cleavage of the 2S3S substrate. This suggests that one or both of these targetted
positions could be involved in determining stereoselectivity in the reaction. To determine
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which of these variants were unique, DNA samples were sent for sequence analysis. This
showed 14 of the 24 samples were unique variants (Figure 4.12D). Those initially displaying
a slight 2S3R preference (5 G5 and 6 E10) returned wild-type sequence data. The 14
unique variants were purified (Appendix Figure A.14) and their selectivity measured (Figure
4.13). 12 of the purified variants still displayed at least a two-fold preference for retro-aldol
cleavage of the 2S3S substrate. The occurrence of each residue at position 30 revealed that
six residues (plus the wild-type tyrosine) were accepted in the 12 stereoselective variants. In
contrast only four (plus the wild-type arginine) were observed at position 229. Interestingly,
half of those contained a R229N substitution (Figure 4.13).
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Figure 4.11: Selectivity analysis for CASTing group 4 (Y30N DT R229N DT ). Selectivity of
variants reaching the threshold level of activity are highlighted for each plate. A measure of
plate selectivity is given by the intensity of the purple or brown colour for 2S3R and 2S3S PS
respectively.Wells H7-9 contain the wild-type eTA positive control and wells H10-12 contain
empty plasmid (pKK-mod) negative control. Values in the top left of each plate denote the
nomenclature used to identify each screening plate. 37 wells met the required criteria for
further analysis.
All of these variants had comparably low levels of 2S3R PS cleavage activity. It was therefore
decided that those displaying the highest level of activity for 2S3S PS would have their
selectivity quantified by kinetic characterisation. Kinetic parameters kcat and Km were
determined for the two variants (Figure 4.13C and D) and their values recorded in Table
4.2. 4 B10 (Y30F R229N) had a kcat value 2.4 times greater for the 2S3S reaction and
comparable Km values, translating to a SP of 3.1 for 2S3S PS. 3 F8 (Y30R) had similar kcat
values for both substrates however a 3.1-fold SP was calculated owing to a 3-fold lower Km
for 2S3S PS. In comparison to wild-type eTA, both variants had increased kcat values for
both of the PS epimers but larger Km values. As a result the specificity constant’s for both
variants are between four to five-fold lower than those of wild-type eTA for the retro-aldol
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cleavage of 2S3S PS. Both positions in the group 4 library are thus involved in determining
the stereoselectivity of eTA catalysed cleavage of L-PS.
Figure 4.12: A: Follow up screen for variants identified in plate 4.1 of Figure 4.11. 14
of the lysate samples were screened revealing six of these to be notably selective for 2S3S
PS. Reactions were performed in a Fluorostar Galaxy plate reader. 30 µL of each lysate
fraction was added to 50 mM sodium phosphate pH 8.0 containing 50 µM PLP. Reactions
were started by addition of the respective PS epimers (2S3R in purple and 2S3S in brown)
to a screening concentration of 0.15 mM. The total reaction volume for each well was 200
µL. Retro-aldol activity was recorded observing the change in absorbance at 260 nm. B:
Follow up screen for variants identified in plates 4.2-4.4 of Figure 4.11. All variants showed
notable selectivity for 2S3S PS. Reactions were performed as in A. C: Follow up screen for
15 variants identified in plates 4.5 and 4.6 of Figure 4.11. 11 variants show notable 2S3S PS
selectivity. Reactions were performed as in A. D: Amino acid substitutions at Y30 and and
R229 for mutations identified from selective variants. 14 unique variants were observed.
No strong preference for a particular residue is observed at position 30 however six of
the unique variants contain the R229N mutation (all of which display at least a two-fold
preference for 2S3S PS.
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Figure 4.13: A: Purified selectivity assay on unique variants identified from Figure 4.12.
Reactions were performed in a Fluorostar Galaxy plate reader. 7µM of each purified enzyme
(50 µg) was added to 50 mM sodium phosphate pH 8.0 containing 50 µM PLP. Reactions
were started by addition of the respective PS epimers (2S3R in purple and 2S3S in brown)
to a screening concentration of 0.15 mM. All enzymes appear to show a two-fold or greater
2S3S PS stereo-preference except for 1 A10 (Y30H) and 1 C1 (Y30N R229) which show
only a slight preference for this reaction. B: The frequency distribution of each amino acid
at position 30 and 229 for the 12 2S3S PS selective variants. No preference for a specific
residue appears at position 30 however, at position 229 six of the 12 variants contain the
R229N mutation. C and D: Michaelis-Menten kinetics curves for Y30F R229N (4 B10) and
Y30R (3 F8) eTA variants. Retro-aldol activity for the cleavage of each of the PS epimers
(2S3R in purple and 2S3S in brown) at a range of concentrations was measured. Each
activity measurement was performed at 30 oC in 50 mM sodium phosphate buffer pH 8.0
containing 50µM PLP, 10% (v/v) DMSO and an appropriate amount of enzyme. The change
in absorbance at 279 nm was measured and the specific activity calculated using the molar
extinction coefficient of 1400 M−1cm−1 as described by Liu et al. [Liu et al., 1998].
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2S3R Phenylserine 2S3S Phenylserine
kcat Km kcat/Km kcat Km kcat/Km SP
Protein (min−1) (mM) (min−1mM−1) (min−1) (mM) (min−1mM−1) 3* (S/R)
wild-type eTA 92± 3 0.016± 0.002 5750± 740 96± 3 0.017± 0.002 5650± 690 1.0
Y30F R229N (4 B10) 172± 4 0.66± 0.03 261± 13 412± 23 0.51± 0.07 808± 120 3.1 (S)
Y30R (3 F8) 212± 15 0.79± 0.15 268± 54 209± 8 0.25± 0.03 836± 105 3.1 (S)
Table 4.2: Kinetic parameters for the purified variants from CASTing, group 4 (Y30N DT
R229NN DT ). Kinetics measured for the enzyme catalysed cleavage of 2S3R and 2S3S
PS. The selectivity preference (SP) at the 3 position is calculated from kcat/KM ratios for
both epimers. Sample 4 B10 contained the double Y30F R229N mutant and displayed a
selectivity factor ratio of of 3.1 for 2S3S PS. Sample 3 F8 also displayed a selectivity factor
ratio of 3.1 and contained a single Y30R mutant.
4.4 Rational combinations of CASTing mutations (1)
A greater than three-fold improvement in selectivity had been made following the first round
of CASTing for 2S3S PS cleavage. It was also investigated whether rational combinations
of identified variants, in a "best with the best" approach could produce an additive effect on
stereoselectivity. This work was carried out in collaboration with an undergraduate student,
Sophie Glendinning (Sections 4.4.1 and 4.4.2).
4.4.1 Y30F R229N eTA with additional H83S and F87Y changes
The two best variants found above were H83S F87Y (Group 1, Table 4.1) and Y30F
R229N (Group 4, Table 4.2). Primers were ordered to combine these four mutations
(Appendix table A.2). Mutagenesis was performed as described in Section 2.5.2 and the
recombinant plasmid was transformed into E. coli XL10-Gold cells. The correct mutations
were confirmed by sequence analysis and the protein was subsequently expressed, purified
(Appendix Figure A.21) and sent for accurate mass determination (Appendix Figure A.22).
Michaelis-Menten kinetics were measured for the variant as shown in Figure 4.14 and the
parameters calculated (Table 4.3).
The quadruple mutant is almost entirely stereoselective for 2S3S PS with a measured SP
of 500. The variant displays a five-fold reduction in kcat , with respect to the wild-type eTA
for 2S3S PS and an 18-fold increase in Km. This however presents as a 100-fold decrease
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in the specificity constant of the enzyme. The quadruple mutant is thus almost entirely
stereoselective for the 2S3S PS retro-aldol cleavage albeit with reduced catalytic efficiency.
Figure 4.14: Michaelis-Menten kinetics curves for the quadruple Y30F R229N H83S F87Y
eTA variant. Retro-aldol activity for the cleavage of each of the PS epimers (2S3R in purple
and 2S3S in brown) at a range of concentrations was measured. Each activity measurement
was performed at 30oC in 50 mM sodium phosphate buffer pH 8.0 containing 50 µM PLP,
10% (v/v) DMSO and an appropriate amount of enzyme. The change in absorbance at 279
nm was measured and the specific activity calculated using the molar extinction coefficient
of 1400 M−1cm−1 as described by Liu et al. [Liu et al., 1998].
2S3R Phenylserine 2S3S Phenylserine
kcat Km kcat/Km kcat Km kcat/Km SP
Protein (min−1) (mM) (min−1mM−1) (min−1) (mM) (min−1mM−1) 3* (S/R)
wild-type eTA 92± 3 0.016± 0.002 5750± 740 96± 3 0.017± 0.002 5650± 690 1.0
Y30F R229N H83S F87Y 1.1± 0.3 10.0± 4.8 0.11± 0.06 17± 1 0.31± 0.08 55± 15 500 (S)
Table 4.3: Kinetic parameters for the Y30F R229N H83S F87Y eTA variant. Kinetics
measured for the enzyme catalysed cleavage of 2S3R and 2S3S phenylserine. The selectivity
preference (SP) at the 3 position is calculated from kcat/Km ratios for both epimers.
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4.4.2 Y30F R229N eTA with separate H83S and F87Y changes
To investigate whether both the H83S and the F87Y changes are required for the observed
increase in in selectivity, the triple mutants, Y30F R229N H83S and Y30F R229N F87Y
were made. Primers were ordered (Appendix Table A.2) and site directed mutagenesis
was performed (Section 2.5.2). The recombinant plasmids were transformed into E. coli
XL10-Gold cells and the proteins were subsequently expressed, purified (Figures A.23 and
A.24) and sent for accurate mass determination (Figures A.25 and A.26). Kinetics were
performed on both variants (Figure 4.15) and parameters recorded in Table 4.4.
The results suggest a cooperative effect is required between H83S and F87Y to produce
the highest level of selectivity when added to the Y30F R229N mutant. No increase in the
selectivity is observed in Y30F R229N H83S eTA with respect to the quadruple mutant. The
Y30F R229N F87Y variant however, is significantly selective for 2S3S PS with a SP of 18.
The specificity constant of this enzyme for the 2S3S substrate is eight-fold greater than that
of the highly selective Y30F R229N H83S F87Y variant, showing improvements in catalytic
efficiency.
Figure 4.15: Michaelis-Menten kinetics curves for Y30F R229N H83S and Y30F R229N
F87Y eTA variants. Retro-aldol activity for the cleavage of each of the PS epimers (2S3R
in purple and 2S3S in brown) at a range of concentrations was measured. Each activity
measurement was performed at 30oC in 50 mM sodium phosphate buffer pH 8.0 containing
50 µM PLP, 10% (v/v) DMSO and an appropriate amount of enzyme. The change in
absorbance at 279 nm was measured and the specific activity calculated using the molar
extinction coefficient of 1400 M−1cm−1 as described by Liu et al. [Liu et al., 1998].
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2S3R Phenylserine 2S3S Phenylserine
kcat Km kcat/Km kcat Km kcat/Km SP
Protein (min−1) (mM) (min−1mM−1) (min−1) (mM) (min−1mM−1) 3* (S/R)
wild-type eTA 92± 3 0.016± 0.002 5750± 740 96± 3 0.017± 0.002 5650± 690 1.0
Y30F R229N H83S F87Y 1.1± 0.3 10.0± 4.8 0.11± 0.06 17± 1 0.31± 0.08 55± 15 500 (S)
Y30F R229N H83S 18± 0.4 1.07± 0.12 17± 2 50± 2 0.88± 0.1 57± 6 3.4 (S)
Y30F R229N F87Y 48± 2 2.04± 0.15 24± 2 373± 14 0.88± 0.09 424± 46 18 (S)
Table 4.4: Kinetic parameters for Y30F R229N H83S F87Y eTA and rational combinants.
Kinetics measured for the enzyme catalysed cleavage of 2S3R and 2S3S PS. The selectivity
preference (SP) at the 3 position is calculated from kcat/Km ratios for both L-PS epimers.
4.5 Iterative CASTing of eTA
Iterative rounds of CASTing (ISM) has proven to be a successful method in developing
highly selective enzymes [Reetz et al., 2006, Prasad et al., 2011]. In this approach the
best (or second best) variant is taken forward for subsequent mutagenesis with the defined
CASTing groups and further screened for the improved characteristic. From Table 4.2,
Y30F R229N and Y30R eTA variants both showed greater than a three-fold SP for 2S3S
PS. The double mutant had around a two-fold greater kcat for the 2S3S PS epimer and
further contained the R229N mutation which was present in 46% of the selective, purified
variants (Figure 4.13B). It was therefore decided that this mutant (Y30F R229N) would be
used as the template for ISM. Figure 4.16 highlights the engineering strategy thus far.
Figure 4.16: The conducted engineering strategy for the directed evolution of eTA. The
first round of CASTing (Round A) identified the most selective variants to be from group 4
at positions Y30 and R229. The next best, not from group 4, were identified in group 1 at
positions H83 and F87. Rational combinations of these mutations were made, identifying
two variants with much improved selectivity for the retro-aldol cleavage of 2S3S PS. The
planned iterative CASTing (CASTing round B) would involve screening of Groups 1-3 with
the best mutant identified from group 4.
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The same principles relating to screening effort, library generation and hit characterisation
were applied as in the first round of CASTing (Section 4.3). One significant change made
to the screening process was that "hits" were required to be at least 10-fold selective in
selectivity analysis if they are to be further analysed. Rather than using wild-type eTA as
the positive control in the screen the selective, Y30F R229N eTA variant would now be used.
This would define an internal known level of selectivity.
4.5.1 Group 4 (Y30F R229N) with group 1 (H83N DT F87N DT)
The first iterative cycle of eTA CASTing used the Y30F R229N mutant as a template for
subsequent screening of the group 1 library (in a group 4 + group 1 manner). The same
mutagenic primers as used in the first round of CASTing with group 1, were used (Table A.2)
as no overlap with the existing mutations was expected to occur. 540 individual colonies
harbouring eTA variants from the 4+1 library were selected (Section 2.5.3) and prepared
for screening (Section 2.5.4). The respective 2S3S and 2S3R PS retro-aldol activity plates
are shown in Figures A.15-A.17. 19 hits were identified from the selectivity analysis as
having at least a 10-fold preference for 2S3S PS (Figure 4.17). These samples were further
analysed with a crude lysate selectivity assay (Figure 4.18A). It was however apparent this
method could not reliably identify variants with improved selectivity over Y30F R229N eTA
due to undetectable levels of 2S3R PS retro-aldol activity in the lysate samples. The DNA
from all 19 mutants was sent for sequence analysis to determine which contained unique
mutations. This revealed three unique variants all of which contained an F87 mutant. These
were purified (Figure 4.18B) and subject to a purified selectivity assay (Figure 4.18C). All
of these showed a strong preference for 2S3S PS and were kinetically characterised.
All variants showed increased stereoselectivity compared to the starting Y30F R229N eTA.
The Y30F R229N F87R (5 A8) variant displayed a SP of 6.7 for 2S3S PS and the Y30F R229N
F87S variant a value of 5.9 for the same reaction. The specificity constants of the enzymes
for 2S3S PS had also further increased and were now only five and seven-fold lower than
the wild-type respectively. The three characterised variants all showed similar Km values
between 0.54 and 0.64 mM for 2S3S PS. This was also seen for Km values with 2S3R PS
however with increased concentrations (0.85-1.05 mM). The largest difference, owing to
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improved selectivity, was seen in the kcat values which were all close to four times greater
with 2S3S PS.
Figure 4.17: Selectivity analysis for CASTing cycle 2: group 4 mutant (Y30F R229N) +
group 1 library (H83N DT F87N DT ). Selectivity of variants reaching the threshold level of
activity are highlighted for each plate. A quantitative measure of plate selectivity is given by
the intensity of the purple or brown colour for 2S3R and 2S3S PS respectively.Wells H7-9
contain the Y30F R229N eTA positive control and wells H10-12 contain empty plasmid
(pKK-mod) negative control. Values in the top left of each plate denote the nomenclature
used to identify each screening plate where 4.1.1 denotes the plate as CASTing group 4
(Y30F R229N) + CASTing group 1 plate 1. 19 wells met the required criteria for further
analysis with at least a 10-fold activity preference for a single diastereomer.
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Figure 4.18: A: Follow up selectivity screen for variants identified in Figure 4.17. 19 of
the lysate samples were screened, revealing little or no measurable 2S3R PS retro-aldol
activity. Reactions were performed in a Fluorostar Galaxy plate reader. 30 µL of each lysate
fraction was added to 50 mM sodium phosphate pH 8.0 containing 50 µM PLP. Reactions
were started by addition of the respective PS epimers (2S3R in purple and 2S3S in brown)
to a screening concentration of 0.15 mM. The total reaction volume for each well was 200
µL. Retro-aldol activity was recorded observing the change in absorbance at 260 nm. B:
SDS-PAGE gel for purified variants 1 G3, 3 A10, 5 A8, Y30F R229N and wild-type (WT) eTA.
Wells were loaded as labelled. Clear bands were observed for each enzyme around 37 kDa.
C: Purified selectivity assay for unique identified variants. All three mutants display similar
levels of selectivity. 50 µg of each enzyme was added to 50 mM sodium phosphate buffer,
pH 8.0 and 50 µM PLP. Reactions were performed in triplicate and started by injection of
the respective PS epimer to a final concentration of 0.15 mM.
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Figure 4.19: Michaelis-Menten kinetics curves for ISM variants from group 4 + group 1:
Y30F R229N F87S (1 G3), Y30F R229N F87N (3 A10) and Y30F R229N F87R (5 A8) eTA.
Retro-aldol activity for the cleavage of each of the PS epimers (2S3R in purple and 2S3S
in brown) at a range of concentrations was measured. Each activity measurement was
performed at 30oC in 50 mM sodium phosphate buffer pH 8.0 containing 50 µM PLP, 10%
(v/v) DMSO and an appropriate amount of enzyme. The change in absorbance at 279 nm
was measured and the specific activity calculated using the molar extinction coefficient for
benzaldehyde of 1400 M−1cm−1 as described by Liu et al. [Liu et al., 1998].
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2S3R Phenylserine 2S3S Phenylserine
kc a t Km kc a t/Km kc a t Km kc a t/Km SP
Protein (min−1) (mM) (min−1mM−1) (min−1) (mM) (min−1mM−1) 3* (S/R)
wild-type eTA 92± 3 0.016± 0.002 5750± 740 96± 3 0.017± 0.002 5650± 690 1.0
Y30F R229N F87S (1 G3) 156± 7 0.85± 0.12 184± 27 587± 8 0.54± 0.02 1090± 40 5.9 (S)
Y30F R229N F87N (3 A10) 155± 9 0.85± 0.13 182± 30 650± 38 0.64± 0.11 1020± 180 5.6 (S)
Y30F R229N F87R (5 A8) 119± 12 1.05± 0.28 113± 32 414± 13 0.55± 0.05 752± 72 6.7 (S)
Table 4.5: Kinetic parameters for the eTA catalysed cleavage of 2S3R and 2S3S
phenylserine. The selectivity preference (SP) at the 3 position is calculated from kc a t/Km
ratios for both 2S3R and 2S3S PS.
4.5.2 Group 4 (Y30F R229N) with Group 2 (H126N DT F127N DT)
Iterative CASTing with group 2 involved screening the Y30F R229N H126N DT F127N DT
library. NDT primers for group 2 (Appendix Table A.2) were again used to produce the
group 4 + group 2 library. Variants were screened for further increases in stereoselectivity.
Screening plates are shown in Appendix Figures A.18-A.20 and the calculated selectivity
analysis in Figure 4.20. From these, 30 wells displayed the threshold levels of activity
and selectivity for further analysis. These were next subject to the selectivity assay screen
(Figure 4.21A). As seen in section 4.5.1, levels of 2S3R PS retro-aldol activity in the
lystate fractions was extermely low or unmeasurable. Although not able to reliably identify
hits with greater levels of selectivity than the Y30F R229N variant, the follow up screen
did confirm that all 30 variants were selective for 2S3S PS. DNA from these samples
was prepared and sent for sequence analysis. Eight unique variants were identified and
subsequently purified (Figure 4.21C). Purified samples were again screened for selectivity
against the Y30F R229N eTA control (Figure 4.21D). Samples 2 B7, 4 A12, 6 B1 and 6 E12
had their selectivity quantified by Michaelis-Menten kinetics (Figure 4.22). The values for
kcat , Km and the SP are shown in Table 4.6. The two variants, Y30F R229N F127I (4 A12)
and Y30F R229N H126R F127L (6 B1) showed similar levels of selectivity for 2S3S PS to
the Y30F R229N mutant. The Y30F R229N F127C (6 E12) eTA shows large increases in Km
for both 2S3R and 2S3S PS with similar kcat values resulting in a SP of 2 for the 3S epimer.
The best hit, and furthermore the best variant identified from CASTing was the Y30F R229N
H126R F127H eTA variant. A SP of 9.6 for 2S3S PS was obtained. Stereoselectivity in this
instance is largely due an increase in Km for binding of the 2S3R PS epimer. A seven-fold
lower Km for the selective PS substrate was observed as well as a 1.5-fold increase in kcat .
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Figure 4.20: Selectivity analysis for CASTing cycle 2: group 4 mutant (Y30F R229N) +
group 2 library (H126N DT F127N DT ). Selectivity of variants reaching the threshold level
of activity are highlighted for each plate. A measure of plate stereoselectivity is given
by the intensity of the purple or brown colour for 2S3R and 2S3S PS respectively.Wells
H7-9 contain the Y30F R229N eTA positive control and wells H10-12 contain cells with the
empty plasmid (pKK-mod) as a negative control. Values in the top left of each plate denote
the nomenclature used to identify each screening plate where 4.2.1 denotes the plate as
CASTing group 4 (Y30F R229N) + CASTing group 2 plate 1. 30 wells met the required
criteria for further analysis where at least a 10-fold activity preference for a single L-PS
epimer was observed.
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Figure 4.21: A: Follow up screen for variants identified in plate 4.2.1-4.2.6 of Figure 4.20.
15 of the lysate samples met threshold levels of activity and selectivity for further analysis.
Reactions were performed in a Fluorostar Galaxy plate reader. 30 µL of each lysate fraction
was added to 50 mM sodium phosphate pH 8.0 containing 50 µM PLP. Reactions were
started by addition of the respective PS epimers (2S3R in purple and 2S3S in brown)
to a screening concentration of 0.15 mM. The total reaction volume for each well was
200 µL. Retro-aldol activity was recorded observing the change in absorbance at 260 nm.
B: As A for a further 15 samples identified in plates 4.2.5 and 4.2.6 of Figure 4.20. C:
SDS PAGE gel of unique variants. Wells loaded as listed: 1: Ladder, 2-10: purified eTA
variants: Y30F R229N, 2 B7 (Y30F R229N H126R F127H), 3 D3 (Y30F R229N F127Y), 3
E6 (Y30F R229N H126N F127S), 3 E10 (Y30F R229N H126L F127I), 4 A12 (Y30F R229N
F127I), 5 B9 (Y30F R229N H126S), 6 B1 (Y30F R229N H126R F127L), 6 E12 (Y30F R229N
F127C) respectively. D: Purified selectivity assay on unique variants identified from A and
B. Reactions were performed in a Fluorostar Galaxy plate reader. 7 µM of each purified
enzyme (50 µg) was added to 50 mM sodium phosphate pH 8.0 containing 50 µM PLP.
Reactions were started by addition of the respective PS epimers (2S3R in purple and 2S3S
in brown) to a screening concentration of 0.15 mM. Samples 2 B7, 4 A12, 6 B1 and 6 E12
showed the highest levels of 2S3S PS retro-aldol activity.
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Figure 4.22: Michaelis-Menten kinetics curves for ISM variants from group 4 + group 2:
Y30F R229N H126R F127H (2 B7), Y30F R229N F127I (4 A12), Y30F R229N H126R F127L
(6 B1) and Y30F R229N F127C (6 E12) eTA. Retro-aldol activity for the cleavage of each
of the PS epimers (2S3R in purple and 2S3S in brown) at a range of concentrations was
measured. Each activity measurement was performed at 30oC in 50 mM sodium phosphate
buffer pH 8.0 containing 50 µM PLP, 10% (v/v) DMSO and an appropriate amount of
enzyme. The change in absorbance at 279 nm was measured and the specific activity
calculated using the molar extinction coefficient for benzaldehyde of 1400 M−1cm−1 as
described by Liu et al. [Liu et al., 1998].
2S3R Phenylserine 2S3S Phenylserine
kc a t Km kc a t/Km kc a t Km kc a t/Km SP
Protein (min−1) (mM) (min−1mM−1) (min−1) (mM) (min−1mM−1) 3* (S/R)
wild-type eTA 92± 3 0.016± 0.002 5750± 740 96± 3 0.017± 0.002 5650± 690 1.0
Y30F R229N H126R F127H (2 B7) 368± 24 2.81± 0.41 131± 21 555± 25 0.44± 0.07 1260± 210 9.6 (S)
Y30F R229N F127I (4 A12) 405± 20 2.80± 0.31 144± 18 560± 31 1.17± 0.19 478± 82 3.3 (S)
Y30F R229N H126R F127L (6 B1) 371± 24 2.24± 0.34 166± 27 507± 28 0.93± 0.16 545± 99 3.3 (S)
Y30F R229N F127C (6 E12) 455± 33 4.69± 0.67 97± 16 598± 28 2.99± 0.30 200± 22 2.1 (S)
Table 4.6: Kinetic parameters for the eTA catalysed cleavage of 2S3R and 2S3S phenylserine
. The selectivity preference (SP) at the 3 position is calculated from kcat/Km ratios for both
2S3R and 2S3S PS.
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4.5.3 Further investigation of the Y30F R229N H126R F127H eTA
variant
The Y30F R229N H126R F127H eTA variant identified during the iterative cycle of CASTing
is close to 10-fold selective for 2S3S PS. Although both the triple mutants, Y30F R229N
H126R and Y30F R229N F127H should have been present in the CASTing library, it is
possible that these variants may not have been screened. We therefore investigated whether
the increase in stereoselectivity owes to the H126R or F127H change, or whether both are
required to produce a synergistic effect.
4.5.3.1 Y30F R229N H126R and Y30F R229N F127H
Primers were ordered to make the Y30F R229N H126R and Y30F R229N F127H eTA variants
(Appendix Table A.2). Mutagenesis was performed (Section 2.5.2) and recombinant
plasmids were transformed into E. coli XL10-Gold (Section 2.3.5). DNA was prepared and
sent for sequencing to confirm the correct mutations had been made. Following successful
results from sequencing the proteins were expressed and purified (Appendix Figure A.27)
and sent for accurate mass determination (Appendix Figures A.28 and A.29). Kinetics were
performed on both variants (Figure 4.23) and the parameters kcat and Km recorded in Table
4.7. The results showed that the 10-fold level of 2S3S PS selectivity can only be achieved
when the quadruple mutant, combining both H126R and F127H mutations, is present.
Despite reductions in the stereoselectivity of the Y30F R229N H126R and Y30F R229N
F127H variants, significant improvements in the kcat values for both 2S3R and 2S3S PS
are observed to levels over 25 times that of wild-type eTA. The Y30F R229N F127H variant
displays a specificity constant for 2S3S PS of 2400 min−1mM−1, 2.4 times lower than that of
wild-type eTA and three times greater than that of the Y30F R229N variant. This suggests a
significant improvement in the catalytic ability of the enzyme, with respect to the best first
round CASTing mutant, while retaining similar levels of stereoselectivity.
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Figure 4.23: Michaelis-Menten kinetics curves for Y30F R229N H126R and Y30F R229N
F126H eTA. Retro-aldol activity for the cleavage of each of the PS epimers (2S3R in purple
and 2S3S in brown) at a range of concentrations was measured. Each activity measurement
was performed at 30oC in 50 mM sodium phosphate buffer pH 8.0 containing 50 µM PLP,
10% (v/v) DMSO and an appropriate amount of enzyme. The change in absorbance at 279
nm was measured and the specific activity calculated using the molar extinction coefficient
for benzaldehyde of 1400 M−1cm−1 as described by Liu et al. [Liu et al., 1998].
2S3R Phenylserine 2S3S Phenylserine
kcat Km kcat/Km kcat Km kcat/Km SP
Protein (min−1) (mM) (min−1mM−1) (min−1) (mM) (min−1mM−1) 3* (S/R)
wild-type eTA 92± 3 0.016± 0.002 5750± 740 96± 3 0.017± 0.002 5650± 690 1.0
Y30F R229N H126R 1770± 250 2.53± 0.63 699± 199 2560± 170 2.38± 0.26 1080± 140 1.5 (S)
Y30F R229N F127H 1860± 150 2.51± 0.36 740± 122 1960± 90 0.82± 0.10 2390± 310 3.2 (S)
Table 4.7: Kinetic parameters for the eTA catalysed cleavage of 2S3R and 2S3S
phenylserine. The selectivity preference (SP) at the 3 position is calculated from kc a t/KM
ratios for both 2S3R and 2S3S
4.5.4 Rational combinations of CASTing mutations (2)
Through CASTing we have achieved and almost 10-fold stereoselective eTA for 2S3S PS.
It was decided that no further screening of CASTing libraries would be performed. The
developed high-throughput screen had shown to be successful in identifying selective
variants, however once a level of selectivity had been achieved it became difficult to
discriminate between further improved hits without full kinetic characterisation. Therefore,
the engineering process for this project would be finished by making a final rational
combination of the two best, separate group hits from the iterative CASTing round (Figure
4.24).
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Figure 4.24: The conducted engineering strategy for the directed evolution of eTA. The
first round of CASTing identified the most selective variants to be from group 4 at positions
Y30 and R229. The next best, not from group 4, were identified in group 1 at positions H83
and F87. Rational combinations of these mutants were made identifying two variants with
much improved selectivity for the retro-aldol cleavage of 2S3S PS. ISM (CASTing round B)
identified further improvements in stereoselctivty. The most selective variant was identified
from group 2 which contained a Y30F R229N H126R F127H variant. The next best variant
was identified in group 1 from Y30F R229N F87R eTA. The rational combination for these
mutations would create a quintuple Y30F R229N F87R H126R F127H variant.
In Section 4.4.1, we showed rational combinations of the best variants from group 1 and
4 resulted in a close to 20-fold stereoselective variant for 2S3S PS. Therefore, by the
same process, the 6.7-fold 2S3S selective Y30F R229N F87R mutation would be combined
with the 10-fold 2S3S selective Y30F R229N H126R F127H mutation as shown in Figure
4.24. Primers to create the quintuple Y30F R229N F87R H126R F127H mutant were
ordered (Appendix Table A.2) and mutagenesis performed. The recombinant plasmid was
transformed into E. coli XL10-Gold cells and single colonies were sent for sequencing.
Following successful cloning of the mutant plasmid, the protein was expressed, purified
(Figure A.30) and sent for accurate mass analysis (Figure A.31). Michaelis-Menten kinetics
were performed as shown in Figure 4.25 and the parameters kcat and Km recorded in Table
4.8. The results showed no increase in the stereoselectivity of the enzyme and a poor SP of
1.8 (3S).
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Figure 4.25: Michaelis-Menten kinetics curves for Y30F R229N H126R F127H F87R eTA.
Retro-aldol activity for the cleavage of each of the PS epimers (2S3R in purple and 2S3S
in brown) at a range of concentrations was measured. Each activity measurement was
performed at 30oC in 50 mM sodium phosphate buffer pH 8.0 containing 50 µM PLP, 10%
(v/v) DMSO and an appropriate amount of enzyme. The change in absorbance at 279 nm
was measured and the specific activity calculated using the molar extinction coefficient for
benzaldehyde of 1400 M−1cm−1 as described by Liu et al. [Liu et al., 1998].
2S3R Phenylserine 2S3S Phenylserine
kc a t Km kc a t/Km kc a t Km kc a t/Km SP
Protein (min−1) (mM) (min−1mM−1) (min−1) (mM) (min−1mM−1) 3* (S/R)
wild-type eTA 92± 3 0.016± 0.002 5750± 740 96± 3 0.017± 0.002 5650± 690 1.0
Y30F R229N F87R
H126R F127H 1530± 120 1.84± 0.29 829± 147 1500± 100 1.03± 0.16 1450± 240 1.8 (S)
Table 4.8: Kinetic parameters for the eTA catalysed cleavage of 2S3R and 2S3S
phenylserine. The selectivity preference (SP) at the 3 position is calculated from kcat/Km
ratios for both 2S3R and 2S3S
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4.6 Summary
A summary of eTA variants is shown in Table 4.9. It was found that rational combinations
of variants from the first round of CASTing could lead to a highly selective eTA. The best
of these (Y30F R229N H83S F87Y) displaying a SP of 500 for 2S3S PS. All variants with
His83 substitutions lead to reductions in kcat whereas all those identified not targeting
this position, displayed higher than wild-type values. This suggests His83 is an important
catalytic residue, however not necessarily the base in the PS retro-aldol cleavage reaction
mechanism. An iterative round of CASTing identified a variant (Y30F R229N H126R
F127H) with a SP of 9.6. This variant displayed good catalytic efficiency with only a 4-fold
reduction in kcat/Km with respect to wild-type eTA for 2S3S PS. This variant can be seen as
one, identified in a total focused sequence space of 124 variants. Around 3200 individual
colonies were screened for improved selectivity. This highlights the effectiveness of the
the CASTing approach where the synergistic effect produced by all four mutations would
otherwise be extremely difficult to obtain by single-site saturation mutagenesis.
CASTing group 4, targeting postions Y30 and R229, appeared to show the largest initial
improvement in stereoselectivity for 2S3S PS. The R229N substitution appeared in close to
half the purified 2S3S PS selective variants which when also paired to a Y30F mutation lead
to a 3.1-fold selective eTA. A single Y30R variant also had a comparable level of selectivity.
We aim to provide rational to this observed increase in Chapter 5.
Interestingly no variants with improved selectivity for 2S3R PS were identified. While
the NDT codon incorporates 12 of the 20 canonical amino acids, it is possible that one
of the eight not included, or a combination thereof, are required for such improvements
in 2S3R PS selectivity. It may also be that the threshold levels set to identify hits in the
initial screening plates was too high. The two-fold activity preference required for further
analysis could have been lowered to allow more variants through with potentially smaller
increases in 2S3R PS selectivity. We could speculate that it may only be in iterative cycles
of CASTing where the larger increases in selectivity would become apparent. Another
possibility is that the conditions of the screen were not suitable for identifying improved
2S3R PS selective variants. If, with respect to the wild-type enzyme, improvements in
selectivity are seen by further reductions in Km, this would be undetectable by the screen.
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In order to observe measurable activity, screening conditions required 0.15 mM substrate.
However, for reaction rates to be roughly proportional to kcat/Km then screening at sub-Km
concentrations is required. Otherwise, only changes in kcat will be identified.
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2S3R Phenylserine 2S3S Phenylserine
kcat Km kcat/Km kcat Km kcat/Km SP
Protein (min−1) (mM) (min−1mM−1) (min−1) (mM) (min−1mM−1) 3* (S/R)
wild-type eTA 92± 3 0.016± 0.002 5750± 740 96± 3 0.017± 0.002 5650± 690 1.0
CASTing
H83S F87Y (4 G10) 61± 5 0.8± 0.18 76± 18 75± 4 0.38± 0.07 197± 38 2.6 (S)
H83C F87Y (5 F9) 51± 3 0.65± 0.09 78±12 58± 2 0.5± 0.05 116±12 1.5 (S)
Y30F R229N (4 B10) 172± 4 0.66± 0.03 261± 13 412± 23 0.51± 0.07 808± 120 3.1 (S)
Y30R (3 F8) 212± 15 0.79± 0.15 268± 54 209± 8 0.25± 0.03 836± 105 3.1 (S)
Rational combinations
Y30F R229N H83S F87Y 1.1± 0.3 10.0± 4.8 0.11± 0.06 17± 1 0.31± 0.08 55± 15 500 (S)
Y30F R229N H83S 18± 0.4 1.07± 0.12 17± 2 50± 2 0.88± 0.1 57± 6 3.4 (S)
Y30F R229N F87Y 48± 2 2.04± 0.15 24± 2 373± 14 0.88± 0.09 424± 46 18 (S)
Iterative CASTing
Y30F R229N F87S (1 G3) 156± 7 0.85± 0.12 184± 27 587± 8 0.54± 0.02 1090± 40 5.9 (S)
Y30F R229N F87N (3 A10) 155± 9 0.85± 0.13 182± 30 650± 38 0.64± 0.11 1020± 180 5.6 (S)
Y30F R229N F87R (5 A8) 119± 12 1.05± 0.28 113± 32 414± 13 0.55± 0.05 752± 72 6.7 (S)
Y30F R229N H126R F127H (2 B7) 368± 24 2.81± 0.41 131± 21 555± 25 0.44± 0.07 1260± 210 9.6 (S)
Y30F R229N F127I (4 A12) 405± 20 2.80± 0.31 144± 18 560± 31 1.17± 0.19 478± 82 3.3 (S)
Y30F R229N H126R F127L (6 B1) 371± 24 2.24± 0.34 166± 27 507± 28 0.93± 0.16 545± 99 3.3 (S)
Y30F R229N F127C (6 E12) 455± 33 4.69± 0.67 97± 16 598± 28 2.99± 0.30 200± 22 2.1 (S)
Iterative CASTing rational combinations
Y30F R229N H126R 1770± 250 2.53± 0.63 699± 199 2560± 170 2.38± 0.26 1080± 140 1.5 (S)
Y30F R229N F127H 1860± 150 2.51± 0.36 740± 122 1960± 90 0.82± 0.10 2390± 310 3.2 (S)
Y30F R229N F87R H126R F127H 1530± 120 1.84± 0.29 829± 147 1500± 100 1.03± 0.16 1450± 240 1.8 (S)
Table 4.9: Kinetic parameters for the purified variants from CASTing and ISM. Kinetics measured for the enzyme catalysed cleavage of 2S3R and
2S3S PS. The selectivity preference (SP) at the 3 position is calculated from kcat/Km ratios for both epimers.
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Chapter 5
Structural Insights into E. coli Threonine
Aldolase Stereoselectivity
5.1 Structural guidance in enzyme engineering
There are now over 130,000 protein structures in the protein data bank (PDB). If we were
to look back 20 years this number falls short of 9,0001. Advances in structural biology are
thanked for this sharp rise. X-ray crystallography, the original technique for obtaining these
macromolecular structures, is now one of several methods used. Neutron crystallography,
electron microscopy (EM) and nuclear magnetic resonance (NMR) spectroscopy all provide
their own unique approaches facilitating the growth of the PDB. With atomic resolution
structures it is possible to observe interactions such as how an inhibitor binds to a receptor
[Christen et al., 2012] or how misfolded proteins interact in aggregation [Moreno-Gonzalez
and Soto, 2011].
One area that has benefited from advances in structural biology is protein engineering.
Directed evolution on enzymes with unknown structures will likely require random
mutagenesis across a gene. This in turn can require huge screening efforts before desirable
traits are identified. However, a well defined structure will localise engineering efforts to an
active site, where mutations leading to improved enantioselectivity [Reuben et al., 2008],
substrate specificity [Wells et al., 1987] and new activities [Williams et al., 2005] are often
located.
1Statistics from https://www.rcsb.org/stats/growth/overall
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The methods listed for obtaining high resolution structures only offer ways of obtaining
static snapshots of proteins at a particular moment in time. Computational modelling
in enzymology offers an in silico approach to visualising these structures at work over
picosecond (psec) to microsecond time scales. This is only possible, however, due to the
wealth of structural information we have on proteins, their functions, understanding of laws
governing atomic and sub-atomic interactions and increases in computational power.
The aims of this chapter are two-fold. Firstly, to use X-ray crystallography to obtain a high
resolution structure of E. coli threonine aldolase (eTA). Secondly we will use this structure
for computational modelling to try and understand the poor stereoselectivity of the enzyme
with phenylserine (PS), which may in turn lead to an understanding of the effects of the
mutations described in Chapter 4.
5.2 A high resolution structure of E. coli threonine aldolase
The first structure of a L-threonine aldolase (TA) was published in 2002 from Thermotoga
maritima [Kielkopf and Burley, 2002]. Since then multiple L-TA structures have been solved.
More recently the first structure of a D-TA, from Alcaligenes xylosoxidans was obtained [Uhl
et al., 2015] revealing an almost mirror symmetry of the L-theonine aldolase active site
residues.
di Salvo et al. published several structures of a low-specificity L-TA from E. coli bound to
threonine, glycine and serine at 2.1 Å resolution (PDB codes 4LNL, 4LNM and 4LNM)
[di Salvo et al., 2014]. A sequence alignment of that gene revealed a 98.8% sequence
identity with the eTA used in this project, highlighting four amino acid changes. It was
therefore decided that an improved structure of the eTA from this project should be
obtained.
5.2.1 Crystallisation
Crystallisation conditions for an E. coli TA had previously been determined [di Salvo
et al., 2014]. These showed that diffracting enzyme crystals could be grown in 0.2 M
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MgCl2 hexahydrate, 0.1 M HEPES (pH 7.5), 30% PEG 400 with 600 µM of the enzyme.
eTA was purified using nickel affinity chromatography (Section 2.4.1) and subject to size
exclusion chromatography (Section 2.4.6). Eluted fractions were analysed by sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) (Section 2.4.5) with those
containing eTA being pooled and concentrated to 9 mg mL−1 (Section 2.4.6). Crystal trays
were set up containing 0.6 mM eTA, 0.2 M MgCl2 hexahydrate, 0.1 M HEPES (pH 6.8-8.0)
and PEG 400 (20-34% (v/v)). The sitting drop vapour diffusion method was performed for
crystal growth which produced large single crystals across multiple conditions after 8 days
at 20 oC. One particularly good crystal-forming condition is: 0.2 M MgCl2 hexahydrate, 0.1
M HEPES pH 7.6, 28.9% (v/v) PEG 400 with 0.6 mM eTA (Figure 5.1). It was from this drop
that the final refined structure is produced. Crystals were selected and flash cooled in liquid
nitrogen prior to data collection at Diamond Light Source synchrotron facility (Oxford, UK).
Figure 5.1: Image of drop showing crystal formation after 8 days in 0.2 M MgCl2
hexahydrate, 0.1 M HEPES pH 7.6 and 28.9% (v/v) PEG 400.
5.2.2 Structure determination of eTA
Data sets for crystals were collected at Diamond Light Source on the macromolecular
crystallography beamline I02 at 100K. The diffraction images were integrated, scaled and
reduced using a set of programs implemented as part of the Xia2 program suite [Winter,
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2010]. Five percent of the reflections from the collected datasets were selected at random
and excluded from the refinement and constituted the R f ree set. Two comparable data sets to
1.6 Å resolution were obtained and efforts were focused on a single one of these. The dataset
belong to space group P2221 with unit-cell parameters a = 77.2 Å, b = 101.5 Å, c = 175.9
Å. There are two eTA molecules (present as a dimer) in the asymetric unit cell with a solvent
content of 47%. The crystal structure was determined by molecular replacement using the
program PHASER [McCoy et al., 2007]with the similar E. coli TA structure (PDB code 4LNL)
[di Salvo et al., 2014] as a search model. One round of rigid body refinement followed by
multiple rounds of restrained refinement were performed using REFMAC [Murshudov et al.,
1997] with rebuilding into both 2Fobs-Fcal and Fobs-Fcal maps using COOT [Emsley et al.,
2010]. Data statistics for the refined eTA are shown in Table 5.1.
The threonine aldoalse family are reported to function as tetramers [Liu et al., 1997,
Kielkopf and Burley, 2002, Qin et al., 2014]. The asymmetric unit of the crystal contains
two identical protamers (monomers) of eTA with the homotetramer generated around
a crystallographic two-fold symmetry axis (Figure 5.2). Those protomers from the
asymmetric unit cell are shown as chains A and D, where chains B and C are the symmetry
generated mates (Figure 5.2A). Six magnesium ions are observed in the tetramer, two of
these position closely at the interface between all four chains where it is proposed they
play a role in oligomerisation [di Salvo et al., 2014]. Two water molecules coordinate
between these ions and further interactions from the negatively charged oxygen atoms of
Ala93 (backbone) Val94 (backbone) and Ser97 (sidechain) from all four monomers are
observed with the magnesium ions (Figure 5.2B). Two equivalent active sites are observed
in the asymmetric unit creating four equivalent active sites in the functional tetramer.
Interestingly residues from three chains form each active site (Figures 5.2C and D). Active
site 1 is composed primarily of chain A with His83, Phe87, Lys197 and Arg308 where the
PLP cofactor is found as a Schiff base to Lys197. Tyr30, Lys222 and Arg229 from chain D
and His126 from chain B are also apparent within this site.
Covalently bound PLP is observed in both active sites of the asymmetric unit (Figures
5.3A and B). Interestingly the density of the covalently bound PLP-Lys197 suggested a
far from planar orientation for the imine Schiff base (NSB) and the pyridinium ring. A
dihedral measurement between C3-C4-C4∗-NSB atoms highlights this non-coplanarity (see
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eTA
Diamond beamline I02
Space group P2221
Cell dimensions a, b, c (Å) 77.2, 101.5, 175.9
α,β ,γ (o) 90, 90, 90
Resolution range (Å) ∗ 58.62-1.60 (1.64-1.60)
R∗mer ge 0.075 (0.852)
Rpim (I)
∗ 0.029 (0.460)
Rpim (I +/-)
∗ 0.038 (0.596)
Observed reflections 635899
Unique reflections 90793
Completeness (%)∗ 99.7 (96.6)
Multiplicity∗ 7.0 (5.0)
<I/σ(σ)∗ 14.6 (1.7)
CC∗1/2 0.998 (0.512)
Refinement
R f actor (%) 0.159
R f ree (%) 0.187
No. of protein atoms 5378
No. of solvent molecules 265
Average overall B-factor ) (Å2) 27.5
RMS bond length (Å) 0.020
RMS bond angles (o) 2.0
Ramachandran analysis
Most favoured 98.2
Outliers 0
Rmer ge =
∑
hkl
∑
i|I i(hkl)−< I(hkl)> |/∑ hkl∑ Ii(hkl)
* Values in parentheses are for highest-resolution shell
Table 5.1: X-ray crystallographic data collection and refinement for eTA. Values given in
parentheses correspond to the outermost shell of the resolution range. Ramachandran
analysis performed using MolProbity [Davis et al., 2007].
nomenclature in Figure 5.3C). These angles were measured as 65o and 56o in active site 1
and 2 respectively. The 9o difference is likely due to the decreased density for Lys197 in
chain A. This non-coplanarity has not been mentioned in any TA literature where similar
cases are observed. These issues have however been addressed for other PLP-fold type I
enzymes [Dajnowicz et al., 2017, Hayashi et al., 2003, 1998]. Aspartate amino transferases
also rely on a PLP dependent mechanism. Structures show when covalently bound to the
enzyme the PLP NSB-C3
∗ non-coplanarity is observed [Hayashi et al., 1998]. It is proposed
that a significant increase in the imine NSB pKa occurs during the transaldimation whereby
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Figure 5.2: A: The tetrameric structure of eTA generated from two protamers of the
asymmetric unit dimer along a crystallographic symmetry axis. The four protein chains
are labelled A (yellow) B (green) C (pink) and D (brown). B: The interface between
the four chains highlights two magnesium ions that coordinate with the negatively charge
oxygen atoms of adjacent residues in each monomer. The 2Fobs-Fcal map of these metal
ions and two closely coordinated waters is shown at at one sigma level. C: Active site 1
predominantly formed of chain A where residues from chains B and D also identify within
this site. The PLP ligand (pink) is clearly seen in the covalently bound form to Lys197 of
chain A. The 2Fobs-Fcal map is shown at one sigma level for key active site residues and
the PLP cofactor. D: Active site 2 of the asymmetric unit dimer whereby chains A, C and D
contribute residues. The PLP ligand is observed (blue) covalently bound via a Schiff base
to Lys197 of chain D. The 2Fobs-Fcal map is shown at one sigma level.
lysine is released and substrate is bound (Figure 1.17). As a result it is likely that two
different protonation states occur at NSB in the enzyme bound and ligand bound forms
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of PLP. Protonation of NSB in the ligand bound form would likely produce a stabilising
hydrogen bonding interaction with the PLP oxygen (O3∗) and create NSB and pyridine ring
coplanarity. This is consistent with structures showing the ligand bound forms of PLP with
threonine [di Salvo et al., 2014] and glycine [Qin et al., 2014]. To investigate whether the
NSB torsion is an effect of the surrounding environment, Dajnowicz et al. [Dajnowicz et al.,
2017] performed density function theory (DFT) calculations on a truncated PLP-Lys ligand
altering the protonation between the NSB and O3
∗. Interestingly this showed that when
both of these positions are unprotonated, the C3-C4-C4∗-NSB dihedral angle is 44o. If either
the NSB or O3
∗ are protonated then the torsion is removed and the NSB becomes coplanar
to the pyridinum ring.
Figure 5.3: A: The PLP Schiff base with Lys197 in chain A. A 65o torsion is observed
between the NSB and the pyridinium ring. The 2Fobs-Fcal map is shown at one sigma level.
B. PLP covalently linked to Lys197 by a Schiff base in chain D. More continuous density is
observed around the NSB where a torsion angle of 56
o is observed to the pyridinium ring.
C: A schematic of the PLP-Lysine highlighting the likely protonation state of the NSB and
the O3∗ based on DFT calculations [Dajnowicz et al., 2017]. The nomenclature of atoms
used in measuring the torsion angle between the NSB and the pyridinium ring are shown
in indigo.
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5.3 Structural modelling of E. coli threonine aldolase
Structural modelling of enzymes through computational (in silico) approaches is an ever
increasingly popular method of studying enzyme systems [van der Kamp and Mulholland,
2013]. Quantum mechanics/molecular mechanics (QM/MM) molecular dynamics (MD)
simulations have been effective in elucidating the mechanisms of enzymes [Bowman
et al., 2008, Daniels et al., 2014]. They use QM methods (semi empirical, DFT and
ab initio) to study the electron rearrangements, involved in bond making and breaking,
while simultaneously sampling the surrounding environment by simpler MM methods.
With relatively small QM regions, semi empirical QM/MM calculations are generally
less computationally expensive than those using DFT or molecular orbital ab initio QM
approaches alone [Siegbahn and Himo, 2009]. However, they are more expensive than
those simulations solely reliant on MM [Warshel, 2003]. No single approach can be
considered as the correct way of studying enzyme reactions. Successful methods in similar
systems would however suggest a sensible starting point when choosing the modelling
approach. QM/MM has been used to observe the enantioselective proton transfer in
the mechanism of citrate synthase for the conversion of fluroacetyl-CoA to flurocitrate
[van der Kamp et al., 2011]. Similar QM/MM methods have also been used to study
the stereoselectivity of N-acetylneuraminic acid lyase; an aldolase catalysing the reversible
condensation of pyruvate and N-acetyl-D-mannosamine [Daniels et al., 2014].
MM and QM/MM methods are used for modelling of the high resolution eTA crystal
structure obtained in Section 5.2. Using these approaches we aim to identify how the
stereochemical step of the reaction proceeds.
5.3.1 Choosing the stereoseletive reaction step
The stereoselectivity of eTA is determined by the free energy difference between the
transition state (TS‡) barriers for each of the possible diastereomers in the aldol/retro-aldol
step of the reaction2 (Figure 5.4A). That is, the proton transfer or abstraction at the
aldol oxygen (Figure 5.4B). It is not possible to model the the whole eTA catalysed
2Assuming the reaction is under kinetic control
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mechanism, but we are concerned with how the enzyme (particularly the variants described
in Chapter 4) can achieve stereoselectivity. We therefore concentrate our modelling on
the stereogenic step in the aldol condensation of glycine and benzaldehyde (Figure 5.4B).
As the 2S stereochemistry remains fixed at the α-carbon, the resulting phenylserine (PS)
diastereomeric products will be referred to by their 3R or 3S stereochemistry.
5.3.2 Modelling of the wild-type eTA
The PLP-glycine ligand (PXG) shown in Figure 5.4 was built for in silico modelling. The
protonation state of PXG was determined whereby the NSB is protonated. This is in
agreement with that described by Fesko et al. in Aeromonas jandaei TA [Fesko et al., 2018].
Additionally, as discussed in Section 5.2, studies on other PLP enzymes have shown the
pKa of the PLP imine group to be around 8.8 when in a non-enzyme bound Michaelis
complex [Hayashi et al., 1998, 2003]. The most suitable pre-simulation orientation of the
PXG ligand was determined by the previously solved E. coli TA structure (PDB code 4LNL)
with the PLP-threonine ligand bound. With structurally aligned protein chains, PXG could
be manually docked into a ligand bound crystallographic orientation. The unbound Lys197
could also be oriented into a suitable rotamer (Figure 5.5A).
Two benzaldehyde molecules were also separately manually docked into the eTA active sites
(Figure 5.5B). A simple flip of the carbonyl group created two orientations that could lead
to si or re face attack, in turn creating the 3R, or 3S, products respectively. From here, the
benzaldehyde orientations leading to the formation of either 3R, or 3S, products (Figure
5.4) will be referred to as pre-3R, or pre-3S structures. Parallel simulations of eTA with
pre-3R, or pre-3S, benzaldehyde orientations are performed for comparable analysis.
Enlighten is a set of protocols and tools to run (automated) atomistic simulations of
enzyme-ligand systems 3. It was created by Dr Marc Van der Kamp (University of Bristol,
UK) and utilises the Assisted Model Building with Energy Refinement (AMBER) suite
of programs (AmberTools). Enlighten provides a logical, stepwise progression through
simulations that can be broken down into several parts. The preparatory step (PREP)
generates ligand parameters, a solvent sphere, adds hydrogens and generates AMBER
3Enlighten is free and available for download from https://github.com/marcvanderkamp/enlighten
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Figure 5.4: A: Free energy diagram for the proposed eTA stereoselectivity determining
step. The difference in transition state (TS) energies for the 3R and 3S PS products in
the C-C bond forming step is expected to be the stereoselectivity determining factor in the
reaction. The greater the difference in this barrier the greater the expected difference in
stereoselectivity. B: Proposed mechanisms for the aldol and retro-aldol steps of PS synthesis
and cleavage. The structural modelling step is highlighted whereby the C-C bond formation
between benzaldehyde (blue) and the PXG ligand (glycine (green) as a Schiff base with
PLP (black)) is mediated by transfer of a proton onto the benzaldehyde oxygen. The
additional electron density, delocalised in the PLP pyridine N, can then move back along
the conjugated pi bond system allowing for the Schiff base imine to attack onto either the
re or si face of benzaldehyde determining the C3 stereochemistry. The retro-aldol cleavage
of the PXPS3R/3S ligand (2S3R PS (pink) or 2S3S PS (orange) with a Schiff base to PLP
(black)) is shown on the right of the equilibrium arrow whereby a catalytic base abstracts
the hydroxyl proton and the C-C bond is cleaved.
topology and coordinate files. The structural optimisation step (STRUCT) takes the
generated topology and coordinate files and performs a brief simulated-annealing and
minimisation protocol. The now-optimised structures can be passed into MD simulations
(DYNAM).
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Figure 5.5: Panel A: The PXG ligand for modelling (indigo) manually docked into position
with respect to the E. coli TA PLP-threonine ligand (green) (PDB structure, 4LN)[di Salvo
et al., 2014]). The Active site lysine (K197) has also been moved into a similar rotamer as
that of the ligand bound structure. Panel B: Pre-3S (brown) and pre-3R (blue) benzaldehyde
were manually docked into a suitable pre-simulation position relative to the PXG ligand
(indigo). A simple flip of the benzaldehyde ligand was performed for either pre-3R or
pre-3S orientations. Parallel simulations for each of these are performed.
The Enlighten protocol was performed on eTA with PXG and benzaldehyde (in the pre-3R
and pre-3S orientations)(Figure 5.6). From PREP, a solvent sphere of 20 Å around the
ligands was formed in addition to existing crystallographic waters. The pKa values for
sidechains within the sphere were predicted using propka [Søndergaard et al., 2011]
and the protonation states assigned. STRUCT performed a brief energy minimisation,
optimising the structure for further MD simulations. For both benzaldehyde orientations
an obvious stabilising salt bridge formed between the carboxylate of PXG and Arg308. The
manually docked benzaldehyde in a pre-3R orientation remained in a similar position after
the minimisation suggesting this to be an energetically favourable pose (Figure 5.6C). When
in a pre-3S orientation the energy minimisation showed a more distinct rotation of the
ligand away from the initially docked pose (Figure 5.6D).
5.3.3 MM MD simulations
The minimised structures offer a static snapshot of two possible ligand conformations. In
reality these ligands will not remain in a fixed position and instead are free to move. Using
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Figure 5.6: A: The eTA homotetramer coloured by each monomer chain. A 20 Å solvent
sphere is shown behind the expansion panel. The homotetramer is coloured by chain: chain
A (yellow), chain B (green) chain C (pink) and chain D (brown) . B: Energy minimisation
from STRUCT for benzaldehyde in a pre-3R orientation. Residues and ligands following the
STRUCT minimisation are shown as opaque and those prior to the simulation are shown
as transparent. Residues within close proximity of the ligands are shown and coloured
according to their chain. Water molecules within 3 Å of the ligands are are shown before
and after STRUCT as red and grey spheres respectively. C: The energy minimised structures
of benzaldehyde (light blue) in a pre-3R orientation and PXG (indigo) from STRUCT. The
pre minimised ligands are shown as transparent for reference. D: As C but for benzaldehyde
in a pre-3S orientation.
MM MD simulations we aim to observe how the ligands behave within the active site.
Furthermore we can used these dynamic simulations to predict the likelihood of a reactive
Michaelis complex forming in the pre-3S and -3R orientations. To ensure the benzaldehyde
ligand did not move away from the active site during the initial heating phase, a restraint
was applied (Section 2.7.2). For this a reaction coordinate is defined between the carbonyl
carbon of benzaldehyde (CA) and the α-carbon of PXG (CG2) where the aldol C-C bond is
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expected to form. This coordinate is subsequently referred to as d(C-C) (Figure 5.7.A)
Figure 5.7: A: The defined distance reaction coordinate (d(C-C)) between the C-C bond
forming atoms of benzaldehyde (CA) and PXG (CG2). B: Stereochemical coordinate
measuring the dihedral between the benzaldehyde oxygen (OA), carbonyl carbon (CA) and
proton (HA) and the α-carbon of PXG (CG2).
20 separate MD simulations (3R/3S MD1-20), for each of the benzaldehyde orientations
were performed. Each simulation was 150 psec, where the first 50 psec included an initial
heating phase to 300 K and a distance restraint along the reaction coordinate (d(C-C)) of
4 Å was applied. This restraint was then removed for the final 100 psec of unrestrained
simulation. The distances along the d(C-C) reaction coordinate were plotted, as shown in
Figure 5.8. It is clear to see that when the distance restraint is removed there is a far greater
range of movement between the ligands in both sets of simulations. A stereochemical
coordinate is also defined to investigate the possibility of each of the pre-3R or -3S
ligands "flipping" into the opposite orientation. For this a dihedral between benzaldehyde
and the PXG is measured (Figure 5.7B). This measured the dihedral angle between the
benzaldehyde oxygen (OA), carbonyl carbon (CA) and proton (HA) and the α-carbon of
PXG (CG2). The results show that throughout all MD simulations the benzaldehyde ligands
remain mostly in a pre-3R or -3S conformation. Where values are close to 0, 180 or -180o,
this would suggest a planar orientation to the PXG CG2 atom and subsequently favour
neither a 3R or 3S product. Those simulations displaying these planar orientations only
occur very briefly (for a few psec) so shall not be considered as significant with respect to
switching orientation.
To obtain representative structures for the conformations sampled in simulation, clustering
analysis is performed [Shao et al., 2007]. This allows for similar conformations to be
partitioned into a representative structure based on the RMSD value of the cluster. Figure
5.9 shows the clustering on the RMSD of the benzaldehyde across the pre-3R and -3S MM
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Figure 5.8: Top left: Changes in the distance reaction coordinate d(C-C) over the 150
psec simulation for pre-3R benzaldehyde orientations. A restraint of 4 Å was applied for
the first 50 psec and then removed for the final 100 psec. Bottom left: Stereochemical
coordinate against time for pre-3R benzaldehyde. To remain in a pre-3R orientation the
reaction coordinate must be between 0 and 180o. Top right: As top left but for pre-3S
benzaldehyde orientations. Bottom right: As bottom left but for pre-3S benzaldehyde
orienations. To remain in this orientation the stereochemical coordinate must be between
0 and -180 o.
MD simulations. The position of PXG is not significantly different for the two representative
conformations. However, the benzaldehyde orientations are almost perpendicular to each
other with their oxygen atoms in very similar positions.
To investigate how many of the MD simulations formed a potentially reactive Michaelis
complex the percentage of those with a d(C-C) of less than 3.5 and 4.0 Å were measured.
These were based on the final 50 psec of the unrestrained simulations (Table 5.2). The
results show that roughly the same number of trajectories form a sub 3.5 Å complex with
13% of pre-3R and 12% of pre-3S simulations. This suggests that there is no preference for
binding of either orientation of benzaldehyde in the wild-type eTA model. If the d(C-C)
reaction coordinate distance is increased to 4 Å the results show a significantly higher
proportion of trajectories within this limit. 50% are seen in a pre-3R and 65% in a pre-3S
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Figure 5.9: Representative conformations from MM MD simulations obtained from
clustering. Benzaldehyde and PXG ligands from the pre-3R (purple) and pre-3S (brown)
simulations are shown.
orientation. This suggests a small 1.3 fold 3S preference for binding at the increased d(C-C)
distance. It is tempting to relate this binding indifference to the eTA Km values for 2S3R
and 2S3S PS in Table 4.9 as these are also virtually identical.
Enzyme / ligand
orientation
d(C-C)
< 3.5 Å
d(C-C)
< 4.0 Å
d(C-C)< 3.5 Å
3R/3S
d(C-C)< 4.0 Å
3R/3S
eTA pre-3R 13% 50% 1.08 (R) 1.28 (S)
eTA pre-3S 12% 64%
Table 5.2: Percentage of reactive poses across the last 50 psec of 20 MM MD simulations in
eTA for pre-3R and pre-3S benzaldehyde orientations. Reactive poses are classed as those
with a d(C-C) of < 3.5 Å or < 4 Å. The same percentage of simulated poses reach a sub 3.5
Å complex in both pre-3R and pre-3S simulations. Increasing the distance to 4 Å suggests
that a pre-3S complex is preferred. The ratio of these at each distance is given to highlight
any preferential reactive binding.
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5.3.4 QM/MM modelling of eTA
While the unrestrained MM MD simulations may give an idea of preferential binding for
one orientation over another, we are unable to simulate the C-C bond forming step with
this approach. Through QM/MM modelling we will use semi-empirical calculations to treat
PXG and benzaldehyde ligands with QM methods and their surroundings with MM methods
(Section 2.7.3). This in turn can provide an in depth analysis of the electrostatic interactions
between the ligands and their surroundings while in a reactive conformation. Furthermore,
QM/MM MD simulations can be used to obtain free energy profiles of reactions. This is
useful when identifying differences in free energy between in silico transition states (TS).
The QM/MM simulations are performed using the umbrella sampling (US) method [Kumar
et al., 1992] (Section 2.7.3). This involves sampling as distance decreases along the
reaction coordinate d(C-C) between benzaldehyde and PXG. The distance is reduced in
0.1 Å increments until less than that of an expected C-C bond (1.6 Å). Different trajectories
from the previous unrestrained MM MD simulations, forming reactive Michaelis complexes,
are used as the starting structures for each of the umbrella sampling simulations. We
might therefore expect to see multiple plausible transition state structures. The umbrella
sampling simulations will aim to identify key interactions in the C-C bond forming step.
Furthermore energy profiling of transition state barriers relating to the formation of the 3R
and 3S products is used as a more quantitative measure of stereoselectivity [Kumar et al.,
1992]. We could expect these to be representative of the TS barriers for C-C bond formation
which are used as a definable measure of stereoselectivity (see Section 5.3.1).
Three representative QM/MM umbrella sampling simulations for each of the product
forming stereochemistries were obtained. These were all started from separate MM MD
trajectories as shown in Table 5.3. Although the proton transfer in the modelling step was
not expected to occur, an interesting case is observed when a 3S MD12 starting trajectory
was used. This will be discussed further in Section 5.3.4.2.
To avoid structural fluctuations (unwanted bond formations and ligand orientation flipping)
restraints were applied for umbrella sampling simulations (Section 2.7.3). Following each
simulation free energies for the C-C bond forming step were calculated using the weighted
histogram analysis method (WHAM) [Kumar et al., 1992] and plotted in Figure 5.10. Across
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Umbrella sampling simulation
eTA MM MD
starting trajectory
3R Stereochemistry
1 3R MD4 120 psec
2 3R MD13 90 psec
3 3R MD17 140 psec
3S Stereochemistry
1 3S MD4 150 psec
2 3S MD16 140 psec
3 3S MD18 140 psec
4* 3S MD12 130 psec
* Investigated as an individual case
Table 5.3: MM MD simulation trajectories used as starting structures for each of the
umbrella sampling simulations.
the three representative umbrella sampling simulations for the 3R and 3S product forming
reactions similar energy maxima were observed. Similar TS energy barriers would suggest
poor stereoselectivity in the PS synthesis reaction. This is in agreement with the similiar
specificity constants observed for wild-type eTA in Table 4.9.
The proton donor in the mechanism for eTA aldol condensation is proposed to be a
conserved active site water molecule [di Salvo et al., 2014]. This is plausible given that
simultaneous mutations of proximal histidines (His83 and His126) still yields retro-aldol
activity [di Salvo et al., 2014]. We might hope to gain further insight into the eTA
mechanism of action through analysis of the QM/MM simulations. As only the ligands
shall be treated quantum mechanically we do not expect to see the proton transfer. Rather,
we aim to identify locations of suitable catalytic entities when near to the TS structures.
Visualisation of each of the three 3R and 3S product forming simulations are shown in
Figure 5.11 and are described in the following sections.
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Figure 5.10: WHAM analysis showing the free energies for each of the 3R and 3S
stereochemistries formed along the d(C-C) reaction coordinate at 0.1 Å intervals. Data
shown for umbrella sampling from 3R MD4,13,17 (purple) and 3S MD4,16,18 starting
trajectories. Both profiles suggest similar energy maxima. As no proton transfer step is
simulated there is no decrease in the energy barrier once the approximate transition state
energy is reached.
Figure 5.11: Representative umbrella sampling simulations for 3R (panel A) and 3S (panel
B) product forming reactions. Stuctures are shown following C-C bond formation wherby
the aldol oxygen is expected to be in position to receive a proton.
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5.3.4.1 3R product formation
All three umbrella sampling simulations leading to 2S3R product formation suggest similar
binding interactions. Those interactions at the C-C bond forming step are shown in
Figure 5.12. No obvious general acid or base residues are in close enough proximity to
mediate proton transfer. The most likely candidate for the general acid or base would be
His126, however this residue is too far away to make direct contact with aldol oxygen
and would require coordination through an active site water molecule. While singly
protonated, we might expect His126 to be the general base in the retro-aldol mechanism.
This seems unlikely given increases in kcat have been observed when changing this residue
to phenylalanine, asparagine [di Salvo et al., 2014]4 and arginine5(Section 4.5.3). Arg229
coordinates to the aldol oxygen through a well placed water. While not unheard of for
arginine to act as a "twisted base" [Schlippe and Hedstrom, 2005, van der Kamp et al., 2008]
a pKa of close to 12 makes this unlikely. Tyr30 coordinates to the aldol oxygen through two
water molecules. It therefore seems far more likely that catalytic proton transfer occurs via
a Grotthu¨ss proton hopping mechanism. This allows for protons to be "shuttled" in and out
of the active site through well coordinated water molecules. Interestingly, Y30F and R229N
mutations, which would seemingly disrupt this coordination, leads to and increase in 3S PS
selectivity.
4For the retro-aldol cleavage of 2S3R and 2S3S threonine
5When paired with Y30F R229N mutations for the cleavage of 2S3R and 2S3S PS
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Figure 5.12: A trajectory from umbrella sampling of a 3R product forming complex.
The 120 psec snapshot from the 3R MD4 simulation was used as the starting structure
for simulation. The 2S3R PS-PLP ligand is shown in turquoise where the CA atom of
benzaldehyde is within C-C bond forming distance of the CG2 of PXG (1.6 Å). Residues are
coloured by their respective chain: Y30, R229N, K229 (brown) chain D, H83 F87 (yellow)
chain A and H126 (green) chain B.
5.3.4.2 3S product formation
Unlike the umbrella sampling from 3R simulations, not all of those leading to a 3S
stereochemistry displayed similar results. Three representative simulations were observed
from starting trajectories in 3R MD4, MD16 and MD18 which all had a similar positioning
of the aromatic ring upon C-C bond formation (Figure 5.11B). As seen in the previously
discussed 3R umbrella sampling simulation, Arg229 also coordinates a water molecule in
the 3S product (Figure 5.13). His126 is in hydrogen bonding distance to coordinate the
same water to within 1.8 Å of the aldol oxygen. Lys222 and His83 both orient a separate
water to within 1.8 Å of the aldol oxygen. We therefore see two well positioned water
molecules in the 3S simulation that could mediate proton transfer in the aldol or retro-aldol
mechanisms. We therefore propose proton transfer could also occur via the Grotthu¨ss
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proton hopping mechanism through the well coordinated water network leading out to
bulk solvent.
Figure 5.13: A snapshot from umbrella sampling of a 3S product forming complex. The
150 psec snapshot from the 3S MD4 simulation was used as the starting structure. The 2S3R
PS-PLP ligand is shown in burgundy where the CA atom of benzaldehyde is within C-C bond
forming distance of the CG2 of PXG (1.6 Å). Residues are coloured by their respective chain:
Y30, R229N, K229 (brown) chain D, H83 F87 (yellow) chain A and H126 (green) chain B.
5.3.5 Suggested mechanisms
In Figures 5.12 and 5.13 we see a representative snapshot of structures close to their product
forming transition states. From these simulations we propose the following mechanisms
for the stereogenic step in the aldol condensation reaction (Figure 5.14). In the 3R product
forming reaction Arg229 plays a key role in coordinating a water close to the aldol oxygen
(1.6 Å). This water further coordinates to a network of other water molecules leading out
to bulk solvent. Abstraction of a proton from the water molecule by benzaldehyde enables
si face attack to form the aldol C-C bond and subsequent 3R product. Protons are able to
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shuttle in and out of the active site through the coordinated water network via the Grotthu¨ss
proton hopping mechanism.
In the 3S product forming reaction an additional water molecule is coordinated to the
aldol oxygen through His83 and Lys222. Further, His126 also forms a hydrogen bonding
interaction with the same water as Arg229. Abstraction of a proton from either of the
two coordinated water molecules is plausible with subsequent re face attack forming
the 3S product. By the same Grotthu¨ss proton hopping mechanism as mentioned above
reprotonation of the respective water molecule may occur.
Given these two suggested mechanisms, in addition to the binding analysis data (Section
5.3.3) and WHAM analysis data (Section 5.3.4), it is unsurprising that eTA shows no
apparent preference for either 2S3R or 2S3S PS. We speculate how a preference for the
3S diasteromer arose, during engineering studies (Chapter 4), in Section 5.4.
Figure 5.14: A schematic representation of suggested mechanisms for the stereogenic aldol
C-C bond forming step. These are given with respect to umbrella sampling trajectories in
Figures 5.12 and 5.13. For 3R product formation a Arg229 coordinated water molecule
allows for proton abstraction and si face attack of PXG onto benzaldehyde. A further
coordinated water network, involving Tyr30, enables shuttling of protons in and out of
the active site via the Grotthu¨ss proton hopping mechanism. In the 3S product forming
reaction an additional water is coordinated the aldol oxygen of benzaldehyde through His83
and Lys222. This offers an alternative proton for abstraction with subsequent re face attack
of PXG onto benzaldehyde. Both water molecules offer coordinated networks out to bulk
solvent for proton shuttling via the Grotthu¨ss proton hopping mechanism.
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5.3.6 An alternative mechanism for 3S product formation
Interestingly a different mechanism for aldol protonation is suggested in one of the
umbrella sampling simulations. As discussed above, simulations from 3S MD4,16 and 18
starting trajectories all displayed similar ring orientations when within C-C bond forming
distance. The simulation from the 3S MD12 starting trajectory however had an altered ring
positioning which directed the carbonyl oxygen of benzaldehyde close enough to the imine
of PXG for proton transfer via the mechanism shown in Figure 5.15. WHAM analysis of the
umbrella sampling simulation revealed a reduction in the free energy following this transfer,
further suggesting this to be a realistic mechanism (Figure 5.16). No other suggestions of
such a mechanism have been proposed in the literature, however the pKa of the imine group
in the external aldimine is reported to be close to 8 in a homologous system [Fesko et al.,
2018]. This is well suited for such a transfer given all buffers used for kinetic assays are
at pH 8. Furthermore a water molecule remains well positioned to reprotonate the imine
following transfer to the aldol oxygen.
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Figure 5.15: The observed proton transfer in umbrella sampling. The simulation was
performed with the 3S MD12 130 psec starting structure. Panel A and below: Benzaldehyde
in a pre-3S orientation is angled in a way that brings the carbonyl oxygen into close
proximity to the protonated imine of PXG. Panel B and below: The transition state forms
whereby the imine proton is abstracted by the benzaldehyde oxygen and PXG attacks onto
the CA atom of benzaldehyde forming the C-C bond. Panel C and below: The newly formed
hydroxyl proton moves away from the imine and a coordinated water molecule is well
placed for reprotonation of the imine.
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Figure 5.16: WHAM analysis showing the free energy profile for umbrella sampling from a
3S MD12 starting trajectory. In the simulation a proton transfer is observed from the imine
to the aldol oxygen. Following this a reduction in the free energy is observed defining a
clear TS energy barrier at 24 kcal mol−1 .
5.4 A rational explanation for improved stereoselectivity in eTA
variants
Through CASTing we identified a double Y30F R229N mutant with improved 3S selectivity
(Chapter 4). The mechanism proposed above for 3R product formation (Figure 5.14)
requires coordination of a single water molecule by Arg229. Mutation of this residue
to an asparagine would make this coordination interaction unlikely; however we might
still expect this residue to form a stabilising interaction with the phosphate group of PXG.
Without this water molecule coordination, or other obvious route for proton abstraction,
it would be unsurprising to see a reduced preference for the 3R product. Further, the
Y30F mutation would also be expected to disrupt water coordination due to removal of
the aromatic hydroxyl group. In the 3S forming reaction both His83 and Lys222 coordinate
an additional water molecule to the aldol oxygen of benzaldehyde. This doesn’t require
Arg229 however still forms a network with additional water molecules leading out to bulk
solvent. We would therefore still expect the shuttling of protons via the Grotthu¨ss proton
hopping mechanism. Future work should focus on the structural modelling of these, and
additional, mutations from Chapter 4 to investigate this.
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5.5 Summary
We were able to obtain the highest resolution structure of a L-TA to date at 1.6 Å. This
showed covalently bound PLP to Lys197 of the enzyme. The refined eTA structure was used
for MM MD simulations to investigate the binding of benzaldehyde in either a pre-3R or a
pre-3S orientation. We further looked at the likelihood of a reactive Michaelis complex
forming for each orientation. As might be expected for the poorly diastereoselective
enzyme, no preferential binding of a pre-3R or -3S reactive complex is observed. QM/MM
umbrella sampling simulations were performed in an attempt to identify the possible
mechanism of proton transfer in the C-C bond forming stereogenic step of the reaction.
Representative 3R and 3S simulations identified well coordinated water networks between
bulk solvent and the aldol oxygen suggesting a proton shuttling mechanism. An interesting
alternative proton transfer is observed when forming the 3S product whereby the aldol
oxygen became protonated through the transfer of the imine NSB proton. While three
representative umbrella sampling simulations were obtained for the 3S product, it is not
unusual to observe differences in the transition state structures when different starting
trajectories are used [Claeyssens et al., 2011, Lodola et al., 2007]. Thus whilst difficult
to prove the feasibility of this mechanism it should not be discounted and makes for an
interesting case especially given that all engineering efforts lead to improvements for the
3S stereochemistry.
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Chapter 6
Summary, Future Work and Perspectives
6.1 Summary
This thesis has demonstrated how a threonine aldolase from Escherichia coli (eTA) can be
engineered for improved diastereoselectivity with phenylserine (PS) by directed evolution
and rational engineering. This was achieved through screening over 3200 transformants
with a developed spectrophotmetric screen. High-quality libraries were produced with a
focused mutagenesis strategy that allowed for synergistic interactions between residues to
be identified. Further, rational combinations of stereoselective variants were made. This
identified a quadruple mutant with a 500-fold preference for 2S3S PS. In this thesis we also
present the highest resolution structure of any L-threonine aldolase at 1.6 Å. We used this
structure for molecular mechanics (MM) and quantum mechanics/molecular mechanics
(QM/MM) simulations to better understand the poor diastereoselective mechanism of the
wild-type enzyme. We also present an alternate mechanism in the stereogenic step of the
aldol condensation for 2S3S PS.
In the introduction of this thesis we describe the emergence of biocatalysis, its industrial
applications and benefits over chemocatalysis. Further we discuss specific examples of
enzymes used to produce sterochemically pure pharmaceutical compounds. One example
includes the production of an anti-asthmatic compound with an engineered aminoalcohol
dehydrogenase. We then present an in depth discussion of a engineered biocatalyst
removing the need for a complex, chemical manufacturing process. This enzyme, a
transaminase for the synthesis of sitagliptin, benchmarks modern day efforts in producing
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viable biocatalytsts over short time frames. Methods of directed evolution are discussed,
these include the generation of diverse gene libraries by error-prone PCR, and homology
based recombination. Further we detail the focused mutagenesis strategy of combinatorial
active site saturation testing (CASTing) and its success against other directed evolution
methods. De novo production of artificial enzymes by in silico methods are discussed with
particular attention paid to an artificial aldolase. In combination with directed evolution
methods, this enzyme was engineered to have near natural levels of catalytic efficiency.
In addition we discuss the natural aldolases, particularly threonine aldolases (TA) which
catalyse the reversible cleavage of threonine. The synthetic uses of these enzymes are
presented with their ability to synthesise β-hydroxy-α-amino acids. These compounds
contain two chiral centres with four possible stereoisomers and are apparent in antibiotics
and as active pharmaceutical ingredients.
In Chapter 3 we clone the gene for a low-specificity L-theonine aldolase from Escherichia
coli into an expression vector. We subsequently transformed this into an expression stain
of E. coli to obtain large amounts of overexpressed enzyme. This is used to kinetically
characterise eTA with 2S3R and 2S3S PS revealing the enzyme to be non-selective for either
diasteromer. We further developed an assay for the retro-aldol cleavage of PS showing any
absorbance between 230-300 nm can be used to follow this activity. This is applied in the
development of a high-throughput screen capable of measuring the activity of eTA in crude
lysate.
Chapter 4 of the thesis includes directed evolution of eTA. High-quality, focused libraries
are generated and screened by the CASTing approach. The developed screen from Chapter
3 is used to identify diastereoselective variants which are further characterised with
Michaelis-Menten kinetics. Rational combinations of the diasteroseletive variants yields
a quadruple mutant (Y30F R229N H83S F87Y) that has a 500-fold selectivity preference
(SP) for 2S3S PS. This enzyme however shows poor catalytic efficiency due to low activity
(kcat) with the selective substrate. Removal of the H83S mutation yields a variant, close to
20-fold selective for 2S3S PS with a good level of activity. This suggests H83 is important
in mediating both activity and diastereoselectivity. By iterative CASTing (ISM), a 10-fold
selective variant for for 2S3S PS is obtained.
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In Chapter 5, X-ray crystallography is used to obtain a 1.6 Å structure of eTA. This showed
the covalently bound PLP cofactor to Lys197 of the enzyme. The refined eTA structure was
used for MM MD simulations to investigate the binding of benzaldehyde in either a pre-3R
or a pre-3S orientation. We further looked at the likelihood of a reactive Michaelis complex
forming for each orientation. As might be expected for the poorly diastereoselective
enzyme, no preferential binding of a pre-3R or -3S reactive complex is observed. QM/MM
simulations were performed to identify the possible mechanism of proton transfer in the
C-C bond forming, stereogenic step of the reaction. Representative 3R and 3S simulations
identified well coordinated water networks between bulk solvent and the aldol oxygen. This
suggests proton abstraction may occur via a Grotthu¨ss hopping mechanism. In this chapter
we also present an alternative mechanism for proton transfer when forming the 3S product
where the aldol oxygen becomes protonated by abstraction of the Schiff base iminium
proton. We also speculate how the mutants in Chapter 4 achieve their diastereoselectivity.
This involves the disruption of the Arg229 and Tyr30 coordinated water molecules which
appear unnecessary for the 3S product forming reaction.
6.2 Future work and perspectives
Research continues on the project following submission of this thesis. Efforts will focus on
the synthesis of PS, using the identified stereoselective variants. Early efforts have shown
proton NMR to be an effective method in identifying peaks corresponding to the formation
of 2S3R and 2S3S PS. This method will allow for stereoselectivity to be quantified in the
aldol condensation reaction. This method could also be used with a range of aldehyde
substrates to see if improved stereoselectivity is transferable across different reactions.
The importance of computational modelling is undisputed in modern day enzyme
engineering. Future work should focus on modelling the identified enzyme variants in silico
with MM and QM/MM molecular dynamics. These may also be used to provide insight into
additional mutations that could lead to further improvements in stereoselectivity or even a
switch in the SP to create 2S3R PS selective enzymes.
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6.3 Concluding remarks
Through this research we have shown that a focused mutagenesis strategy, coupled with an
effective screening method, enables improvements in the diastereoselectivity of an enzyme
to be achieved. For this we used a plate based high-throughput screening technique. I
anticipate this method of screening will become obsolete in the near future given the
emergence of ultra-high-throughput, Microfluidics based approaches. With reports of
screening up to 5 million variants a day [Ma et al., 2018], the "numbers problem" described
in Chapter 1 will likely become more a numbers "hump" as this technology becomes more
widely available. In addition, as time progresses so will the advances in computation. We
should expect fully robust algorithms that can deliver de novo enzymes straight "out the
box" and ready for use as effective biocatalysts.
It is fair to say we are at an exciting point in structural and molecular biology. The future
is certainly bright for enzymes.
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Additional Figures and Tables
Figure A.1: Codon optimised ItaE gene sequence. The gene was designed to incorporate
an N-terminal His-tag into the enzyme and is 1038 bp in length.
Name Sequence
ItaE forward 5’ - ACAGGAAACAGAATTC ATGGAACATCACCATCACCACCAC -3’
ItaE reverse 5’ - AGAAGCTTGGCTGCAG TTATTAACGCGCCAGAAACGCACG-3’
pKK223-3 forward 5’ - CTGCAGCCAAGCTTCTGTTTTG -3’
pKK223-3 reverse 5’ - GAATTCTGTTTCCTGTGTAAATTGTTATCC -3’
Table A.1: Primer sequences for ligation independent cloning. Primers were designed to
contain complementary overlapping regions for the gene and plasmid using the methods
described by Li et al. [Li et al., 2011].
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Name Sequence
CASTing
Group 1 forward 5’ - GTCAGGCGGCCNDTAATTACCTGNDTGAAGCGGGCGG -3’
Group 1 reverse 5’ - CCGCCCGCTTCAHNCAGGTAATTAHNGGCCGCCTGAC -3’
Group 2 forward 5’ - CCGGATGACATCNDTNDTGCACGTACCAAACTGC -3’
Group 2 reverse 5’ - GCAGTTTGGTACGTGCAHNAHNGATGTCATCCGG -3’
Group 3 forward 5’ - GCACCGCCCGCTTCGAAAHNGTAATTGTGGGCAHNCTGACC -3’
Group 3 reverse 5’ - GGTCAGNDTGCCCACAATTACNDTTTCGAAGCGGGCGGTGC -3’
Group 4 forward 1 5’ - GTTGGCGATGACGTCNDTGGTGATGACCCGACC -3’
Group 4 forward 2 5’ - GACGGGCGGTGGCATGNDTCAATCGGGTATTCTGG -3’
Rational combinants 1
H83S F87Y forward 5’-GTCAGGCGGGCCTCTAATTACCTGTATGAAGCGGGCGG-3’
H83S F87Y reverse 5’-CCGCCCGCTTCATACAGGTAATTAGAGGCCCGCCTGAC-3’
H83S forward 5’-CTTCGAACAGGTAATTGCTGGCCGCCTGACCGACG 3’
H83S reverse 5’-CGTCGGTCAGGCGGCCAGCAATTACCTGTTCGAAG-3’
F87Y forward 5’-TGCACCGCCCGCTTCATACAGGTAATTGTGGGC-3’
F87Y reverse 5’-GCCCACAATTACCTGTATGAAGCGGGCGGTGCA-3’
Rational combinants 2
H126R forward 5’-CAGTTTGGTACGTGCAAAACGGATGTCATCCGGTTTAAT- 3’
H126R reverse 5’-ATTAAACCGGATGACATCCGTTTTGCACGTACCAAACTG-3’
F127H forward 5’-AGCAGTTTGGTACGTGCATGATGGATGTCATCCGGTTTAATTTTC-3’
F127H reverse 5’-GAAAATTAAACCGGATGACATCCATCATGCACGTACCAAACTGCT-3’
H126R F127H forward 5’-CCGGATGACATCCGTCATGCACGTACCAAACTGC-3’
H126R F127H reverse 5’-GCAGTTTGGTACGTGCATGACGGATGTCATCCGG-3’
Table A.2: Primers for eTA CASTing groups and those used to make rational combinants.
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Figure A.2: Screening plates for CASTing group 1 (H83N DT F87N DT ) library plates 1 (left)
and 2 (right). For each library plate containing eTA variants, two screening plates are set up
identically to measure retro-aldol activity of either 2S3R (top) or 2S3S (middle) PS. Positive
controls are shown in wells H7-9 and negative controls in wells H10-12. The activity of each
well is measured from the change in Abs260. Those wells with an activity of 0.2 ∆Abs260
or greater are highlighted in green. Identifier analysis (bottom) shows the 2S3R / 2S3S
activity ratio for wells highlighted in green above. Those in purple will have greater levels
of activity for the 2S3R PS retro-aldol cleavage and those in brown for 2S3S.
Figure A.3: As Figure A.2 for library plates 3 (left) and 4 (right).
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Figure A.4: As Figure A.2 for library plates 5 (left) and 6 (right).
Figure A.5: Screening plates for CASTing group 2 (H126N DT F127N DT ) library plates 1
(left) and 2 (right). For each library plate containing eTA variants, two screening plates
are set up identically to measure retro-aldol activity of either 2S3R (top) or 2S3S (middle)
PS. Positive controls are shown in wells H7-9 and negative controls in wells H10-12. The
activity of each well is measured from the change in Abs260. Those wells with an activity
of 0.2 ∆Abs260 or greater are highlighted in green. Identifier analysis (bottom) shows the
2S3R / 2S3S activity ratio for wells highlighted in green above. Those in purple will have
greater levels of activity for the 2S3R PS retro-aldol cleavage and those in brown for 2S3S.
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Figure A.6: As Figure A.5 for library plates 3 (left) and 4 (right).
Figure A.7: As Figure A.5 for library plates 5 (left) and 6 (right).
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Figure A.8: Screening plates for CASTing group 3 (A81N DT L86N DT ) library plates 1 (left)
and 2 (right). For each library plate containing eTA variants, two screening plates are set up
identically to measure retro-aldol activity of either 2S3R (top) or 2S3S (middle) PS. Positive
controls are shown in wells H7-9 and negative controls in wells H10-12. The activity of each
well is measured from the change in Abs260. Those wells with an activity of 0.2 ∆Abs260
or greater are highlighted in green. Identifier analysis (bottom) shows the 2S3R / 2S3S
activity ratio for wells highlighted in green above. Those in purple will have greater levels
of activity for the 2S3R PS retro-aldol cleavage and those in brown for 2S3S.
Figure A.9: As Figure A.8 for library plates 3 (left) and 4 (right).
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Figure A.10: As Figure A.8 for library plates 5 (left) and 6 (right).
Figure A.11: Screening plates for CASTing group 4 (Y30N DT R229N DT ) library plates 1
(left) and 2 (right). For each library plate containing eTA variants, two screening plates
are set up identically to measure retro-aldol activity of either 2S3R (top) or 2S3S (middle)
PS. Positive controls are shown in wells H7-9 and negative controls in wells H10-12. The
activity of each well is measured from the change in Abs260. Those wells with an activity
of 0.2 ∆Abs260 or greater are highlighted in green. Identifier analysis (bottom) shows the
2S3R / 2S3S activity ratio for wells highlighted in green above. Those in purple will have
greater levels of activity for the 2S3R PS retro-aldol cleavage and those in brown for 2S3S.
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Figure A.12: As Figure A.11 for library plates 3 (left) and 4 (right).
Figure A.13: As Figure A.11 for library plates 5 (left) and 6 (right).
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Figure A.14: SDS PAGE analysis of Group 4 (Y30FN DT R229NN DT ) purified variants. Top:
Lanes: 1 - protein ladder, 2 - eTA, 3 - 1 A10, 4 - 1 C1, 5 - 1 C12, 6 - 1 D11, 7 - 1 F11, 8 - 2
A2, 9 - 2 A6, 10 - 2 D12. Bottom: Lanes: 1 - protein ladder, 2 - eTA, 3 - 2 H6, 4 - 3 F8, 5 -
4 B10, 6 - 5 E1, 7 - 6 A2, 8 - 6 F8.
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Figure A.15: Screening plates for CASTing Round 2 group 1 (Y30F R229N + H83N DT
F87N DT ) library plates 1 (left) and 2 (right). For each library plate containing eTA variants,
two screening plates are set up identically to measure retro-aldol activity of either 2S3R
(top) or 2S3S (middle) PS. Positive controls are shown in wells H7-9 and negative controls
in wells H10-12. The activity of each well is measured from the change in Abs260. Those
wells with an activity of 0.2∆Abs260 or greater are highlighted in green. Identifier analysis
(bottom) shows the 2S3R / 2S3S activity ratio for wells highlighted in green above. Those
in purple will have greater levels of activity for the 2S3R PS retro-aldol cleavage and those
in brown for 2S3S.
Figure A.16: As Figure A.15 for library plates 3 (left) and 4 (right).
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Figure A.17: As Figure A.15 for library plates 5 (left) and 6 (right).
Figure A.18: Screening plates for CASTing Round 2 group 2 (Y30F R229N + H126N DT
F127N DT ) library plates 1 (left) and 2 (right). For each library plate containing eTA variants,
two screening plates are set up identically to measure retro-aldol activity of either 2S3R
(top) or 2S3S (middle) PS. Positive controls are shown in wells H7-9 and negative controls
in wells H10-12. The activity of each well is measured from the change in Abs260. Those
wells with an activity of 0.2∆Abs260 or greater are highlighted in green. Identifier analysis
(bottom) shows the 2S3R / 2S3S activity ratio for wells highlighted in green above. Those
in purple will have greater levels of activity for the 2S3R PS retro-aldol cleavage and those
in brown for 2S3S.
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Figure A.19: As Figure A.18 for library plates 3 (left) and 4 (right).
Figure A.20: As Figure A.18 for library plates 5 (left) and 6 (right).
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Figure A.21: SDS PAGE analysis of fractions from the purification for Y30F R229N H83S
F87Y eTA. Lanes: 1 - protein ladder, 2 - soluble, 3 - insoluble, 4 - unbound, 5 - wash 1, 6 -
wash 2, 7 - wash 3, 8 - wash 4, 9 - elution at 20 times dilute, 10 - elution at 40 times dilute.
Figure A.22: Deconvoluted spectrum for Y30F R229N H83S F87Y eTA. The observed mass
37351 was within 3 Da of the expected mass for the variant (37354).
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Figure A.23: SDS PAGE analysis of fractions from the purification of Y30F R229N H83S
eTA. Lanes: 1 - protein ladder, 2 - soluble, 3 - insoluble, 4 - unbound, 5 - wash 1, 6 - wash
2, 7 - wash 3, 8 - wash 4, 9 - elution at 20 times dilute, 10 - elution at 40 times dilute.
Figure A.24: SDS PAGE analysis of fractions from the purification of Y30F R229N F87Y
eTA. Lanes: 1 - protein ladder, 2 - soluble, 3 - insoluble, 4 - unbound, 5 - wash 1, 6 - wash
2, 7 - wash 3, 8 - wash 4, 9 - elution at 20 times dilute, 10 - elution at 40 times dilute.
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Figure A.25: Deconvoluted spectrum for Y30F R229N H83S eTA. The observed mass 37337
was within 1 Da of the expected mass for the variant (37338).
Figure A.26: Deconvoluted spectrum for Y30F R229N F87Y eTA. The observed mass 37404
was within 1 Da of the expected mass for the variant (37405).
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Figure A.27: SDS PAGE analysis for Y30F R229N H126R and Y30F R229N F127H eTA
variants. Lanes: 1 - protein ladder, 2 - Y30F R229N H126R soluble, 3 - Y30F R229N H126R
elution, 4 - Y30F R229N F127H soluble, 5 - Y30F R229N F127H elution.
Figure A.28: Deconvoluted spectrum for Y30F R229N H126R eTA. The observed mass
37407 was within 1 Da of the expected mass for the variant (37408).
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Figure A.29: Deconvoluted spectrum for Y30F R229N F127H eTA. The observed mass
37377 was within 2 Da of the expected mass for the variant (37379).
Figure A.30: SDS PAGE analysis for Y30F R229N F87R H126R F127H eTA. Lanes: 1 -
protein ladder, 2 - soluble fraction, 3 - eluted fraction
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Figure A.31: Deconvoluted spectrum for Y30F R229N F87R H126R F127H eTA. The
observed mass 37407 was within 1 Da of the expected mass for the variant (37408).
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